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ABSTRACT 
 
Cardiovascular diseases (CVD) are the main cause of death worldwide, and the long-term 
consequences of the non-fatal events also represent a great burden. The multifactorial etiology of 
these complex pathologies, involves the interaction between lifestyle, environmental, and genetic 
factors. The study of the influence of single nucleotide polymorphisms (SNPs) on intermediate 
and final CVD phenotypes, is helping recognize the molecular biological means of these diseases. 
From all of the modifiable factors of CVD, diet is of particular relevance, both because people eat 
and drink on a daily basis, and also due to its potential to interact with non-modifiable risk 
factors, such as SNPs. This thesis presents five studies: four genetic association studies in two 
different study populations, and a systematic review of informatic tools available to asses diet in 
epidemiological studies, which facilitate the study of diet as a risk factor for different chronic 
diseases including CVD. 
The first study cross-sectionally investigated whether the common genetic variant rs4988235 
(C/T), located -13910 pb upstream the gene coding for lactase (LCT), was associated with obesity 
in a Spanish population at high CVD risk, sampled in the Mediterranean area (PREDIMED-
Valencia Study, n = 940). Further, its potential modulation by consumption of dairy products was 
examined. This SNP, which is strongly associated with lactase persistence, is an emerging 
candidate for obesity. Results from this study suggested that, despite dairy product consumption 
did not substantially differ by genotype, participants homozygote for the C allele had lower mean 
body mass index (BMI) (29.7±4.2 vs. 30.6±4.2 kg/m2; P = 0.003) and waist circumference 
(101.1±1.8 vs. 103.5±11.5 cm; P = 0.005) than T-allele carriers. Obesity prevalence was also 
significantly higher in T-allele carriers than in CC individuals, however only among participants 
consuming moderate or high lactose intakes (>8 g/day). 
The second study investigated whether the gene variant rs2943634 (C/A), located in a non-
coding region of chromosome 2q36.3, and recently associated with coronary artery disease in two 
GWA studies, was associated with myocardial infarction and ischemic stroke in the Potsdam arm 
Abstract 
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of the European Prospective Investigation into Cancer and Nutrition (EPIC). A case-cohort 
design was used, with a subsample of 2500 persons randomly drawn from the total population of 
27,548 middle-aged men and women, along with all incident cases of myocardial infarction (n = 
211) and ischemic stroke (n = 144), occurring during a mean follow-up of 8.2 years. Because the 
mode of mechanism by which this SNP may increase CVD risk is unknown, associations of this 
SNP with 12 available intermediate risk phenotypes of CVD were also investigated. The minor 
allele of rs2943634 was associated in an additive fashion with lower risk of ischemic stroke after 
adjustment for age and sex (per-allele hazard ratio 0.66, 95% CI 0.50-0.87) but not with 
myocardial infarction (per-allele hazard ratio 1.02, 95% CI 0.82-1.28). Furthermore, the minor 
allele was related to slightly higher levels of plasma adiponectin (CC 6.94, CA 7.27, AA 
7.86"g/ml, P=0.0002) and HDL-cholesterol (CC 52.08, CA 53.05 and AA 55.27mg/dl, P=0.002) 
in an additive fashion. Adjustment for adiponectin and HDL-cholesterol did, however, not 
attenuate the association between the SNP and ischemic stroke risk. In contrast, adjustment for 
adiponectin abolished the association between the SNP and HDL-cholesterol and adjustment for 
HDL-cholesterol attenuated the association between the SNP and adiponectin. 
In the third study, the impact of common genetic variation in the Stearoyl-CoA desaturase-1 
(SCD1) gene, captured by means of 7 tagging SNPs and 5 inferred haplotypes, on the modulation 
of 8 metabolic risk factors linked to the activity of SCD1 (triglycerides, body mass index, waist 
circumference, glycated haemoglobin, high-sensitivity C-reactive protein, gamma-
glutamyltransferase, alanine aminotransferase and fetuin-A) was investigated. SCD1 is the rate 
limiting enzyme catalyzing the conversion of the endogenous and dietary saturated fatty acids 
palmitic and stearic into the monounsaturated palmitoleic and oleic, respectively. Its activity has 
been associated with traits of the metabolic syndrome in mice and humans, but also with the 
prevention of saturated fatty acids accumulation and subsequent inflammation, whereas for liver 
fat content inconsistent results have been reported. In the EPIC-Potsdam Study (n = 2157), 
however, no associations between common variants of SCD1 or its inferred haplotypes and the 
investigated metabolic risk factors were observed. 
The fourth study was conducted in EPIC-Potsdam following a case-cohort design (193 incident 
myocardial infarction, 131 incident ischemic stroke cases and 1978 non-cases). Further, the 
Heinz Nixdorf Recall Study (30 CVD cases and 1,188 controls) was used to replicate findings. 
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The microsomal triglyceride transfer protein (MTTP), encoded by the MTTP gene, plays an 
important role in the assembly and secretion of apolipoprotein-B containing lipoproteins as 
chylomicrons in the intestine, and of very low density lipoproteins in the liver. MTTP is regulated 
by cholesterol. In this study the investigated hypothesis was that, the -164T>C polymorphism, 
located in the promoter region of MTTP, could modify the risk of CVD, depending on cholesterol 
levels. This SNP had inconsistently been associated with CVD in previous studies. In the EPIC-
Potsdam study, individuals with cholesterol levels <200 mg/dL showed a significant increased 
risk of CVD (HRadditve= 1.38, 95% CI: 1.07 to 1.78); while HRadditve for subjects with cholesterol 
levels #200 mg/dL was 0.77 (0.58-1.03). HRadditive for participants in the Heinz Nixdorf Recall 
Study were 1.06 (0.33-3.40) and 0.60 (0.29-1.25) respectively for participants with cholesterol 
levels <200 mg/dL and #200 mg/dL. These results suggest that risk allele carriers with low 
cholesterol levels may be predisposed to an increased risk of developing CVD, which seems to be 
abolished among risk allele carriers with high cholesterol levels. 
In the last years, the tedious task of a assessing a person’s diet has started to benefit from the fast 
development of the information and communication technologies. Thus, a variety of new tools 
now makes it possible to study diet as a risk factor for different chronic diseases in large 
epidemiological studies, without too much labour costs. In the fifth study of this thesis, a state-
of-the-art review of applications for automating the most commonly used dietary surveys in 
nutritional research, that is food-frequency questionnaires and 24-hour dietary recalls, is 
provided. 
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RESUMEN 
 
Las enfermedades cardiovasculares (ECV) constituyen la principal causa de mortalidad en todo el 
mundo. Su etiología es multifactorial y compleja e incluye la interacción de factores de estilo de 
vida, ambientales y genéticos. Mediante estudios de asociación acerca de la influencia de 
polimorfismos de un sólo nucleótido (SNP) sobre fenotipos intermedios y finales de ECV, es 
posible identificar rutas metabólicas implicadas en ECV. De todos los factores de riesgo 
modificables de ECV, la dieta es de particular relevancia, tanto porque la gente come y bebe a 
diario como por su potencial para interactuar con factores de riesgo no modificables, tales como 
factores genéticos. En esta tesis se presentan cinco estudios: cuatro de ellos de asociación 
genética en dos cohortes diferentes y una revisión sistemática sobre herramientas informáticas 
disponibles para la medida de la dieta en grandes estudios epidemiológicos, que facilitan su 
estudio como factor de riesgo de diversas enfermedades, incluidas las ECV. 
El primer estudio se llevó a cabo en una muestra de población mediterránea española de alto 
riesgo cardiovascular (estudio PREDIMED-Valencia, n = 940). Mediante un diseño transversal, 
se investigó la relación con obesidad de la variante genética rs4988235 (C/T), localizada a 13910 
pares de bases del gen que codifica la $-galactosidasa Lactasa (LCT). Así mismo de determinó su 
possible modulación por consumo de productos lácteos. Este polimorfismo, ha sido 
consistentemente relacionado con la persistencia del enzima lactasa y es además un candidato 
emergente de obesidad. A pesar de que el consumo de productos lácteos no varió sustancialmente 
de acuerdo a genotipo, los participantes homocigotos para el alelo C, presentaron menor índice de 
masa corporal (29.7±4.2 vs 30.6±4.2 kg/m2; P = 0.003) y perimétro de de cintura (101.1±11.8 vs 
103.5±11.5 cm, P = 0.005) que los portadores del alelo T. La prevalencia de obesidad fue 
también significativamente mayor en los portadores del alelo T, sin embargo, sólo entre aquellos 
participantes cuyo consumo de lactosa fue moderado o alto (>8g/día). 
En el segundo estudio, desarrollado en la cohorte de Potsdam del Estudio Europeo Prospectivo 
sobre Cáncer y Nutrición (EPIC), se investigó la asociación de la variante genética rs2943634 
(C/A) con incidencia de infarto de miocardio y accidente cerebrovascular isquémico. El 
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polimorfismo rs2943634 se localiza en una región no codificante del cromosoma 2q36.3, sin 
embargo, había sido asociado con enfermedad arterial coronaria en dos GWAS previos. Se utilizó 
un diseño caso-cohorte, que incluyó una submuestra aleatoria de 2500 participantes y todos los 
casos de infarto de miocardio (n = 211) y accidente cerebrovascular isquémico (n = 144) 
ocurridos en EPIC-Potsdam durante un periodo de seguimiento medio de 8.2 años. Dado que el 
mecanismo por el que rs2943634 podría modular el riesgo de ECV es desconocido, también se 
investigó de forma transversal su posible asociación con 12 fenotipos intermedios disponibles de 
ECV. El alelo C fue asociado de manera aditiva con menor riesgo de accidente cerebrovascular 
isquémico (ratio de riesgo (HR) por alelo 0.66, intervalo de confianza IC al 95%: 0.50-0.87), pero 
no con infarto de miocardio [1.02 (82-1.28)]. Además los portadores de este alelo, también 
presentaron mayores niveles plasmáticos de adiponectina (CC 6.94, CA 7.27, AA 7.86 "g/ml, P = 
0.0002) y de cholesterol-HDL (CC 52.08, CA 53.05, AA 55.27mg/dl, P = 0.002). Sin embargo, el 
ajuste por adiponectina y cholesterol-HDL de los análisis de asociación del SNP con accidente 
cerebrovascular hisquémico, no atenuó la asociación. 
El enzima Estearoil-CoA Desaturasa-1 (SCD1) cataliza la conversión de los ácidos grasos 
saturados palmítico y esteárico a los monoinsaturados palmitoléico y oléico, respectivamente. Su 
actividad se ha asociado con rasgos del síndrome metabólico en ratones y seres humanos, pero 
también con la prevención de la acumulación de ácidos grasos saturados y posterior inflamación, 
mientras que para contenido de grasa del hígado los resultados hasta ahora publicados son 
inconsistentes. En el tercer estudio de esta tesis, en una muestra aleatoria (n = 2500) de la 
cohorte del estudio EPIC-Potsdam, a través de 7 tagging-SNPs y 5 haplotipos inferidos, se 
investigó el efecto de la heterogeneidad genética común del gen que codifica la enzima SCD1 
(SCD1), en la modulación de 8 factores de riesgo metabólico vinculados a la actividad de: SCD1: 
triglicéridos, índice de masa corporal, circunferencia de cintura, hemoglobina glicosilada, 
proteína-C-reactiva, gamma-glutamil transferasa, alanina aminotransferasa y fetuina-A. No se 
encontraron asociaciones estadísticamene significativas entre los genotipos y fenotipos 
estudiados. 
La proteína microsomal transferidora de triglicéridos (MTTP), participa en el ensamblaje y 
secreción de lipoproteínas con apolipoproteína-B. Esta proteína está codificada por el gen MTTP, 
que se regula mediante colesterol. Polimorfimos en la zona promotora de este gen, tales como el -
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164 T>C, han sido inconsistentemente asociados con ECV en distintos estudios. En el cuarto 
estudio de esta tesis, utilizando un diseño caso-cohorte, se investigó la asociación del 
polimorfismo -164T> C con riesgo de padecer un evento cardiovascular, en función de los 
niveles de colesterol (subcohorte, n = 1978; casos de infarto de miocardio, n = 193; casos de ictus 
isquémico, n = 131). Los resultados obtenidos fueron replicados en la cohorte del estudio Heinz 
Nixdorf Recall (30 casos, 1188 controles). Los participantes de EPIC-Potsdam con niveles de 
colesterol inferiores a 200 mg/dL, mostraron un incremento significativo del riesgo 
cardiovascular [HRaditivo 1.38 (1.07-1.78)], mientras que para participantes con niveles de 
colesterol #200 mg/dL se observó una disminución del riesgo [HRadditvo = 0.77 (0.58-1.03)]. En el 
estudio Heinz Nixdorf Recall, los respectivos HR para niveles de colesterol <200 mg/dL y 
colesterol #200 mg/dL fueron 1.06 (0.33-3.40) y 0.60 (0.29-1.25). Estos resultados sugieren una 
interacción entre el SNP investigado y colesterol, de manera que los portadores del alelo de 
riesgo, en presencia de niveles elevados de colesterol podrían evitar el riesgo conferido por el 
SNP. 
En los últimos años, la tediosa tarea de evaluar la dieta de una persona, se ha beneficiado del 
rápido desarrollo de las tecnologías de la información y la comunicación. Con la nueva variedad 
de herramientas, ahora el estudio de la dieta como factor de riesgo para diferentes enfermedades 
crónicas en grandes estudios epidemiológicos es posible a costes inferiores. En el quinto estudio 
de esta tesis, se presenta una revisión de las aplicaciones existentes para la automatización de las 
encuestas más comúnmente utilizadas para la medida de la dieta en estudios de investigación, es 
decir, el cuestionario de frecuencia de consumo de alimentos y el recordatorios de 24 horas. 
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Chapter 1: Introduction 
1.1 CARDIOVASCULAR DISEASES 
Cardiovascular diseases (CVD) are pathological conditions involving the cardiovascular system, 
i.e., the heart, blood vessels and pericardium. They have been described as a continuum that 
begins with the presence of risk factors, and proceeds via progressive vascular disease to target 
organ damage, end-organ failure, and death (1). CVD are the main cause of death worldwide (2) 
and the long-term consequences of the non-fatal events also represent a great burden (3). 
According to the 10th revision of the International Classification of Diseases (ICD-10) (4), CVD 
can be classified in 10 categories (I00-I99) of which, in terms of mortality, two subcategories, 
myocardial infarction (MI) (I21), followed by ischemic stroke (IS) (I63) are the most important 
with about 12.8 million people worldwide dying from them in 2010 (2). 
MI and IS are complex multifactorial diseases that are thought to occur due to the interaction of 
lifestyle, environmental, and genetic factors. They mostly arise when arteries that supply blood to 
the heart or the brain are obstructed, which is usually instigated by the disruption of 
atherosclerotic plaques in the wall of the arteries, and subsequent activation of a clotting cascade 
(5). 
1.2 RISK FACTORS FOR CARDIOVASCULAR DISEASES 
Because CVD are such a large public health problem, many efforts have been taken worldwide to 
identify its modifiable risk factors. Regarding MI, a remarkable initiative is the INTERHEART 
study (6). In this standardized case-control study including 15152 acute MI cases and 14820 
controls from 52 countries representing all inhabited continents, nine modifiable risk factors were 
identified that accounted for 90% of the population attributable risk to develop MI. Smoking and 
a raised ratio of the apolipoprotein B to A1 (respectively the major protein components of low-
density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol) were the 
dominating factors. These were followed by, in different degrees of importance according to 
geographic location, psychosocial factors (which included depression, locus of control, perceived 
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stress, and life events), abdominal obesity (approximated by the waist-to-hip ratio), diabetes, 
history of hypertension, low consumption of fruit and vegetables, lack of regular physical 
activity, and consumption of alcohol less than three times per week (6). 
Concerning stroke, a similar initiative, although smaller in size, was undertaken in the 
INTERSTROKE study (7). This case-control study of 3000 stroke cases (of which 78% ischemic 
stroke, the most common form of stroke) and 3000 controls without stroke, from 22 countries 
worldwide, identified ten modifiable risk factors for IS also accounting for 90% of the population 
attributable risk. Consistent with the fact that MI and IS share common pathological pathways 
due to atherosclerotic disease (8), all the nine risk factors identified for MI were also identified 
for IS, although with different relative importance. The list of risk factors for stroke was 
completed with cardiac causes, with atrial fibrillation as the most common source (7). 
Apart from the INTERHEART and INTERSTROKE initiatives, which despite their large sample 
sizes were case-control studies and therefore sensitive to bias, results of a number of prospective 
studies also support a role for the following CVD risk factors: cigarette smoking (9-15); 
dyslipidemia (16-21), obesity (22-24); diabetes mellitus mellitus (25-31), hypertension (32-35), 
physical activity (36, 37); psychosocial factors (38-41); the consumption of fruit and vegetables 
(42-44); and alcohol intake (45-50). Additionally, results from interventional studies have 
confirmed the cardiovascular benefits of dietary modification (51, 52), antihypertensive 
treatments (34, 53, 54), correction of dyslipemia (55-60), moderate alcohol use (61) and also of 
anticoagulation treatments for stroke prevention in atrial fibrillation (62). 
Further, the so-called metabolic syndrome (MetS), a clustering of abdominal obesity, high 
triglycerides (TG), low HDL-cholesterol, elevated blood pressure, and glucose intolerance (63), 
has been associated with a ~2-fold increased risk for CVD (64) (65), and it has been shown that 
the higher the number of individual MetS traits a person has, the greater the risk of developing an 
adverse outcome (66). 
Other suggested risk factors that contribute to the development of CVD include, but are not 
limited to, the aging (67), chronic low-grade inflammation (68, 69), sleeping less than 6 or more 
than 9 hours (70-73) non-alcoholic fatty liver disease (74) or chronic kidney disease (75).  
Hypoadiponectinemia has also been suggested as a possible independent risk factor, given that 
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adiponectin exerts anti-inflammatory, antiatherogenic, antithrombotic and insulin-sensitizing 
effects (76, 77). 
1.3 PARTICULAR RELEVANCE OF DIET AS A RISK FACTOR FOR CVD 
From all the potentially modifiable established CVD risk factors, diet is of particular relevance 
given that it is the only factor everyone is exposed to from birth to death, and also for its potential 
to interact with non-modifiable risk factors such as genetic polymorphisms. Supporting the 
results from INTERHEART and INTERSTROKE, adherence to the traditional Mediterranean 
diet, characterised by high intakes of fruits, vegetables, legumes, nuts, unrefined cereals, olive 
oil, a moderate intake of alcohol (particularly in the form of red wine), and a low to moderate 
intake of dairy products, fish, meat, poultry, and saturated fats (78), has consistently been 
associated with reduced risk of developing CVD (79). 
The assessment of a person’s typical diet should consist of the analysis of his or her daily food 
intake throughout one or more years. In large epidemiological studies, however, this is not 
feasible and, in practice, a portion of it is captured and habitual dietary intake is extrapolated. 
Tools to collect dietary data in these settings, which can then be transformed into energy and 
nutrient intake by means of food composition tables, include: food-frequency questionnaires 
(FFQ), 24-hour dietary recalls (24HDRs), dietary records (DRs), and dietary histories. As the 
information and communication technologies gained importance in the last years, a great effort 
has been done to automate questionnaires used in epidemiological studies, with the aim to reduce 
random errors and save costs by accelerating the tasks of extraction and processing of data. First, 
computer programs were developed for the interviewer-administration or self-administration of 
FFQs, 24HDRs or combinations of both. Later, when access to the Internet became widespread, 
Web-based on-line FFQs, on-line 24HDRs, and combinations of both were introduced to 
substitute paper questionnaires. In Chapter 2 of this thesis a FFQ is used to estimate dairy intake 
in a population-based study. Characteristics of dietary surveys and methods developed for their 
automation in medical studies are reviewed in Chapter 5. 
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1.4 ROLE OF GENETICS IN THE ETIOLOGY OF CVD 
Lifestyle factors are known to influence certain biological risk factors of CVD. It is thought, 
however, that biological risk factors also have a genetic component. This is supported by the 
observation that modifiable risk factors have a certain degree of heritability and genetic 
modulation (80). Also, parental history has been proposed as an independent risk factor for MI 
(81) and ischemic stroke (82, 83). Thus, in order to recognize persons at risk, it is also essential to 
identify genetic factors conferring susceptibility (80). 
Except for rare forms that follow a Mendelian inheritance pattern (84), CVD are multifactorial 
diseases influenced by many genetic loci interacting with each other and with lifestyle and 
environmental factors (85). The increased risk can be driven by epigenetic changes, but also by 
mutations such as deletions, insertions, variable number tandem repeat or single nucleotide 
polymorphisms (SNPs). SNPs are the most common genetic variations, and occur on average 
once in every 300 nucleotides. Most of them have no direct effect on CVD, but some may 
modulate intermediate or final CVD phenotypes. Their influence on MI and IS is not fully 
understood. However, the development of studies testing for heterogeneity of SNPs across 
persons with different phenotypes, such as candidate-gene studies, gene-wide studies, and 
particularly genome-wide association (GWA) studies, is leading to the identification of several 
gene loci associated with an elevated risk of CVD, and thus helping recognize its molecular 
biological means (86). 
Candidate gene studies are hypothesis-based. These studies test the hypothesis that heterogeneity 
of a given gene, typically encoding a protein that determines or influences an intermediate 
phenotype, may modulate its function, and eventually, the risk of clinical disease. A limitation of 
this approach is that only a few SNPs are examined (80), thereby missing other potential 
important SNPs. The gene-wide strategy overcomes this limitation by assessing the smallest 
number of SNPs (tagging-SNPs) necessary to extract the maximum amount of information for a 
given gene, taking into account allele frequencies, linkage disequilibrium, and position on the 
gene. Gene-wide studies also provide the possibility to predict haplotype structures, thereby 
capturing more genetic variation than assessing single SNPs (80).  
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To date, many candidate-gene and gene-wide studies examining the association of genetic factors 
with cardiovascular endpoints are underpowered (87), and few have been replicated (88). 
However, these studies have been successful for some intermediate phenotypes. Some examples 
include the identification of the genes encoding the apolipoproteins A, E and A5, which regulate 
levels of lipoprotein-A, cholesterol and triglycerides, respectively (87). 
If the etiology of a disease is unknown, the candidate-gene and the gene-wide approaches are not 
useful. This limitation is overcome by the GWA approach, which allows examining genetic 
variants across the entire genome without assumptions about the genomic location of the causal 
variants. In fact, GWA studies have led to the discovery of unsuspected pathological pathways 
(80). However, although to date GWA studies are the most reliable type of genetic studies (80), 
they also often show the limitation of lack of reproducibility. 
Regarding MI risk, eleven chromosomal regions identified in GWA studies have been 
successfully replicated (86), making the evidence for the associations more robust. These regions 
were summarized by Erdman et al. (86), and are reproduced in Table 1 of this chapter. Only two 
of them (1p13.3 and 6q26–27) are associated with traditional risk factors (LDL-cholesterol and 
lipoprotein-A). For the remainder, the associations with the risk of MI appear not to be mediated 
by traditional biological risk factors and their mechanisms are not yet understood (perhaps long-
range regulation of gene expression). The strongest and most replicated genetic effect is that of a 
genetic variant in a non-coding region of chromosome 9p21.3 (86). 
Furthermore, results from a recent meta-analysis including 8140 MI cases and 10522 controls of 
Caucasian, Asian, and African-American origin, from 30 case-control studies, suggested that the 
SNP rs1801133 of the gene coding for the enzyme methylenetetrahydrofolate reductase 
(MTHFR) is related to risk of MI. This enzyme catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine 
remethylation to methionine (89). Another meta-analysis including 9569 MI cases and 7264 
controls of Asian and Caucasian origin from 18 case-control studies, indicated that, depending on 
the ethnic origin, SNPs rs3025058 and rs3918242 from the genes coding for matrix 
metalloproteinases 3 and 9 respectively, also confer susceptibility to develop MI. These enzymes 
weaken the arterial wall and contribute to the destabilization and rupture of atheromatous plaque, 
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by attacking the major components of the basal lamina around blood vessels (that is, type IV 
collagen, laminin and fibronectin) (90). 
Concerning the genetic susceptibility to develop IS, the largest meta-analysis so far conducted, 
the METASTROKE collaboration, included 12389 IS cases and 62004 stroke-free controls of 
European ancestry from 15 case-control studies. The novel associations identified, were further 
replicated in the same study in an independent set of 13347 cases and 29083 controls from 18 
independent case-control studies. This study identified loci near the genes coding the paired-like 
homeodomain transcription factor 2 (PITX2) and the Zinc finger homeobox protein 3 (ZFHX3) 
to be associated with cardioembolic stroke, and loci in 9p21 and histone deacetylase 9 (HDAC9) 
with large-vessel stroke (two of the most common IS subtypes) (91). 
Another recent meta-analysis, including 2247 IS cases and 1813 controls of Chinese and 
Caucasian origin, from 10 case-control studies, pointed to the T833C genetic polymorphism of 
the Cystathionine $ Synthase (CBS) gene as a risk factor for ischemic stroke (92). Finally, 
another meta-analysis including 4681 ischemic stroke cases and 8516 controls of Caucasian and 
Asian origin from 3 case-control studies suggested the Ser447Ter and Asn291Ser polymorphisms 
of the lipoprotein lipase gene to be associated with risk of ischemic stroke (93). 
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Table 1. Chromosomal regions associated with MI and identified by  GWA studies and 
successfully replicated (taken from reference (86) ) 
Chromosomic 
region SNP 
Risk 
allele 
Freq. 
OR (95% CI) Nearby Genes Gene function 
1p13.3 rs599839 77% 1.13 (1.08–1.19) PSCR1, CELSR2, SORT1, MYBPHL LDL increase 
1q41 rs3008621 72% 1.10 (1.04–1.17) MIA3 Collagen processing
2q33 rs6725887 14% 1.17 (1.11–1.23) WDR12 Apoptosis 
3q22.3 rs9818870 15% 1.15 (1.11–1.19) MRAS Adhesion signaling
6p24 rs12526453 65% 1.13 (1.08–1.17) PHACTR1 Coronary calcification 
6q26–27 rs2048327 18% 1.20 (1.13–1.28) SLC22A3, LPAL2, LPA Lp(a) 
9p21.3 rs3127599 52% 1.36 (1.27–1.46) MTAP, CDKN2A, CDKN2B, ANRIL Unknown 
10q11 rs7767084 84% 1.11 (1.05–1.18) SDF1 EPC recruiting and inflammation 
12q24 rs10755578 34% 1.14 (1.10–1.19) SH2B3 Unknown 
12q24.3 rs1333049 36% 1.08 (1.05–1.11) HNF1A, C12orf43 Unknown 
21q22 rs501120 13% 1.19 (1.14–1.27) SLC5A3, MRPS6, KCNE2 Unknown 
 
1.5 AIM AND OUTLINE OF THIS THESIS 
This thesis presents four genetic association studies (Chapters 2-5) which aim to add further 
understanding of the role of selected SNPs on intermediate and final phenotypes of CVD. Also a 
systematic review on available methods for the automation of food questionnaires is presented 
(Chapter 6). 
Chapter 2 presents a genetic association study based on a cohort of 940 persons at high 
cardiovascular risk from the Spanish Mediterranean area (PREDIMED-Valencia Study). In this 
study the candidate-gene approach was used to investigate whether the gene variant rs4988235, 
located nearby the lactase (LCT) gene, and strongly associated with lactase persistence in 
Europeans, was associated with obesity-related variables. Its potential modulation by 
consumption of dairy products was also examined. 
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Chapters 3-5 present three separate genetic association studies, conducted in the Potsdam 
(Germany) arm of the European Prospective Investigation into Cancer and Nutrition (EPIC-
Potsdam), a prospective cohort study with baseline measurements on 27,548 participants between 
1994-1998.  
Chapter 3 reports on the association of the gene variant rs2943634, which is located in a non-
coding region of chromosome 2q36.3 and recently has been associated with coronary artery 
disease in two GWA studies, with incident MI and IS. This association was assesed using a case-
cohort design, including a representative subsample of the total EPIC-Potsdam cohort (n = 2500) 
and all incident cases of  MI (n = 211) and IS (n = 144) that occurred during a mean follow-up 
period of 8.2 year. Furthermore, the association of this SNP with 12 available potential 
intermediate risk phenotypes of CVD was investigated  in the representative subsample of 2500 
participants. 
The study on Chapter 4 used the gene-wide approach to examine the impact of common genetic 
variation in the Stearoyl-CoA desaturase-1 (SCD1) gene, captured by means of 7 tag-SNPs and 5 
inferred haplotypes, on the modulation of 8 metabolic risk factors linked to the activity of SCD1. 
SCD1 is an enzyme involved in lipid metabolism. Its activity has been associated with traits of 
the metabolic syndrome in mice and humans, but also with the prevention of saturated fatty acids 
accumulation and subsequent inflammation, whereas for liver fat content inconsistent results 
have been reported. This study was conducted in the sample of 2500 EPIC-Potsdam participants. 
The study presented on Chapter 5 of this thesis, reports on the differential association of the 
gene variant -164T>C with CVD, according to different cholesterol cutpoints. This 
polymorphism is located in the promoter region of the gene encoding for the microsomal 
triglyceride transfer protein (MTTP). MTTP plays an important role in the assembly and 
secretion of apolipoprotein-B containing lipoproteins as chylomicrons in the intestine, and of 
very low density lipoproteins in the liver. MTTP is regulated by cholesterol. The study was 
conducted following a case-cohort design within the EPIC-Potsdam cohort (193 incident 
myocardial infarction cases , 131 incident ischemic stroke cases and 1978 non-cases). Further, 
the Heinz Nixdorf Recall Study (30 CVD cases and 1,188 controls) was used to replicate 
findings. While the PhD candidate did not lead this study, she actively participated on it by 
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performing the genotyping work and providing critical revision of the article for important 
intellectual content. 
In Chapter 6 of this thesis, a state-of-the-art review of software applications for automating the 
most commonly used dietary surveys in nutritional research, that is FFQs and 24hDR, is 
presented. 
Although results  and conclusions from each study are discussed in the separate chapters, 
Chapter 7 compiles the main findings of the work presented, and discusses some methodological 
issues. Chapter 8 enumerates the mean conclusions derived in this thesis. 
During the predoctoral training period, besides the studies presented in the compendium of 
publications that conforms this thesis, the PhD candidate had the opportunity to conduct 
additional genetic association studies and also to work in the field of biomedical informatics 
applied to nutrigenetic research. As a result, she obteined the “Diploma de Estudios Avanzados” 
degree, granted by the Universitat de València, Spain. Additionally she wrote several 
comunications for Spanish and international congresses. Although it is beyond the scope of this 
PhD thesis to provide a detailed description of this additional work, Chapter 9 summarizes its 
main objectives, and the publicacions that derived from it. 
Finally it is worth mentioning that during the development of this thesis, the PhD candidate had 
the opportunity to complete her education, by actively collaborating in field work tasks derived 
from epidemiological studies running at the University of Valencia, such as recruitment of 
participants, administration and processing of questionnaires (dietary, socio-demographic, life-
style), collaboration in interventional studies, DNA extraction, genotyping, etc. 
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ABSTRACT  
The single nucleotide polymorphism (SNP) upstream (-13910C>T; rs4988235) from the lactase 
(LCT) gene, strongly associated with lactase persistence (LP) in Europeans, is emerging as new 
candidate for obesity. Our aim was to analyze the association of the rs4988235 with obesity-
related variables as well as its modulation by dairy product intake in an elderly population. We 
studied 940 white subjects (aged 67+/-7 years) from the Spanish Mediterranean population. Dairy 
product consumption was assessed by a validated questionnaire. Anthropometric variables were 
directly measured, and metabolic-syndrome (MetS) related variables were obtained. Prevalence 
of the CC genotype [lactase non-persistent (LNP)] was high (38.0%). CT (LP) and TT (LP) were 
45.7% and 16.3%, respectively.  The CC genotype was not associated with lower milk or dairy 
product consumption in the population as a whole. Only in women was dairy product 
consumption significantly lower in CC. The most important association was obtained with 
anthropometric measurements. CC individuals presented lower weight (P=0.032), lower BMI 
(29.7+/-4.2 vs. 30.6+/-4.2 Kg/m2; P=0.003) and lower waist circumference (101.1+/-11.8 vs. 
103.5+/-11.5 cm; P=0.005) than T-allele carriers. Obesity risk was also significantly higher in T-
allele carriers than in CC individuals (OR: 1.38; 95% CI: 1.05-1.81; P=0.01) and remained 
significant after adjustment for sex, age, diabetes, physical activity and energy. Dairy lactose 
intake modulated these associations, being higher with higher lactose intake. No significant 
associations with lipids, blood pressure or MetS were obtained. In conclusion, despite not finding 
marked differences in dairy product consumption, the CC genotype was strongly associated with 
obesity in this Mediterranean population. 
 
 
Key words: Lactase, obesity, gene, dairy products, metabolic syndrome, Mediterranean  
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INTRODUCTION 
The association of dairy food consumption with obesity and other cardiovascular risk factors has 
been investigated in several studies, but with contradictory results (1-6). A beneficial effect of 
dairy consumption on the incidence of various metabolic syndrome components (including 
obesity, glucose intolerance, hypertension, and dyslipidemia) was reported by Pereira et al (1) in 
the CARDIA study and replicated in some (2-4), but not all (5,6) subsequent studies. Some meta-
analyses carried out for this purpose reflect the inconsistency of results and underline the need to 
analyse the different factors involved in greater depth (7-9). One of the potential factors that may 
affect the quantity of milk consumed as well as the effects of dairy products on obesity and 
obesity-related variables in adults is lactose intolerance or lactase non-persistence (LNP). Lactose 
intolerance is the syndrome of diarrhea, abdominal pain or flatulence, occurring after lactose 
ingestion (10). These symptoms, caused by a decreased ability to hydrolyze lactose due to a 
deficiency in the enzyme lactase, may have an influence in the amount of dairy product 
consumed. On the other hand, if there is no restriction of dairy products in LNP subjects, the 
undigested lactose may have several metabolic effects that may be related to obesity. 
Lactase is coded by the lactase gene (LCT), and LCT activity remains high until weaning, then it 
fades away in most of the adult population (adult-type hypolactasia or LNP). A single nucleotide 
polymorphism (SNP) (rs4988235), located at -13910 bp upstream from the LCT gene (-13910C > 
T) within intron 13 of the adjacent minichromosome maintenance 6 (MCM6) gene was found to 
be associated with LNP (11). Various studies (11-13) have demonstrated that the -13910C > T 
SNP is functional and is associated with changes in LCT gene expression.  Individuals 
homozygous for the C allele (LNP) have almost undetectable levels of intestinal lactase 
production compared to TC or TT individuals [lactase persistent (LP), following a codominant 
model] (11). Pohl et al (14) found an excellent agreement between the lactose hydrogen test (10) 
and the genetic test based on this SNP for LNP in Europeans. The frequency of LP is high in 
northern European populations, decreases across southern Europe and more than half of the 
world’s population is LNP (15). Although some studies have associated the CC genotype with a 
lower consumption of milk (16-18), this association is not always observed (19-21). 
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Interestingly, the LCT gene is emerging as a new candidate gene related with obesity and other 
anthropometric measurements. Hence, in a recent Genome-Wide Association Study (GWAs) 
carried out by CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology), the 
Consortium (22) found a strong association between various SNPs in the LCT gene and waist 
circumference. Likewise, Kettunen et al (23), undertook a meta-analysis on eight European 
cohorts (in which the Mediterranean population was not included) finding a strong association 
between the LP variant (T allele, rs4988235) and higher body mass index (BMI). However, none 
of the published studies has analyzed the joint influence of the LP genotype and dairy product 
consumption on obesity. Therefore, our aim was to study the association of the -13910C > T SNP 
with obesity and obesity-related variables as well as its modulation by lactose intake in an elderly 
Mediterranean population. 
MATERIAL AND METHODS 
Subjects and study design 
We included 940 unrelated White individuals (338 men and 602 women), mean age 67.3+/-6.5 
years, who participated in the PREDIMED (Prevención con Dieta MEDiterránea) study, were 
consecutively recruited in the Valencia Region (on the East Mediterranean coast of Spain) from 
October 2003 to December 2008 and had the lactase genotype determined. All participants gave 
their informed consent. The ethics committee of the University of Valencia approved the study. 
Details of this study have been previously reported (24). Briefly, high cardiovascular risk subjects 
were selected by physicians in Primary Care Centers participating in the study. Eligible subjects 
were community-dwelling people (55-80 years of age for men; 60-80 years of age for women) 
who fulfilled at least one of two criteria: type 2 diabetes; 3 or more cardiovascular risk factors 
(current smoking, hypertension, dyslipidemia, overweight, or a family history of premature 
cardiovascular disease).  
Demographic, anthropometric and clinical measurements 
The baseline examination included assessment of standard socio-demographic factors, clinical, 
biochemical and lifestyle variables, as previously detailed (24). Anthropometric variables were 
directly measured by trained nurses by standard techniques at baseline (24). Height and weight 
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were measured with light clothing and no shoes. Obesity was defined as BMI>=30kg/m2. Waist 
circumference was measured midway between the lowest rib and the iliac crest using an 
anthropometric tape. Trained personnel measured blood pressure with a validated semi-automatic 
sphygmomanometer (Omron HEM-705CP, The Netherlands) in a seated position after a 5-min 
rest. Physical activity was estimated by the Minnesota Leisure Time Physical Activity as 
previously reported (24). Blood samples were obtained for each participant after an overnight fast 
and were frozen at -80ºC. Fasting glucose, total cholesterol, triglycerides, HDL-C and LDL-C 
were determined as previously reported (24). The metabolic syndrome was defined according to 
updated ATP III criteria (25), which require that 3 or more of the following conditions be met: 
abdominal obesity (waist circumference >102 cm in men and >88 cm in women), 
hypertriglyceridemia (triglycerides level 150 mg/dL), low HDL cholesterol level (<40 mg/dL in 
men and <50 mg/dL in women), elevated fasting blood glucose level (100 mg/dL), and elevated 
blood pressure (systolic 130 mm Hg, diastolic 85 mm Hg, or taking antihypertensive medication). 
Participants who were being treated with antidiabetic, antihypertensive, or triglyceride-lowering 
medications were considered to be diabetic, hypertensive, or hypertriglyceridemic, respectively. 
Dietary measurements 
Food consumption was determined by a validated (26, 27) semi-quantitative 137-item food 
frequency questionnaire (FFQ). Energy and nutrient intake were calculated from Spanish food 
composition tables (28). Lactose content was not available in the Spanish tables and so foreign 
food composition tables were used (Fineli Food Composition Database, Finland, release 2010). 
The questionnaire was based on the typical portion sizes that were multiplied by the consumption 
frequency for each food.  Information about dairy products was assessed in fifteen items of the 
semi-quantitative FFQ (whole-fat milk, partially skimmed milk, skimmed milk, condensed milk, 
whipped cream, yoghurt, skimmed yoghurt, milkshake, ricotta cheese or junket, petit Suisse 
cheese, spreadable cheese wedges, cottage cheese, other cheese, custard, and ice cream). We 
calculated total dairy products intake (in g/d) for each individual on the basis of the type and 
amount consumed. 
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DNA extraction and genotyping 
Genomic DNA was isolated from blood. The rs4988235 LCT SNP was determined using a 
7900HT Sequence Detection system (Applied Biosystems) and a customized fluorescent allelic 
discrimination TaqMan assay by standard procedures. For quality control purposes, 50% of 
randomly selected samples were also genotyped by restriction fragment length polymorphism 
analysis. Concordance between techniques was higher than 95%. Discrepant samples were 
sequenced. Information on probes and polymerase chain reaction conditions for genotyped single 
nucleotide polymorphisms can be obtained from the authors upon request. 
Statistical analysis 
X2 tests were used to test differences in percentages. Taking into account that the genetically 
defined LP is considered to follow a dominant model, CT and TT subjects (LP) were grouped and 
compared with CC subjects for the statistical analysis after having checked that this dominant 
model is observed in this Mediterranean population. We applied the t tests to compare crude 
means for normally distributed variables. Alcohol and dairy product consumption did not follow 
a normal distribution and we applied the non-parametric Mann-Whitney U test. For continuous 
anthropometric variables, multivariate adjustment was carried out by linear regression analysis. 
Model were adjusted for sex, age (as continuous), diabetes, total energy intake (as continuous) 
and physical activity (as continuous). Additional adjustment for dairy product consumption was 
also done. Multivariate adjustment of plasma lipids, fasting glucose and blood pressure was also 
carried out by linear regression. Regression coefficients and adjusted means for each predictor 
were estimated from the multivariate models. Regression models with interaction terms and as 
well as stratified analysis were applied to test the homogeneity of effects by gender and lactose 
intake. Logistic regression models were fitted to estimate the odds ratio (OR) and 95% 
confidence interval (CI) of obesity and obesity-related variables associated with the LP genotype 
compared with LNP. Multiple logistic regression models were also fitted to check for the effect 
of covariates and effect modifiers as well as to test the interaction between the SNP and selected 
variables. Analyses were performed using the SPSS statistical software, version 17.0 (SPSS Inc, 
Chicago, Illinois). 
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RESULTS 
Table 1 shows general characteristics of the study subjects by gender. Prevalence of obesity, 
diabetes and metabolic syndrome was high given that this study involved a population that was 
selected for being elderly and with a high cardiovascular risk. Total dairy product consumption 
was higher in women than in men (395.2+/-229.6 g/d vs. 322.3+/-193.9 g/d, respectively; 
P<0.001). Men consumed a greater amount of whole-fat milk (43.1+/-123.1 g/d vs. 35.3+/120.3 
g/d; P=0.040), whereas women consumed more skimmed milk (114.8+/-191.0 g/d vs. 77.3+/-
145.0 g/d; P=0.035). Women consumed a significantly greater amount of skimmed yoghurt 
(P<0.001), and there were no significant differences between men and women in the amount of 
whole-fat yoghurt consumed. Likewise, total cheese intake did not differ between men and 
women. The amount of lactose intake derived from dairy products was also significantly higher 
in women than men (P=0.01). However, there were no significant differences in the percentage of 
men and women who claim never to consume milk (14.2% vs. 14%; P=0.994).  
Prevalence of the LCT -13910 C>T genotypes were: CC (LNP) 38.0% (n=357), CT 45.7% 
(n=430) and TT 16.3% (n=153). Carriers of the T allele were the genetically determined LP 
subjects. This distribution was in Hardy-Weinberg equilibrium (P=0.221) and did not differ 
between men and women (P=0.577).   
Association between the rs4988235 SNP and dairy product intake 
Table 2 shows mean intake of milk and dairy products (total and by gender) depending on the 
LCT -13910 C>T genotypes.  The results are shown grouping the T carriers together (LP) and 
comparing them with CC subjects (LNP). Total energy intake did not differ between CC and 
subjects carrying the T- allele. Likewise, we did not find significant differences in physical 
activity depending on the LCT genotype (not shown). On analysing the results for men and 
women jointly, it is observed that although diary product consumption tended to be lower in CC 
subjects, the differences did not reach statistical significance.  Neither was the total consumption 
of milk or the contribution of lactose or calcium through dairy products lower. Statistically 
significant differences were only reached in the consumption of skimmed yoghurt, which was 
lower in CC subjects.  
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On analysing the results per gender, it can be observed that in men the differences in milk and 
dairy product intake depending on genotype were minimal and did not reach statistical 
significance for any comparison. In women, these differences were more accentuated; reaching 
statistical significance in the consumption of skimmed yoghurt (lower in CC subjects) and when 
the consumption of skimmed yoghurt, skimmed milk and partially skimmed milk were analyzed 
together (265.1 +/- 207.9 g/d vs. 317.6+/-239.2 g/d in CC vs. CT+TT; P=0.014). Likewise, the 
total consumption of dairy products also reached statistically significant differences in women 
depending on the LCT genotype (P=0.045). No significant differences of lactose intake were 
observed. 
Association between the rs4988235 SNP with anthropometric variables 
On studying the relationship between the LCT genotype and anthropometric measurements 
(Table 3), we observed that this SNP presented a strong association with BMI and with waist 
circumference. CC individuals, although they do not differ in height from the other genotypes, 
presented less weight, a lower BMI and less waist-circumference than T-allele carriers. These 
differences remained statistically significant when the models were adjusted for gender and age, 
and even after additional adjustment for diabetes, physical activity and total energy intake. These 
associations are homogeneous by gender, and both in men and women CC subjects have lower 
means of anthropometric measurements than T-allele carriers (P for interaction LCT genotype x  
gender >0.05 for all the anthropometric variables). 
Next, we analyzed the association of the LCT genotype with obesity (Table 3). Considering CC 
individuals as the reference category, we observed that T-allele carriers have a greater risk (OR) 
of obesity, both unadjusted (OR: 1.39; 95% CI: 1.07-1.82; P=0.014) and after adjustment for 
gender, age, diabetes, physical activity and total energy intake (OR: 1.37; 95% CI: 1.03-1.81; 
P=0.029). Homogeneity by gender was also observed between men and women in this 
association (P for interaction LCT x gender>0.05). Subsequent adjustments for dairy product 
intake do not modify the statistical significance of the associations of the LCT -13910 C>T SNP 
with the anthropometric variables (not shown).   
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Modulation of the association between the rs4988235 SNP with anthropometric variables 
by lactose intake 
Considering that CC subjects may tolerate low amounts of lactose intake without gastrointestinal 
symptoms, we hypothesized that a higher lactose intake may modulate the effects of the 
rs4988235 SNP on anthropometric variables. We first tested the interaction effect between the 
rs4988235 SNP and dairy lactose intake as continuous. Taking into account that lactose intake 
was not normally distributed, eight identified outliers (corresponding to 8 TC+TT subjects with 
lactose intake higher that 50g/d) were removed to improve normality for this linear regression 
analysis.  A statistically significant interaction term between lactose intake and the LCT -13910 
C>T SNP in determining waist circumference was found (P=0.044 after adjustment for sex, age, 
diabetes, total energy intake and physical activity). According to this interaction, a higher dairy 
lactose intake increases the differences in waist-circumference between CC and CT+TT 
individuals (Figure 1 A). We also tested this modulation by lactose intake as categorical variable. 
Three categories of lactose intake based on habitual equivalents of milk consumption were 
considered (Figure 1B). If lactose intake was low [less than one small cup per day (<=8 g 
lactose/d)], we did not find significant differences in waist-circumference between CC and T-
allele carriers (P=0.808). When lactose intake was higher [between 1 and 2 small or large cups of 
milk per day (8-24 g lactose/d)], significant differences in waist circumference between LCT 
genotypes were detected (P=0.012). These differences increased in magnitude when higher 
intakes of lactose were observed [more than 2 large cups of milk per day (>24 g lactose/d)]. 
 In terms of obesity risk, in subjects with a low lactose intake (<=8 g/d) we did not find 
significant association between the LCT -13910 C>T SNP and obesity in the unadjusted model 
(OR=1.03, 95%CI: 0.55-1.912; P=0.910) or the model adjusted for sex, age, diabetes, physical 
activity and total energy intake. However, when lactose intake was higher (>8 g/d), we did 
observe a significant association of the CT+TT genotype with higher obesity risk (OR: 1.50, 
95%CI: 1.10-2.03; P=0.012). 
Association between the rs4988235 SNP with the metabolic syndrome related variables 
 Finally, we studied the association of the LCT genotype with biochemical parameters 
(fasting glucose, and plasma lipids), and blood pressure (Table 4) and observed that, after 
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adjustment for BMI, there were no statistically significant differences in total cholesterol 
concentrations, LDL-C, HDL-C, TG, fasting glucose and blood pressure between CC subjects 
and T-allele carriers. Likewise, when we analyzed the association of the LCT genotype with the 
Metabolic syndrome, taking CC individuals as the reference category, although the magnitude of 
the OR in T-allele carriers was greater than 1, it did not reach statistical significance, either in the 
crude model, or after adjustment for gender and age  (OR: 1.26; 95%CI: 0.94-1.67). 
DISCUSSION 
In this study carried out on an elderly Mediterranean population, we have detected a high 
prevalence of CC individuals (LNP) in contrast to that found in northern European populations, 
where the opposite situation is reported (15,29). Although the effect of this genotype on the 
differences of milk and dairy produce consumption is not very high in the population as a whole, 
the association that we have found with anthropometric measurements is particularly relevant. In 
this Mediterranean population, CC individuals present lower BMI, lesser waist circumference and 
lower risk of obesity than T-allele carriers even after adjustment for sex, age, diabetes, physical 
activity and total energy intake. These results are in line with the results obtained in a recently 
published meta-analysis (23) that reported novel evidence of association between genetically 
defined LP and BMI (P = 7.9*10-5) in 31,720 individuals from four European populations. 8 
cohorts were included in this study, 5 of which were of Finnish origin, and the others from 
Holland and England, without including a Mediterranean population. They observed that the CC 
genotype was associated with decreased BMI compared to CT/TT genotypes in the meta-
analysis, and that this effect was observed in the same direction for both men and women. They 
also observed that this effect was due to the influence of the genotype on weight and not on 
height and discarded population stratification as being responsible for these effects. In our study, 
the probability of the influence of population stratification is very low, as we carried it out on 
White subjects recruited in a single region of Spain with a homogenous ethnic background. 
Moreover, another study undertaken on a sample recruited in another Spanish region (Catalonia) 
obtained a similar frequency of genotypes (30). In that study, aimed to investigate the association 
of the LCT SNP with osteoporosis phenotypes in 944 postmenopausal Spanish women, the 
researchers also found a significant association of the LCT SNP with weight. Hence, TT women 
were 1.91 kg heavier than CT+CC women, adding consistency to the association found in our 
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study. However, in that same study, the researchers did not analyse the possible differences in 
waist circumference or obesity risk associated with the LCT SNP, our study being the first to 
report such associations in a Mediterranean population.   
Furthermore, our results are also the first to replicate the observations of the CHARGE 
Consortium, where strong associations were found between various SNPs in the LCT gene and 
waist-circumference (22). In line with those observations, a study carried out by  Almon et al on 
551 individuals of the general population of the Canary Islands (31), found that the prevalence of 
central obesity was higher in CT+TT (62%) individuals than in CC individuals (55.9%). 
However, those differences did not reach statistical significance possibly due to a smaller sample 
size.   Nevertheless, what they did observe was a greater risk of metabolic syndrome in CT+TT 
individuals than in CC individuals (OR: 1.56;  95%CI: 1.06–2.31). In our study, carried out on a 
Mediterranean population, and despite the tendency of the association with metabolic syndrome 
being similar to that observed in the Canary islands, our results did not reach statistical 
significance, given that we observed the effects of the SNP mainly on anthropometric 
measurements and not on lipid concentrations or blood pressure. The differences observed 
between these two studies may be due to the different ages of the population and associated risk 
factors. Thus, although in the study carried out in the Canary Islands CC individuals were found 
to consume less milk than  CT+TT  individuals (246 vs. 300 g/d; P<0.05), our study found no 
significant differences in the amount of total milk consumed by carriers of these genotypes. 
Possibly, on dealing with an elderly population in which calcium requirements are greater to 
minimize osteoporosis, medical advice recommending higher milk consumption may have a 
greater influence, that recommendation offsetting the genetic influence.  
Other studies that have analysed the influence of the LCT SNP on milk and dairy product 
consumption have also found differing associations depending on the age and gender of the 
population analysed (16-20). In general, it seems that the influence of the LCT genotype on dairy 
consumption is higher in women than in men (32, 33). So, for example, in the study carried out 
by Laaksonen et al in Finland (17), it was observed that until the age of 12 years, the 
consumption of milk and milk products in males with the C/C and C/T213910 genotypes was 
very similar and lower than for the T/T 213910 genotype. In females with the C/C213910 
genotype, milk and milk product consumption was lowest from the age of 6 years. In our study, 
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CC women presented lower skimmed and semi-skimmed milk consumption than T-carriers, as 
well as a lower total dairy product consumption, which was not observed in men.  One possible 
explanation could be that females and males differ in their sensitivity to gastrointestinal 
symptoms caused by mal-digested lactose. Previous studies have shown that women with lactose 
mal-digestion may experience stronger symptoms than men with lactose mal-digestion (34).  
Another possible explanation could be that as men consume less milk than women, the amount of 
lactose does not pose a problem even for the lactase non-persistent, as it has been reported that 
gastrointestinal symptoms of intolerance to lactose are not severe until consuming amounts 
greater than 12 g of lactose/day (approximately 1 cup of milk) (35-36). The symptoms of lactose 
intolerance result from bacterial fermentation of undigested lactose in the colon (10). Various 
studies have shown differences in the microbial composition of fecal samples of the LP and LNP 
groups (37, 38). For example, Szilagyi et al (38), observed that lactose mal-digesters had a mean 
change difference (0.72 log10 colony forming units/g stool; P=0.04) in bifidobacteria counts 
compared with lactose digesters. Lactobacilli counts were also increased. Bearing in mind that 
recent studies have shown differences between the gut microbiota in obese and non-obese 
individuals (39, 40), changes in the gut microbiota may be involved in the lower risk of obesity 
observed in CC individuals, due to differing lactase fermentation capacity. This hypothesis, as 
well as the identification of additional mechanisms to explain the association of the LCT SNP 
with anthropometric measurements, requires further studies in order to substantiate it. Supporting 
this hypothesis is our observation of a possible greater effect of the LCT SNP on anthropometric 
measurements when the amounts of lactose consumed are greater.   
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LEGENDS TO FIGURES 
Figure 1 Modulation by dairy lactose intake of the association between the LCT %13910C>T 
polymorphism and waist circumference (cm) in the elderly Mediterranean population.  
(a) Predicted values of waist circumference by the LCT %13910C>T  
(b) Adjusted means of waist circumference (cm) in the study subjects (n = 940) depending on the 
LCT %13910C>T polymorphism according to three strata of lactose intake: low (&8 g 
lactose/day; 20% of the population (n = 68 CC, 122 CT+TT)), intermediate (8–24 g lactose/day; 
50% of the population (n = 188 CC, 284 CT+TT), and high (>24 g lactose/day; 30% of the 
population (n = 101 CC, 177 CT+TT).  
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ABSTRACT 
Background: rs2943634 C/A single nucleotide polymorphism (SNP), located in a non-coding 
region of chromosome 2q36.3, has been associated with coronary artery disease in two genome 
wide association studies. Our goal was to investigate its relation with myocardial infarction (MI) 
and ischemic stroke (IS), as well as with 12 intermediate risk phenotypes, in a population-based 
prospective cohort study.  
Methods: rs2943634 was genotyped in a case-cohort study including a random sample of 1891 
individuals (subcohort) and all incident MI (n = 211) and IS (n = 144) cases during a mean 
follow-up of 8.2 ± 2.2 years, nested within the European Prospective Investigation into Cancer 
and Nutrition (EPIC)-Potsdam cohort comprising 27548 middle-aged men and women. 
Results: rs2943634 minor allele (A) was associated in an additive fashion with lower risk of IS 
but not with MI [hazard ratio (HR) = 0.66; 95% confidence interval (CI): 0.50-0.87; P = 0.003; 
HR = 1.02; 95% CI: 0.82-1.28; P = 0.83 respectively, for the age and sex adjusted model]. 
Furthermore, it was related to slightly higher levels of plasma adiponectin [CC 6.94, CA 7.27, 
AA 7.86 µg/ml, P = 0.0002] and high density lipoprotein (HDL)-cholesterol (CC 52.08, CA 
53.05 and AA 55.27 mg/dl, P = 0.002), based on additive models. Adjustment for adiponectin 
and HDL-cholesterol did not attenuate the association between the SNP and IS risk. In contrast, 
adjustment for adiponectin abolished the association between the SNP and HDL-cholesterol and 
adjustment for HDL-cholesterol attenuated the association between the SNP and adiponectin. 
Conclusions: Our findings suggest that rs2943634 is associated with IS risk and with plasma 
levels of HDL-cholesterol and adiponectin in this German population. Further investigations are 
needed to confirm these results and to clarify the mechanisms underlying the association.3.1.  
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INTRODUCTION 
rs2943634 C/A single nucleotide polymorphism (SNP) is located in a non-coding region on 
Chromosome 2q36.3, however the Welcome Trust Case Control Consortium (WTCCC) Study, 
which enrolled 1926 coronary artery disease (CAD) cases and 2938 controls of white European 
origin, imputed an association between its most frequent allele (C) and CAD (1). Authors could 
reproduce the association in the German myocardial (MI) family study which involved 875 MI 
cases and 1644 controls (1), however, further replication studies have not been able to confirm 
this association (2-7). Ischemic stroke (IS) shares common physiopathological mechanisms with 
MI due to atherosclerotic disease (8). Thus rs2943634 has been investigated on its relationship 
with IS (2) and carotid artery intima-media thickness, a subclinical marker of atherosclerosis 
associated with stroke (9), with no significant results. Association data between rs2943634 and 
intermediate risk phenotypes of cardiovascular diseases is scarce and inconsistent (1, 2, 9), 
although significant associations have been reported with body mass index (BMI) (1), blood 
pressure (2), low density lipoprotein (LDL) cholesterol (1) and high density lipoprotein (HDL) 
cholesterol (2). In the present study our goal was to investigate the association of rs2943634 with 
MI, IS, both cardiovascular diseases (CVD) combined, and with intermediate risk phenotypes 
that may implicate causal pathways, in a middle-aged population. 
METHODS 
Study population 
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort 
comprises 27548 men and women from the general population of the Potsdam area in Germany, 
mainly aged 35–65 years at recruitment (1994–1998) (10). The associations of rs2943634 with 
risk of MI, IS and CVD were analysed using a case-cohort design. With this type of study design, 
the results are expected to be generalizable to the entire cohort (11, 12). The study population 
included a random sample of 2500 individuals (subcohort) and all newly occurred MI and IS 
cases from the EPIC-Potsdam cohort verified during a mean follow-up of 8.2 ± 2.2 years. 
Identification and verification of incident cases have been described in detail before (13). Of 
individuals who had both, MI and IS, we considered only the first event. After exclusion of 
individuals with a history of MI or IS at baseline, and those without fully obtained follow-up data 
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or with missing biomarkers, covariates or genotype data, the final study population comprised a 
subcohort of 1887 participants and a total of 211 MI cases,144 IS cases, (21 MI cases and 20 IS 
cases belonging to the subcohort). Participants were not required to be fasted at the baseline 
assessment, however, 654 individuals did not eat for at least 8 h before the blood drawing. The 
subcohort was used in a cross-sectional study to investigate the association between rs2943634 
alleles and the following cardiovascular intermediate risk phenotypes: BMI, waist circumference 
(WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides (TG), glucose, glycated haemoglobin (Hba1c), high-
sensitivity C-Reactive Protein (hs-CRP), adiponectin and creatinine. Informed consent was 
obtained from all study participants, and approval was given by the Ethical Committee of the 
State of Brandenburg, Germany. 
Biochemical and genetic analyses 
At baseline 30 mL of venous blood was collected from all the study participants, it was 
fractionated into serum, plasma, buffy coat and erythrocytes and stored in liquid nitrogen until 
the time of analysis. All biomarkers were analysed between 2007 and 2008 at the Internal 
Medicine Department of the University of Tübingen, Germany. Plasma levels of total cholesterol, 
HDL-cholesterol, TG, hs-CRP, glucose and creatinine were determined with the automatic 
ADVIA 1650 analyser (Siemens Medical Solutions, Erlangen, Germany). LDL-cholesterol was 
determined using the Friedewald formula (14). Plasma total adiponectin was determined with an 
enzyme-linked immunosorbent assay (Linco Research, St Charles, Mo). Genotyping of whole 
genome amplified DNA samples was performed in 2008 with the TaqMan® System (Applied 
Biosystems, Foster City, CA, USA) at the Max Delbrück Center for Molecular Medicine (MDC), 
Berlin, Germany. The genotyping success rate was 99%.  
Statistical analysis 
Hardy–Weinberg equilibrium (HWE) of the SNP was tested using the '2 test. Baseline 
characteristics of the study populations were described as means ± standard deviation (SD) for 
continuous traits, medians and 25th and 75th percentiles for the skewed variables, and % for 
categorical variables. Association of the SNP with risk of MI, IS and CVD, was calculated as 
hazard ratios (HR) with 95% confidence interval (95% CI) using Cox proportional-hazard 
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regression, modified according to the Prentice method (11) to account for the case-cohort design, 
using a robust estimator for CI and considering the additive and co-dominant genetic models. 
Age was the underlying time variable in the counting processes, with entry defined as the 
individuals’ age at the time of recruitment and exit defined as age at the diagnosis of CVD, or 
censoring. Analysis of covariance considering the additive genetic model was used to assess the 
association between rs2943634 genotypes (independent variables) and BMI, WC, SBP, DBP, 
Total Cholesterol, HDL-cholesterol, LDL-cholesterol, TG, blood glucose, Hba1c, hs-CRP, 
creatinine, and adiponectin (dependent variables). Data is reported as means and standard error 
(SEM), except for TG, hs-CRP, creatinine, and adiponectin which were used log-transformed in 
order to normalize their distributions, and data is reported as geometric means and 95% CI. Also 
to better reach normality of their distributions, glucose was used squared root transformed and 
Hba1c inversed transformed, data for them is respectively reported as squared and inverse means 
and 95% CI. P for trend was calculated with a linear regression model. Association analysis 
between rs2943634 and fasting depending variables were performed only in participants who 
were fasting at the time of blood drawing. Association between adiponectin and HDL-cholesterol 
in the subcohort was examined by means of Spearman partial correlation coefficient. 
The statistical models were adjusted for sex and age. Further adjustment included known 
cardiovascular risk factors: smoking status (never smoker, former smoker, current smoker < 20 
cigarettes per day, current smoker # 20 cigarettes per day), sports activity (< 2 h/wk versus # 2 
h/wk), educational attainment (vocational school or less, technical school, university), BMI 
(continuous), WC (continuous), alcohol consumption (men: =0 g/d, >0 to 12 g/d, >12 to 24 g/d; 
>24 g/d;  women: =0 g/d, >0 to 6 g/d, >6 to 12 g/d; >12 g/d), Hba1c, systolic blood pressure, 
antihypertensive medication, total cholesterol and hs-CRP. Effect modification by sex was 
evaluated by modeling the product term sex x genotype along with main effects (in the age-
adjusted linear regression analysis). All statistical analyses were performed using the SAS 
Version 9.2 (SAS Institute, Cary, NC). The detectable odds ratio of the SNP with CVD, MI and 
IS was calculated with Quanto (http://hydra.usc.edu/GxE/) (15) concerning a log-additive model, 
a desirable power > 80%, ! = 0.05, and a baseline overall disease prevalence in the EPIC-
Potsdam population of 3.1 % for CVD (n=847), 2.0% for MI (n=544) and 1.1% for IS (n=303). 
Our estimates suggested that the detectable odds ratio were 1.26 for CVD, 1.34 for MI and 1.41 
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for IS when considering a possible harmful effect of the SNP, and 0.79, 0.75 and 0.71 
respectively when considering a possible protective effect. 
RESULTS 
Characteristics of participants 
Demographic, biochemical, clinical and lifestyle characteristics of the subcohort and incident IS 
and MI cases are given in Table 1. The genotype frequency of rs2943634 in the subcohort 
followed HWE (P = 0.80). The A allele (ancestral allele) frequency across the subcohort was 
36%, in accordance with other European populations (1, 2). No significant effect modifications 
by sex were found for the SNP on CVD, MI or IS and the studied intermediate risk phenotypes 
except for glucose (P = 0.03), for which we therefore present results further adjusted for the 
interaction term. 
Association between rs2943634 and intermediate risk phenotypes of cardiovascular diseases 
Table 2 shows results for age and sex adjusted association analysis between rs2943634 and 
intermediate risk phenotypes of cardiovascular diseases in the subcohort. No significant 
associations were found when considering BMI, WC, SBP, DBP, total cholesterol, LDL-
cholesterol, glucose, Hba1c, hs-CRP or TG. However, the rs2943634 A allele, was associated 
with increased HDL-cholesterol and adiponectin, and very modestly decreased creatinine. 
Exclusion of participants taking lipid or antihypertensive medication did not modify these results 
(data not shown). Further (mutual) adjustment for lifestyle, biochemical and socio-demographical 
variables did not modify these results. However, further adjustment of the association analysis 
between rs2943634 and HDL-cholesterol for adiponectin, abolished the association, and further 
adjustment of the association analysis between the rs2943634 and adiponectin for HDL-
cholesterol, slightly attenuated the association (Table 2). Adiponectin and HDL-cholesterol were 
positively correlated (Spearman correlation coefficient for the age and sex adjusted model: 0.44; 
P < 0.0001)  
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Association between rs2943634 and CVD, MI and IS 
Disease risk was evaluated in 355 CVD, 211 MI and 144 IS incident cases, and 1846 persons 
who remained free of cardiovascular events during follow-up. Table 3 shows HR and 95% CI, 
for the association analysis based in the co-dominant and additive models between rs2943634 and 
CVD, MI and IS, adjusted for age and sex (model 1) and further adjusted for known 
cardiovascular risk factors (model 2). No significant associations were found between the SNP 
and CVD or MI regardless of the adjusting model used. However rs2943634 minor allele A, 
presented lower risk of IS in an allele dosage fashion (HR = 0.66; 95% CI: 0.51-0.86; P = 0.002). 
Further adjustment for model 2, or for model 2 plus the intermediate risk phenotypes significantly 
associated with the SNP, HDL-Cholesterol and adiponectin (model 3) did not affect this 
association (HR = 0.66; 95% CI: 0.51-0.87; P = 0.003; and HR = 0.66; 95% CI: 0.50-0.86; P = 
0.002, respectively). 
DISCUSSION 
In this study we found a novel association between rs2943634 minor allele (A) and decreased risk 
of IS. Interestingly, this allele was also associated with slightly higher HDL-cholesterol and 
adiponectin. HDL-cholesterol has been associated with lower IS risk (16), and although in the 
scarce prospective studies available (17-21) adiponectin has been reported not to be associated 
with stroke risk, it has been proposed to be a marker of conditions that prompt to cardiovascular 
diseases (19). However, adjustment for these biomarkers, did not attenuate the association 
between rs2943634 and IS, remaining still to be elucidated the biological mechanism underlying 
this association. Adiponectin is an adipocyte-derived hormone suggested to exert antiatherogenic, 
anti-inflammatory, insulin-sensitizing and cardioprotective effects (22). It is thought to regulate 
the synthesis of HDL-cholesterol by means of the up-regulation of Apolipoprotein A-I (apoA-I) 
synthesis and secretion (23), and by the enhance of the expression of ATP-binding cassette 
transporter (ABCA1) mRNA and protein levels (24). Adiponectin has also been suggested to 
have a role in the regulation of HDL-cholesterol catabolism and remodelling mediated by 
cholesteryl ester transfer protein (CETP) and lipoprotein lipase (LPL) (25, 26), and it has been 
shown to correlate negatively with the fractional catabolic rate of ApoA-I (27). Several 
epidemiological studies have shown adiponectin to be positively correlated with HDL-cholesterol 
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(27-30). In accordance to this, adiponectin and HDL-cholesterol were positively correlated in our 
study, and when we adjusted the association analysis of rs2943634 with HDL-cholesterol for 
adiponectin, the association was abolished, suggesting the SNP might be related to HDL-
cholesterol by means of adiponectin. Besides the role of adiponectin on HDL-cholesterol 
regulation, it has recently been suggested that HDL-cholesterol exerts reciprocal effects on 
adiponectin expression and adipocyte metabolism (31). Thus, HDL-cholesterol has been seen to 
increase plasma adiponectin concentrations and enhance adiponectin expression in adipocytes in 
a phosphatidylinositol-3- kinase (PI3K) dependent manner (31). In agreement with this 
observation, when we adjusted rs2943634 association analysis with adiponectin for HDL-
cholesterol, the association was slightly attenuated. 
Since MI and IS share common risk factors, it is surprising that we found a strong association of 
the SNP with risk of IS, but not with risk of MI. However, several genetic polymorphisms (32-
36) and also established risk factors for both endpoints, including hypertension or smoking (37, 
38), also have shown to differ in their importance for the development of MI and IS. In line with 
our results for MI, no replication studies have been able to confirm the association between 
rs2943634 and CAD (2-7) after it was first suggested by the WTCCC study and replicated in the 
German MI family study (1). Thus, not the three case-control replication studies with European 
[3] Tunisian [5] and Caucasian from the Cleveland genebank (6) populations, nor a biracial, 
prospective cohort study of US persons (7) reported significant results. Further, a case-cohort 
study on the effect of rs2943634 on incident CHD and stroke, based on five cohorts within the 
MORGAM project (from Finland, Sweden, France and Northern Ireland), and including a 
subcohort of 2341 participants, 1436 incident CHD cases and 571 incident stroke cases, also 
found no significant associations with cardiovascular endpoints (2). This study is in addition the 
only previous to investigate the effect of the SNP on incident stroke, and its results are 
inconsistent with ours for this outcome (2). Unfortunately, authors do no provide separate risk 
estimates for the five European cohorts, thus although adjusted for the different cohorts, we 
cannot exclude that results might be driven by the two Finish cohorts, since they represent 80% 
of the study population. Also in contrast with our study, 88% of the participants were men, nearly 
half of them belonged to cohort of smokers (39), and the average age was 60.5 years. In our 
study, participants are of German origin, only 37% are men, the average age is 10 years younger, 
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and only 21% are current smokers. Perhaps these differences may have played a role in the 
inconsistent results. 
rs2943634 was not associated with BMI, WC, SBP, DBP, total cholesterol, LDL-cholesterol, 
glucose, Hba1c and hs-CRP in our study population. Concerning the associations between 
rs2943634 and these intermediate risk phenotypes, results across studies are also inconsistent. 
Thus, rs2943634 has been reported to be associated with BMI, LDL-cholesterol (1) and blood 
pressure (1, 2). and not be associated with HDL-cholesterol (6, 9), however, and in line with our 
results, rs2943634 minor allele (A) has also been reported not to be associated with blood 
pressure, BMI, WC, cholesterol, hs-CRP (9), LDL-cholesterol and TG (6, 9), and to be associated 
with higher HDL-cholesterol (1.05 mg/dL increase per allele) (2). We are the first to report 
association analysis results between rs2943634 and adiponectin, glucose, Hba1c and creatinine. 
Strengths and limitations of our study should be mentioned. The prospective design may include 
other cases than case-control studies and thereby come up with new insights into the relationship 
between genetic information and disease risk. The risk factors were assessed at baseline only, 
therefore, we assumed that these variables remained stable over time; fasting data was available 
only for about one third of the population, thus, association analysis for TG, LDL-cholesterol and 
glucose were performed in this reduced sample. Our study sample consisted of a modest number 
of incident MI cases (n = 211), however, given that the estimated hazard ratios for MI were close 
to 1.0 regardless of the adjusting model used or the heritage model considered, we believe the 
lack of association of the SNP with MI in our population was not derived from insufficient 
statistical power. Finally, all the reported significance levels were nominal p values and were not 
adjusted for multiple comparisons, however after stringent Bonferroni correction for the testing 
of multiple hypotheses (Pcorrected <0.003) results for IS, adiponectin and HDL-cholesterol 
remained significant. 
CONCLUSIONS 
rs2943634 minor allele A was associated with lower risk of IS in this European population but 
not by means of the classic risk factors investigated in this study. rs2943634 was also related to 
plasma levels of adiponectin and HDL-cholesterol. However, considering the inconsistent results 
across studies, these findings need to be replicated in further investigations. 
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Table 1. Baseline characteristics in EPIC-Potsdam subcohort, incident MI and IS cases. 
 Subcohort MI cases IS cases 
 (N = 1891) (N = 211) (N = 144) 
Men (%) 36.62 72.51 49.31 
Age (year) 50.13 ± 9.03 55.79 ± 7.10 56.64 ± 8.05 
Smoking status (%):    
Current #20 cigarettes/d 6.09 20.38 8.33 
Current <20 cigarettes/d 14.85 23.22 15.28 
Former &5 years 7.15 6.16 3.47 
Former >5 years 24.27 22.75 29.86 
Never 47.64 27.49 43.06 
Use of medication (%)    
Antihypertensive 17.22 30.81 35.42 
Lipid lowering medication 4.03 7.11 8.33 
Educational attainment (%):    
Vocational school or less 37.41 39.81 42.36 
Technical school 24.54 20.38 30.56 
University degree 38.05 39.81 27.08 
Physical activity (h/w):    
< 2 76.21 80.57 83.33 
# 2 23.79 19.43 16.67 
Alcohol intake (%):    
Men: = 0 g/d; women: = 0 g/d  0.00 0.00 0.00 
Men: > 0-12 g/d; women: >0-6 g/d  47.32 57.35 47.92 
Men: >12-24 g/d; women: >6-12 g/d  25.28 18.48 23.61 
Men: > 24 g/d; women: > 12 g/d 27.40 24.17 28.47 
Body mass index (kg/m2) 26.02 ± 4.31 27.66 ± 4.02 26.70 ± 4.07 
Waist circumference (cm)    
Men 94.06 ± 10.16 97.37 ± 10.05 95.09 ± 11.55 
Women 80.59 ± 11.62 86.31 ± 11.96 83.74 ± 11.16 
Systolic blood pressure (mm/Hg) 129.09 ± 17.66 139.69± 18.46 140.50 ± 19.99  
Diastolic blood pressure (mm/Hg) 83.55 ± 10.78 87.91 ± 11.12 88.49 ± 10.47 
Total cholesterol (mg/dl) 173.85 ± 36.50 190.18 ± 39.39 175.03± 40.06 
HDL-cholesterol (mg/dl) 52.96 ± 14.25 45.42 ± 13.92 50.13 ± 15.82 
LDL-cholesterol (mg/dl)a 108.56 ± 29.76  125.73 ± 30.21 108.74 ± 31.22  
Triglycerides (mg/dl)b 101.20 (71.50; 148.50) 139.70 (90.20; 215.60) 113.30 (77.00; 183.70)
Blood glucose (mg/dl) 95.43 (88.25; 104.70) 99.86 (91.21; 110.20) 97.53 (86.76; 114.28)
HbA1c (%) 6.37 (6.09; 6.73) 6.67 (6.39; 7.07) 6.58 (6.29; 7.11) 
Hs-C-reactive protein (mg/l) 6.60 (2.20; 20.90) 15.40 (5.50; 35.20) 9.90 (3.30; 34.10) 
Adiponectin (ng/ml) 7.44 (5.30; 10.27) 6.04 (4.60; 8.90) 7.37 (5.44; 10.88) 
Creatinine (mg/dl) 0.71 (0.62; 0.81) 0.79 (0.70; 0.90) 0.71 (0.64; 0.84) 
Mean ± SD or %. a, Due to missing fasting data, LDL-cholesterol, TG and glucose are based on 543 subcohort individuals, 68 MI cases, and 55 IS 
cases. b, Median (25th percentile; 75th percentile), all such values. MI indicates myocardial infarction, IS indicates ischemic stroke. 
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Table 2. Associations between rs2943634 polymorphism and cardiovascular diseases 
intermediate risk phenotypes in the EPIC-Potsdam subcohort. 
 CC CA AA P add 
Characteristics (N = 767) (N = 876) (N = 244)  
Body mass index (kg/m2)a 26.18 ± 0.15 25.88 ± 0.14 26.02 ± 0.27 0.29 
Waist circumference (cm)     
Men 94.45 ± 0.61 93.57 ± 0.53 94.92 ± 1.13 0.82 
Women 80.72 ± 0.49 80.69 ± 0.48 79.83 ± 0.85 0.46 
SBP (mm/Hg)  129.18 ± 0.59 129.07 ± 0.55 128.92 ± 1.04 0.82 
DBP (mm/Hg) 83.66 ± 0.38 83.54 ± 0.35 83.26 ± 0.67 0.62 
Total Cholesterol (mg/dl) f174.80 ± 1.27 173.07 ± 1.19 173.67 ± 2.26 0.40 
HDL-cholesterol (mg/dl) 52.08 ± 0.49 53.05 ± 0.46 55.27 ± 0.87 0.002 
HDL-cholesterol (mg/dl)b 52.47 ± 0.46 52.99 ± 0.43 54.39 ± 0.81 0.06 
LDL-cholesterol (mg/dl)c 109.55 ± 2.04 108.64 ± 1.76 105.46 ± 3.43 0.35 
Triglycerides (mg/dl)d 94.81 (88.14-101.98) 83.11 (78.02-88.52) 94.29 (83.45-106.55) 0.28 
Blood glucose (mg/dl)e, f 98.97 (91.03-107.24) 96.10 (92.73-99.52) 92.22 (79.48-105.91) 0.56 
HbA1c (%) g 6.47 (6.42-6.51) 6.43 (6.39-6.47) 6.41 (6.33-6,49) 0.15 
Hs-C-reactive protein (mg/l) 7.59 (6.89-8.36) 6.94 (6.34-7.60) 7.93 (6.68-9.42) 0.84 
Adiponectin (µg/ml) 6.94 (6.72-7.17) 7.27 (7.05-7.49) 7.86 (7.43-8.33) 0.0002 
Adiponectin (µg/ml)h 7.01 (6.80-7.23) 7.26 (7.06-7.47) 7.66 (7.25-8.08) 0.005 
Creatinine (µg g/dl) 0.72 (0.71-0.73) 0.70 (0.69-0.71) 0.70 (0.69-0.72) 0.004 
 
All analyses were adjusted for age and sex. a, Means and standard error (SEM), all such values. b, Further adjusted for adiponectin; c, LDL-
cholesterol, TG and glucose are based on 543 individuals due to missing fasting data. d, Geometric means and 95% CI, all such values. e, Squared 
means and 95% CI; f, Further adjusted by the sex x rs2943634 interaction term; g, inverse and 95% (CI); h, further adjusted for HDL-cholesterol. 
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Table 3. Hazard ratios (HR) and 95% confidence intervals (95% CI) for the associations between 
rs2943634 polymorphism and cardiovascular endpoints. 
 CC CA AA Per A allele P add 
CVD cases N = 158 N =158 N =39   
Model 1a 1.0 0.84 (0.66-1.08) 0.74 (0.49-1.10) 0.85 (0.71-1.02) 0.08 
Model 2b 1.0 0.83 (0.64-1.07) 0.73 (0.49-1.10) 0.85 (0.71-1.02) 0.08 
Model 3c 1.0 0.87 (0.66-1.13) 0.71 (0.46-1.10) 0.85 (0.70-1.03) 0.09 
      
MI cases N = 86 N = 96 N = 29   
Model 1a 1.0 1.02 (0.74-1.41) 1.06 (0.64-1.73) 1.02 (0.82-1.28) 0.83 
Model 2b 1.0 1.02 (0.73-1.42) 1.06 (0.64-1.74) 1.02 (0.82-1.29) 0.83 
Model 3c 1.0 1.03 (0.72-1.47) 1.04 (0.62-1.74) 1.02 (0.81-1.30) 0.86 
      
IS cases N = 72 N = 62 N = 10   
Model 1a 1.0 0.72 (0.50-1.04) 0.38 (0.18-0.81) 0.66 (0.50-0.87) 0.003 
Model 2b 1.0 0.70 (0.48-1.02) 0.36 (0.17-0.77) 0.64 (0.49-0.85) 0.002 
Model 3c 1.0 0.75 (0.51-1.10) 0.34 (0.15-0.78) 0.65 (0.49-0.86) 0.003 
 
CVD, cardiovascular diseases; MI, myocardial infarction; IS, ischemic stroke 
a Model 1: Derived from Cox proportional-hazards regression, with age as underlying time variable, stratified by age at baseline, and adjusted for 
sex.  
b Model 2: Adjusted for model 1, and further for HDL-cholesterol (continuous), and adiponectin (continuous).  
c Model 3: Adjusted for model 2 and further for smoking status (never smoker, former smoker, current smoker < 20 cigarettes per day, current 
smoker # 20 cigarettes per day), sports activity (< 2 h/wk versus # 2 h/wk), educational attainment (vocational school or less, technical school, 
university), BMI (continuous), WC (continuous), alcohol consumption (men: =0 g/d, >0 to 12 g/d, >12 to 24 g/d; >24 g/d; women: =0 g/d, >0 to 6 
g/d, >6 to 12 g/d; >12 g/d), Hba1c (continuous), SBP (continuous), antihypertensive medication, total cholesterol (continuous) and hs-CRP 
(continuous). 
Chapter 3!Association of rs2943634 with CVD!
78 
 
Supplementary table 1. Associations between rs2943634 polymorphism and cardiovascular 
diseases intermediate risk phenotypes in the EPIC-Potsdam subcohort assuming a dominant 
heritage model. 
 CC CA + AA P dom 
Characteristics (N = 769) (N = 1122)  
Body mass index (kg/m2) a 26.18 ± 0.15 25.91 ± 0.12 0.17 
Waist circumference (cm)    
Men 93.95 ± 0.40 94.92 ± 1.13 0.42 
Women 80.72 ± 0.49 80.49 ± 0.42 0.71 
SBP (mm/Hg) 129.18 ± 0.58 129.04 ± 0.48 0.85 
DBP (mm/Hg) 83.66 ± 0.38 83.48 ± 0.31 0.71 
Total Cholesterol (mg/dl) 174.8 ± 1.27 171.138 ± 1.05 0.33 
HDL-cholesterol (mg/dl) 52.09 ± 0.49 53.56 ± 0.40 0.02 
LDL-cholesterol (mg/dl)b 109.55 ± 2.04 107.97 ± 2.04 0.54 
Triglycerides (mg/dl)c 94.80 (88.12-101.98) 85.36 (80.70-90.28) 0.03 
Blood glucose (mg/dl)d, e 96.80 (92.17-101.54 96.54 (93.43-99.69) 0.94 
HbA1c (%) f 6.47 (6.42-6.51) 6.42 (6.39-6.46) 0.15 
Hs-C-reactive protein (mg/l) 7.59 (6.89-8.36) 7.15 (6.60-7.74) 0.35 
Adiponectin (µg/ml) 6.94 (6.72-7.17) 7.40 (7.20-7.60) 0.003 
Creatinine (µg g/dl) 0.72 (0.71-0.73) 0.70 (0.69-0.71) 0.001 
 
All analyses were adjusted for age and sex. a, Means and standard error (SEM), all such values. b, LDL-cholesterol, TG and glucose are based on 
543 individuals due to missing fasting data. c, Geometric means and 95% CI, all such values. d, Squared means and 95% CI; e, Further adjusted 
by the sex x rs2943634 interaction term; f, inverse and 95% (CI). 
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Supplementary table 2. Associations between rs2943634 polymorphism and intermediate risk 
phenotypes of cardiovascular diseases in the EPIC-Potsdam subcohort assuming a recessive 
heritage model. 
 CC+ CA AA P rec 
Characteristics (N = 1647) (N = 244)  
Body mass index (kg/m2) a 26.02 ± 0.10 26.02 ± 0.27 1.00 
Waist circumference (cm)    
Men 94.45 ± 0.61 93.81 ± 0.48 0.41 
Women 80.71 ± 0.34 79.83 ± 0.85 0.33 
SBP (mm/Hg) 129.12 ± 0.40 128.92 ± 0.86 0.86 
DBP (mm/Hg) 83.59 ± 0.257 83.26 ± 0.67 0.64 
Total Cholesterol (mg/dl) 173.88 ±  173.66 ± 1.04 0.93 
HDL-cholesterol (mg/dl)  52.62 ± 0.33 55.28 ± 0.87 0.004 
LDL-cholesterol (mg/dl)b 109.03 ± 1.33 105.46 ± 3.43 0.33 
Triglycerides (mg/dl)c 87.93 (83.81-92.25) 94.23 (83.33-106.55) 0.30 
Blood glucose (mg/dl)d, e 96.83 (94.73-98.95) 95.36 (88.54-102.43) 0.71 
HbA1c (%) f 6.45 (6.41-6.48)  6.41 (6.33-6.49) 0.40 
Hs-C-reactive protein (mg/l) 7.24 (6.77-7.73) 7.93 (6.68-9.42) 0.33 
Adiponectin (µg/ml) 7.12 (6.96-7.27) 7.87 (7.43-8.33) 0.001 
Creatinine (µg g/dl) 0.71 (0.70-0.72) 0.70 (0.69-0.72) 0.32 
 
All analyses were adjusted for age and sex. a, Means and standard error (SEM), all such values. b, LDL-cholesterol, TG and glucose are based on 
543 individuals due to missing fasting data. c, Geometric means and 95% CI, all such values. d, Squared means and 95% CI; e, Further adjusted 
by the sex x rs2943634 interaction term; f, inverse and 95% (CI). 
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Supplementary table 3. Hazard ratios (HR) and 95% confidence intervals (95% CI) for the 
associations between rs2943634 polymorphism and cardiovascular endpoints according to the 
dominant and recessive heritage models. 
 CA vs CC+AA P dom AA vs CC+CA P rec 
CVD cases     
Model 1 a 0.90 (0.71-1.14) 0.39 0.80 (0.54-1.18) 0.26 
Model 2 b 0.89 (0.70-1.14) 0.35 0.80 (0.54-1.19) 0.27 
Model 3 c 0.93 (0.72-1.21) 0.60 0.76 (0.50-1.16) 0.20 
     
MI cases     
Model 1 a 1.01 (0.74-1.36) 0.97 1.04 (0.66-1.66) 0.85 
Model 2 b 1.00 (0.73-1.37) 0.99 1.05 (0.65-1.68) 0.84 
Model 3 c 1.02 (0.73-1.42) 0.92 1.03 (0.63-1.68) 0.92 
     
IS cases     
Model 1 a 0.85 (0.59-1.23) 0.39 0.45 (0.21-0.93) 0.03 
Model 2 b 0.84 (0.58-1.21) 0.34 0.43 (0.21-0.91) 0.03 
Model 3 c 0.90 (0.61-1.33) 0.59 0.39 (0.17-0.89) 0.02 
 
CVD, cardiovascular diseases; MI, myocardial infarction; IS, ischemic stroke 
a Model 1: Derived from Cox proportional-hazards regression, with age as underlying time variable, stratified by age at baseline, and adjusted for 
sex. b Model 2: Adjusted for model 1, and further for HDL-cholesterol (continuous), and adiponectin (continuous). c Model 3: Adjusted for model 
2 and further for smoking status (never smoker, former smoker, current smoker < 20 cigarettes per day, current smoker # 20 cigarettes per day), 
sports activity (< 2 h/wk versus # 2 h/wk), educational attainment (vocational school or less, technical school, university), BMI (continuous), WC 
(continuous), alcohol consumption (men: =0 g/d, >0 to 12 g/d, >12 to 24 g/d; >24 g/d; women: =0 g/d, >0 to 6 g/d, >6 to 12 g/d; >12 g/d), Hba1c 
(continuous), SBP (continuous), antihypertensive medication, total cholesterol (continuous) and hs-CRP (continuous). 
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ABSTRACT 
Background: Stearoyl-CoA desaturase-1 (SCD1) is an enzyme involved in lipid metabolism. In 
mice and humans its activity has been associated with traits of the metabolic syndrome, but also 
with the prevention of saturated fatty acids accumulation and subsequent inflammation, whereas 
for liver fat content inconsistent results have been reported. Thus, variants of the gene encoding 
SCD1 (SCD1) could potentially modify metabolic risk factors, but few human studies have 
addressed this question. 
Methods: In a sample of 2157 middle-aged men and women randomly drawn from the Potsdam 
cohort of the European Prospective Investigation into Cancer and Nutrition, we investigated the 
impact of 7 SCD1 tagging-single nucleotide polymorphisms (rs1502593, rs522951, rs11190480, 
rs3071, rs3793767, rs10883463 and rs508384) and 5 inferred haplotypes with frequency >5% 
describing 90.9% of the genotype combinations in our population, on triglycerides, body mass 
index (BMI), waist circumference (WC), glycated haemoglobin (HbA1c), high-sensitivity C-
reactive protein (hs-CRP), gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT) 
and fetuin-A. 
Results: No significant associations between any of the SNPs or haplotypes and BMI, WC, 
fetuin-A and hs-CRP were observed. Associations of rs10883463 with triglycerides, GGT and 
HbA1c as well as of rs11190480 with ALT activity, were weak and became non-significant after 
multiple-testing correction. Also associations of the haplotype harbouring the minor allele of 
rs1502593 with HbA1c levels, the haplotype harbouring the minor alleles of rs11190480 and 
rs508384 with activity of ALT, and the haplotype harbouring the minor alleles of rs522951, 
rs10883463 and rs508384 with triglyceride and HbA1C levels and GGT activities did not 
withstand multiple-testing correction.  
Conclusion: These findings suggest that there are no associations between common variants of 
SCD1 or its inferred haplotypes and the investigated metabolic risk factors. However, given the 
results from animal models, heterogeneity of human SCD1 warrants further investigation, in 
particular with regard to rare variants. 
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INTRODUCTION 
The human stearoyl-CoA desaturase-1 (SCD1) gene maps to chromosome 10q24.31, has 6 exons 
and is remarkably expressed in adipose tissue and the liver. It encodes the endoplasmatic 
reticulum enzyme SCD1, which catalyses the conversion of the saturated fatty acids (SFAs) 
palmitic and stearic, into the monounsaturated fatty acids (MUFAs) palmitoleic and oleic 
respectively [1]. These MUFAs are the major components of triglycerides, likely due to its 
production within the environs of the enzyme diacylglycerol acyltransferase (DGAT) [1]. 
Accordingly, it has been suggested that the increased activity of SCD1 in the liver, could result in 
an excess assembly and accumulation of triglycerides and subsequent development of hepatic 
steatosis [2]. Further, the overflow of triglycerides could also be incorporated into very low 
density lipoprotein (VLDL) particles and transported to adipose tissue and other sites, 
contributing to the development of obesity [3]. Both these conditions have been associated with 
insulin resistance [4]. Additionally, SCD1 deficiency has been associated with the reduced 
expression of fatty acid synthesis genes [5] and the up-regulation of genes involved in fatty acid 
$-oxidation [5,6]. In fact mice with a natural or a targeted deletion of the SCD1 gene, have shown 
to be protected against hypertriglyceridemia [7], hepatic steatosis [8-10], obesity [3,5,8,11,12] 
and insulin resistance [11,13,14]. Conversely, there is also evidence that by channelling SFA, into 
triglyceride pools, increased SCD1 activity may prevent from lipoapoptosis [15], steatohepatitis 
[2] and inflammation [6,15-17]. Therefore, SCD1 seams to convey both, positive and negative 
roles in the development of metabolic risk factors of cardiovascular diseases. 
Despite the strong scientific interest in SCD1, most of the existing knowledge on its function 
comes from mice models [18]. Some human studies have provided indirect evidence of the role 
of its activity (approximated as fatty acids product-to-precursor ratios measured in serum, 
plasma, erythrocytes or adipose tissue), and have proposed that its elevation might be associated 
with harmful effects such as elevated plasma triglycerides levels [19,20], liver fat [21-23], obesity 
[19,24], diabetes [25], high-sensitivity C-reactive protein (hs-CRP) levels [26] and even with 
cardiovascular mortality [27]. Conversely the scarce human studies investigating the tissue-
specific activity and expression of SCD1, suggest that elevated SCD1 activity may protect from 
liver fat accumulation [28,29]. Further, the impact of SCD1 heterogeneity on metabolic risk 
factors, has so far only been investigated in four human studies with focus on diabetes and 
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obesity [30,31], metabolic syndrome (MetS) [32] or inflammation [33]. Thus, a case control 
study in men and women from the United Kingdom, found no associations between 6 SCD1 
single nucleotide polymorphisms (SNPs) or its inferred haplotypes and diabetes, body mass index 
(BMI) or waist-to-hip ratio [30]; a cross-sectional study in Swedish elderly men reported that 4 
out of 8 SCD1 tagging SNPs (tag-SNPs) related to decreased BMI and waist circumference 
(WC), and increased insulin sensitivity [31]; the haplotype consisting of the rare alleles of these 
SNPs was also associated with decreased WC; a cross-sectional study in Costa Rican middle-
aged men and women reported that 1 out of 7 SCD1 tag-SNPs was associated with an increased 
prevalence of MetS, and among women, also with elevated systolic blood pressure and fasting 
blood glucose levels [32]. Also 2 haplotypes carrying the minor allele of this SNP were 
associated with elevated prevalence of MetS; finally a cross-sectional study in European and 
Asian young adults found 1 out of 10 tag-SNPs to be associated with CRP levels [33]. 
In the Potsdam cohort of the European Prospective Investigation into Cancer and Nutrition 
(EPIC-Potsdam), we investigated the impact of common genetic variation in SCD1, captured by 
means of 7 tag-SNPs and their inferred haplotypes, on the modulation of 8 metabolic risk factors 
related to the activity of SCD1. The investigated traits were plasma triglyceride levels, traits 
related to obesity (BMI and waist circumference (WC)), glucose metabolism (glycated 
haemoglobin (HbA1c)) and chronic inflammation (hs-CRP), and, for the first time, crude 
estimates of the presence of liver fat  (the liver enzymes gamma-glutamyltransferase (GGT) and 
alanine amino transferase (ALT) [34,35]), and fetuin-A, a biomarker which has been associated 
with fat accumulation in the liver [36-40] as well as with insulin resistance, type 2 diabetes and 
cardiovascular events [40-42]. 
METHODS 
Ethics Statement 
Written informed consent was obtained from all study participants, and approval was given by 
the Ethics Committee of the Medical Association of the State of Brandenburg, Germany. 
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Study population 
EPIC-Potsdam comprises 27548 individuals (10904 men and 16644 women) from the general 
population of the Potsdam area in Germany. Men were mainly aged 40-65 and women 35-65 
years old at recruitment, which took place between 1994 and 1998 [43]. The baseline 
examination included a personal interview and a questionnaire on sociodemographic and lifestyle 
characteristics and prevalent diseases as well as anthropometric measurements[44]. The 
associations of 7 SCD1 tag-SNPs and their inferred haplotypes with anthropometric and 
metabolic markers were investigated in a random sample of 2500 individuals (subcohort) drawn 
from the participants in the total cohort who had provided blood samples at baseline, following a 
cross-sectional design. After exclusion of individuals with missing covariates or genotype data, 
the final study population comprised 2157 participants. Fasting was not required at the time of 
blood draw, however, 615 participants were in fasting state for at least 8 h. 
Laboratory analyses 
From all the study participants a 30 mL sample of venous blood was collected, fractionated into 
serum, plasma, buffy coat and erythrocytes, and stored in liquid nitrogen until the time of 
analysis. Plasma levels of triglycerides, HbA1c, GGT, ALT, fetuin-A, hs-CRP ,total cholesterol 
and high density lipoprotein (HDL)-cholesterol were determined with the automatic ADVIA 1650 
analyser (Siemens Medical Solutions, Erlangen, Germany) at the Department of Internal 
Medicine of the University of Tübingen, Germany, in 2007. 
SNP selection and genotyping  
Seven SCD1 tag-SNPs (ordered according to chromosomic location: rs1502593, rs522951, 
rs11190480, rs3071, rs3793767, rs10883463 and rs508384) were identified in the HapMap 
22/phaseII CEU population data (Utah residents with ancestry from northern and western 
Europe) [45] using stringent criteria (minor allele frequency (MAF) >0.05 and pairwise r2 #0.8) 
by means of the Tagger software [46] implemented in the version 4.2 of Haploview [47]. The 
tagged region comprised the coding region of SCD1 as well as a 4.1 Kb upstream (promoter) and 
4.3 Kb downstream (3’ untranslated) region of the gene. Six SNPs were located in intronic sites 
and one in the 3( untranslated region (rs508384). Genotyping of whole genome amplified DNA 
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samples was performed with a 7900HT Sequence Detection System with TaqMan assays 
(Applied Biosystems, Foster City, CA, USA) at the Max Delbrück Centre for Molecular 
Medicine, Berlin, Germany, in 2009. The average genotyping success rate in the 7 SNPs was 
>98%. 
Statistical analyses 
Normality of variables was tested by estimating their skewness and kurtosis, by comparing their 
means and median values and by plotting their distributions in histograms. To better reach 
normality of their distributions, triglycerides, GGT, ALT and hs-CRP were natural log-
transformed and HbA1c inverse-transformed, and were used like that in all analyses. Hardy–
Weinberg equilibrium (HWE) of the SNPs was tested using the '2 test. Linkage disequilibrium 
between SNPs was assessed with the r2 measure using Haploview 4.2 [47]. Each SNP was coded 
as 0, 1 and 2 according to the number of minor alleles a participant carried. Analysis of 
covariance considering the additive, dominant and recessive genetic models was used to assess 
the associations between the SNPs (independent variables) and triglycerides, BMI, WC, HbA1c, 
GGT, ALT, fetuin-A and hs-CRP (dependent variables). Haplotypes were constructed to test 
whether multiple genetic variants of SCD1 or a possible unobserved risk variant captured by the 
haplotypes, modulated the investigated traits. Haplotype frequencies were estimated based on the 
observed unphased genotypes by the expectation-maximization algorithm [48]. The effects of a 
particular haplotype load (0, 1 or 2 copies) were tested also by means of a regression-based 
analysis (ANCOVA) as suggested by Zaykin et al. [49]. Analyses were restricted to participants 
with a probability of 49-50% to carry one copy of the haplotype, or 100% probability to carry 
either none or two copies. Only haplotypes with frequencies >5% were considered. The additive, 
dominant and recessive models were examined. Analyses for triglycerides were performed only 
in participants who were fasting at the time of blood draw. Data are reported as means and 
standard errors, geometric means and 95% confidence intervals (CI) or inverse and 95% CI as 
appropriate. Regression coefficients and standard errors (SE) were also estimated. All analyses 
were adjusted for age and sex. Further (mutual) adjustment for known cardiovascular risk factors 
including smoking status (never smoker, former smoker, current smoker <20 cigarettes per day, 
current smoker #20 cigarettes per day), sports activity (<2 h/wk versus #2 h/wk), educational 
attainment (vocational school or less, technical school, university), BMI (continuous), WC 
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(continuous), alcohol consumption (men: =0 g/d, >0 to 12 g/d, >12 to 24 g/d; >24 g/d; women: 
=0 g/d, >0 to 6 g/d, >6 to 12 g/d; >12 g/d), prevalent diabetes, prevalent hypertension, total 
cholesterol, HDL cholesterol and hs-CRP) were also explored for the tag-SNPs. Effect 
modification by sex was evaluated by modeling the cross product term sex times genotype or 
haplotype, along with main effects (in the age-adjusted general linear model). All statistical 
analyses were performed using SAS Enterprise Guide 4.3 (SAS Institute Inc., Cary, NC, USA).  
Power calculations were performed with Quanto [50] considering an additive model, a desirable 
power of 80%, a two-sided ) of 0.05, the means and standard deviations of the traits in the 
subcohort (non-normal variables were transformed to normality) and the genotype frequencies of 
the least (rs10883463, MAF = 8%) and most (rs522951, MAF = 46%) common tag-SNPs. The 
detectable differences in our study ranged between 0.1 and 0.2 SD for BMI, WC, GGT, ALT, 
fetuin-A, hs-CRP and HbA1c and between 0.2 and 0.3 SD for triglycerides. Conservative 
Bonferroni correction for multiple comparisons was performed (P Bonferroni = )/(n individual 
hypothesis tested) = 0.05/((7 SNPs + 5 haplotypes) x 3 genetic models per SNP x 8 traits 
investigated). The corrected significance threshold was P Bonferroni = 0.0002. 
RESULTS 
Characteristics of the study population 
Demographic, lifestyle, clinical, biochemical and genetic characteristics of the study population 
are given in Table 1, both for the subcohort and separately for men and women. Men (38%) were 
older than women due to sampling strategy. After adjusting for age, they also showed to smoke 
and drink more and to take more often antidiabetic medication. Further their BMI, WC and their 
activities of GGT and ALT were higher. They were more likely to be higher educated and also 
had lower hs-CRP levels than women. The genotype frequency of all SCD1 tag-SNPs followed 
HWE (P >0.05), their allele frequencies were comparable to those observed in HapMap 
22/phaseII CEU population data [45] and did not differ among sexes. Table S1 presents further 
information regarding genotype and allelic frequencies of the tag-SNPs across the EPIC-Potsdam 
subcohort and separately for men and women. 
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Linkage disequilibrium values (r2) between each pair of tag-SNPs ranged from 0 to 0.66. Five 
haplotypes inferred from the genotyped SNPs, with frequency >5% described 90.9% of the 
genotype combinations in our population: A-B-A-A-B-A-A (34.1%); B-A-A-B-A-A-A (29.8%), 
B-A-A-A-A-A-A (11.0%), A-A-B-A-A-A-B (8.6%) and A-B-A-A-A-B-B (7.4%) (Haplotypes are 
composed of variants rs1502593 (C>T), rs522951 (G>C), rs11190480 (A>G), rs3071 (T>G), 
rs3793767 (T>C), rs10883463 (T>C), rs508384 (C>A) in that order; A indicates common allele, 
B indicates rare allele). 
Associations between SCD1 tag-SNPs and inferred haplotypes and the investigated traits 
No significant effect modifications by sex were found for any of the tag-SNPs or inferred 
haplotypes on the investigated traits, thus results are presented combined for men and women. 
Table 2 shows results for age- and sex-adjusted mean values of the 8 investigated metabolic traits 
for each of the 7 SCD1 tag-SNPs. No significant associations were found between rs1502593, 
rs522951, rs3071, rs3793767 or rs508384 and any of the investigated traits. Also no significant 
associations were found between any of the investigated SNPs and fetuin-A, BMI, WC or hs-
CRP. However, carriers of the rs11190480 rare allele, presented slightly lower activities of ALT in 
a dominant fashion (19.91 vs. 21.07 U/L, P = 0.03). Carriers of the rs10883463 rare allele, 
showed higher triglycerides (160.97 vs. 94.02 mg/dL, P = 0.03) and lower HbA1c levels (6.10 vs. 
6.49 %, P = 0.03) in a recessive fashion, and slightly higher activities of GGT (22.22 vs. 19.88 
U/L, P = 0.02) in a dominant fashion. Results were weak in precision, as shown by the wide 
confidence intervals, and after applying the Bonferroni correction for the multiple hypothesis 
tested (P Bonferroni = 0.0002), none of them remained significant. After further (mutual) 
adjustment of the statistical models for known cardiovascular risk factors, results remained 
essentially similar (table S2). Also they were not modified by adjustment for fasting status or 
exclusion of participants taking lipid-lowering or antidiabetic medication.  
Table 3 shows results for age- and sex-adjusted mean values of the investigated metabolic traits 
for each of the 5 SCD1 haplotypes. No associations between the two most common haplotypes 
and the investigated variables became apparent. Homozygotes for haplotype B-A-A-A-A-A-A 
harbouring the minor allele of the SNP rs1502593 presented lower HbA1c levels (6.03 vs. 6.49 
%, P = 0.003). Carriers of haplotype A-A-B-A-A-A-B harbouring the minor alleles of the SNPs 
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rs11190480 and rs508384 exhibited slightly lower activities of ALT in a dominant fashion (19.85 
vs. 21.08 U/L, P = 0.02). Carriers of haplotype A-B-A-A-A-B-B harbouring the minor alleles of 
the SNPs rs522951, rs10883463 and rs508384 showed higher triglyceride values 179.77 vs. 
94.08 mg/dL and lower HbA1C levels (6.09 vs. 6.49 %, P = 0.03) in a recessive fashion, and 
higher GGT activities (22.24 vs. 19.93 U/L, P = 0.03) in a dominant fashion. However, after 
correction for multiple testing, also none of these results remained significant. Table S3 
summarizes all of these results in the form of age- and sex-adjusted regression coefficients. 
DISCUSSION 
In the present study of a middle-aged sample of German men and women, we evaluated the 
impact of 7 SCD1 tag-SNPs and 5 inferred haplotypes on MetS related traits on suggested crude 
estimates of the presence of liver fat and on inflammation. Our study is, so far, the largest 
performed in a European population, and also the first to report association results between SCD1 
genetic variants and liver parameters. We hypothesized that any functional variant affecting the 
activity of SCD1 would possibly result in the modulation of one or more of the traits. At most, we 
found some associations weak in magnitude, precision, and statistical significance, which after 
conservative Bonferroni-correction for the number of traits, SNPs and haplotypes tested, did not 
remain significant, thus being suggestive of chance findings. 
Four previous studies in humans have investigated the association of SCD1 polymorphisms with 
different metabolic traits [30-33]. In a UK case-control study of 608 cases and 600 controls, Liew 
et al. [30] reported upon the association of 6 SCD1 SNPs with type 2 diabetes, BMI and waist-to-
hip ratio. Three of these SNPs were in common or highly linked to SNPs of our study: rs670213 
(a good proxy for rs522951, r2 = 0.87 according to HapMap data for Caucasians of European 
origin [45], rs3071 and rs11598233 (a perfect proxy for rs3793767, r2 = 1 [45]). Consistent with 
our results, they also reported no significant associations. Warensjö et al. [31] investigated 
associations of 8 SCD1 tag-SNPs with obesity and insulin sensitivity in 1143 Swedish elderly 
men. Five of these SNPs, were in common or highly linked to SNPs of our study, rs3870747 
(linked with rs1119040, r2= 0.94 [45]), rs3071, rs3793767, rs10883463 and rs508384. In line 
with our results, they found a tendency of rs10883463 carriers towards increased insulin 
sensitivity, and no significant associations for rs3870747 and rs3793767. In contrast, they 
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reported lower WC in carriers of rs10883463, lower WC and higher insulin sensitivity in 
homozygotes for rs508384 rare allele and lower insulin sensitivity in heterozygotes for rs3071. 
This last association was also inconsistent with the results from Liew et al. [30]. Compared with 
our study population, the study of Warensjö et al. [31] was smaller and included only elderly 
men. However, we found no significant sex interaction for any of the SNPs with any of the 
studied phenotypes, and further all our association analyses were adjusted for age, what makes 
the overall evidence for an association of SCD1 genetic variability with WC and insulin 
sensitivity less consistent. Recently, Gong et al. [32] analysed the association of 7 SCD1 tag-
SNPs with MetS prevalence in 2152 Costa Rican adult men and women. Only one SNP, 
rs1502593, was found to be associated with MetS. This SNP was also analysed in our population. 
In line with our results, they did not observe significant associations between rs1502593 and 
triglyceride levels or WC. They did point out a borderline association of rs1502593 with elevated 
fasting blood glucose levels among women. In our population we found no significant 
associations for this SNP. Homozygotes for the haplotype harbouring its minor allele showed 
lower HbA1c levels, measure of the average plasma glucose levels over prolonged periods of 
time, but this association did not withhold after multiple-testing correction. We cannot discard the 
possibility that the different ethnic origin may explain the different findings. Finally, Stryjecki et 
al. [33] examined the relationships between 10 SCD1 tag-SNPs and CRP levels in 279 European 
and 249 Asian young adults. Only one SNP located 9 Kb upstream SCD1, and thus not included 
in our study, was associated with CRP levels, and only among females of both groups.  
Limitations of our study should be mentioned. It is possible that, due to sample size limitations 
we were not able to detect minor contributions of the alleles. This limitation was stronger in the 
case of the association analyses for triglycerides levels, as fasting data was available only for 
about one third of the population. Thus while some of our results could represent a replication for 
certain relationships inspected in the four association studies that precede ours [30-33], to 
evaluate the outcome of our work, further studies in independent cohorts analysing the same 
SNPs, or those in perfect linkage disequilibrium, are necessary [51]. Also, we cannot exclude the 
possibility that a rare causal variant exists within the typed region but was not picked up by the 
chosen markers. 
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In summary, our findings suggest that common variants of SCD1 do not modulate the 
investigated metabolic factors in this European population. However, given its biological 
relevance, the still scarce number of studies available and the inconsistency of their results, 
genetic heterogeneity of human SCD1 in relation to impaired metabolism rewards further 
investigation in independent study populations, in particular with regard to rare variants of SCD1. 
SUPPORTING INFORMATION LEGENDS 
Table S1 Genotype and allelic frequencies of the SCD1 tag-SNPs across the EPIC-Potsdam 
subcohort and separately for men and women.  
Table S2 Association analysis between the 7 SCD1 tag-SNPs and the 8 investigated metabolic 
traits in the EPIC-Potsdam Study, (mutually) adjusted for known cardiovascular risk factors. 
Table S3 $ regression coefficients for the age- and sex-adjusted association analysis between the 
SCD1 tag-SNPs and inferred haplotypes and the 8 investigated metabolic traits in the EPIC-
Potsdam study. 
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Table 1. Baseline characteristics of the EPIC-Potsdam subcohort and separately for men and 
women. 
 Subcohort (N = 2157) 
Men 
(N = 819; 38%) 
Women 
(N = 1338; 62% ) P value 
a 
Age (year) 50.3±9.0 52.4 (51.8-53.0) 49.0 (48.5-49.4) <0.0001 
Educational attainment (%):     
Vocational school or less 37.4 30.8 41.5 <0.0001 
Technical school 24.9 15.9 30.4 <0.0001 
University degree 37.7 53.4 28.1 <0.0001 
Physical activity (hours/week):     
< 2 75.9 74.7 76.7 0.3 
# 2 24.1 25.3 23.3 0.3 
Smoking status (%):     
Current #20 cigarettes/d 6.3 11.3 3.2 <0.0001 
Current <20 cigarettes/d 14.9 16.7 13.8 0.07 
Former &5 years 7.5 9.5 6.3 0.006 
Former >5 years 24.4 35.3 17.7 <0.0001 
Never 46.9 27.2 59.0 <0.0001 
Alcohol intake:     
Men: = 0 g/d; women: = 0 g/d 0.05 0.1 0.0 0.3 
Men: > 0-12 g/d; women: >0-6 g/d 47.2 36.4 53.9 <0.0001 
Men: >12-24 g/d; women: >6-12 g/d 24.7 26.1 23.9 0.3 
Men: > 24 g/d; women: > 12 g/d 28.0 37.5 22.2 <0.0001 
Use of medication (%):     
Antidiabetic 2.6 3.5 2.0 0.03 
Antihypertensive 19.3 19.6 19.2 0.8 
Lipid lowering medication 5.1 5.7 4.7 0.3 
Body mass index (kg/m2) 26.1±4.3 26.6 (26.3-26.8) 25.8 (25.6-26.1) 0.0002 
Waist circumference (cm): 85.8±12.9 93.4 (92.6-94.1) 81.2 (80.6-81.7) <0.0001 
Triglycerides (mg/dL) b 90.2 (64.9-126.5) 109.3  (102.1-117.0) 82.1 (77.6-86.7) <0.0001 
Gamma-glutamyltransferase (U/L) 16.8 (11.0-30.8) 28.3 (26.8-29.9) 14.4 (13.8-15.0) <0.0001 
Glutamic-pyruvate transaminase (U/L) 18.7 (14.3-26.4) 25.9(25.1-26.7) 16.8 (16.4-17.3) <0.0001 
Fetuin-A (mg/dL) c 0.25±0.06 0.25 (0.24-0.25) 0.25 0.25-0.26) 0.03 
Glycated haemoglobin (%) 6.4 (6.1-6.8) 6.5 (6.4-6.6) 6.4 (6.4-6.5) 0.002 
hs-C-reactive protein (mg/L)  0.8 (0.2-2.1) 0.6 (0.6-0.7) 0.8 (0.6-0.7) <0.0001 
Minor allele frequency (%) d     
rs1502593 (C>T) 44 45 43 0.2 
rs522951 (G>C) 46 46 47 0.6 
rs11190480 (A>G) 9 9 9 0.6 
rs3071 (T>G) 35 35 34 0.8 
rs3793767 (T>C) 38 36 39 0.2 
rs10883463 (T>C) 8 8 8 0.7 
rs508384 (C>A) 17 17 17 1.0 
Subcohort: Mean ± SD, %, or median (25th percentile; 75th percentile), all such values. Men and women: mean and 95% confidence interval (CI) 
or %. Results obtained using analysis of covariance, all variables other than age are adjusted for age. a P value for the difference between men and 
women. b, based on the 615 participants fasting at blood draw. c, based on 2077 participants due to missing biomarker data. d Alleles given in 
brackets (most >less frequent allele).
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Table S1. Genotype and allelic frequencies of the SCD1 tag-SNPs across the EPIC-Potsdam 
subcohort and separately for men and women. 
SNP Group Genotype N (%) Allele N (%) 
  AA AB BB A B 
rs1502593 Subcohort 679 (31.48) 1072 (49.70) 406 (18.82) 2430  (56) 1884(44) 
 Men 233 (28.45) 434 (52.99) 152 (18.56) 900 (55) 738 (45) 
 Women 446 (33.33) 638 (47.68) 254 (18.98) 1530 (57) 1146 (43) 
rs522951 Subcohort 607 (28.14) 1095 (50.76) 455 (21.09) 2309 (54) 2005 (46) 
 Men 223 (27.23) 441 (53.85) 155 (18.93) 887 (54) 751 (46) 
 Women 384 (28.70) 654 (48.88) 300 (22.42) 1422 (53) 1254 (47) 
rs11190480 Subcohort 1787 (82.85) 357 (16.55) 13 (0.60) 3931 (91) 383 (9) 
 Men 681 (83.15) 136 (16.61) 2 (0.24) 1498 (91) 140 (9) 
 Women 1106 (82.66) 221 (16.52) 11 (0.82) 2433 (91) 243 (9) 
rs3071 Subcohort 944 (43.76) 936 (43.39) 277 (12.84) 2824 (65) 1490 (35) 
 Men 356 (43.47) 353 (43.10) 110 (13.43) 1065 (65) 573 (35) 
 Women 588 (43.95) 583 (43.57) 167 (12.48) 1759 (66) 917 (34) 
rs3793767 Subcohort 845 (39.17) 998 (46.27) 314 (14.56) 2688 (62) 1626 (38) 
 Men 330 (40.29) 384 (46.89) 105 (12.82) 1044 (64) 594 (36) 
 Women 515 (38.49) 614 (45.89) 209 (15.62) 1644 (61) 1032 (39) 
rs10883463 Subcohort 1840 (85.30) 304 (14.09) 13 (0.60) 3984 (92) 330 (8) 
 Men 695 (84.86) 120 (14.65) 4 (0.49) 1510 (92) 128 (8) 
 Women 1145 (85.58) 184 (13.75) 9 (0.67) 2474 (92) 202 (8) 
rs508384 Subcohort 1489 (69.03) 610 (28.28) 58 (2.69) 3588 (83) 726 (17) 
 Men 561 (68.50) 244 (29.79) 14 (1.71) 1366 (83) 272 (17) 
 Women 928 (69.36) 366 (27.35) 44 (3.29) 2222 (83) 454 (17) 
A, most frequent allele in each SNP; B, least frequent allele in each SNP (A>B): rs1502593 (C>T), rs522951 (G>C), rs11190480 (A>G), rs3071 
(T>G), rs3793767 (T>C), rs10883463 (T>C), rs508384 (C>A).
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Abstract 
Background: The microsomal triglyceride transfer protein (MTTP) is encoded by the MTTP 
gene that is regulated by cholesterol in humans. Previous studies investigating the effect of 
MTTP on ischemic heart disease have produced inconsistent results. Therefore, we have 
tested the hypothesis that the rare allele of the -164T>C polymorphism in MTTP alters the 
risk of cardiovascular disease (CVD), depending on the cholesterol levels.  
Methods: The -164T>C polymorphism was genotyped in a case-cohort study (193 incident 
myocardial infarction (MI) and 131 incident ischemic stroke (IS) cases and 1 978 non-cases) 
nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)–
Potsdam Study, comprising 27 548 middle-aged subjects. The Heinz Nixdorf Recall Study 
(30 CVD cases and 1,188 controls) was used to replicate our findings.  
Results: Genotype frequencies were not different between CVD and CVD free subjects 
(P=0.79). We observed an interaction between the -164T>C polymorphism and total 
cholesterol levels in relation to future CVD. Corresponding stratified analyses showed a 
significant increased risk of CVD (HRadditve= 1.38, 95% CI: 1.07 to 1.78) for individuals with 
cholesterol levels <200 mg/dL in the EPIC-Potsdam Study. HRadditive was 1.06, 95% CI: 0.33 
to 3.40 for individuals in the Heinz Nixdorf Recall Study. A borderline significant decrease in 
CVD risk was observed in subjects with cholesterol levels #200 mg/dL (HRadditve=0.77, 95% 
CI: 0.58 to 1.03) in the EPIC-Potsdam Study.A similar trend was observed in the independent 
cohort (HRadditve=0.60, 95% CI: 0.29 to 1.25). 
Conclusions: Our study suggests an interaction between MTTP -164T>C functional 
polymorphism with total cholesterol levels. Thereby risk allele carriers with low cholesterol 
levels may be predisposed to an increased risk of developing CVD, which seems to be 
abolished among risk allele carriers with high cholesterol levels.  
Keywords: epidemiology, genetics, myocardial infarction, ischemic stroke, cholesterol, 
additive interaction.  
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BACKGROUND 
The microsomal triglyceride transfer protein (MTTP), a lipid transfer protein encoded by the 
MTTP gene, is located in the luminal side of the endoplasmic reticulum [1, 2]. It plays an 
important role in the assembly and secretion of apolipoproteins B (ApoB) containing 
lipoproteins as chylomicrons in the intestine, and of very low density lipoproteins (VLDLs) in 
the liver [3-5]. In turn, chylomicrons transport exogenous lipids to cells, while VLDLs carry 
endogenous triglycerides through the bloodstream. Thus, considering the important role 
played by MTTP in fat absorption and lipoprotein regulation, several studies have been 
conducted on MTTP promoter polymorphisms [6-24].  
Three polymorphisms of the MTTP gene (4q24), Ile128Thr (rs3816873), -164T>C 
(rs1800804), and -493G>T (rs1800591), have been described which are in complete linkage 
disequilibrium [6]. The rare alleles of these polymorphisms have been reported to decrease 
plasma lipoprotein-lipid levels [6-14] and some features of metabolic syndrome [16-19]. 
However, conflicting or negative findings have been reported by others [20-26]. The same 
inconsistent results have been published with regard to coronary heart disease (CHD) [7, 24-
26]. Two studies reported null findings [23, 24]. In contrast, in the INTERGENE [26], 
ULSAM and WOSCOPS [7] studies homozygosity for the -164C and the -493T alleles was 
associated with increased risk of ischemic heart disease (IHD) though, in the latter, 
concomitantly to a decrease in total plasma cholesterol [7]. Nevertheless, considered the 
reduced expression of the MTTP gene in carriers of the rare alleles [26], it is reasonable to 
expect lower cholesterol levels which have previously been shown to regulate MTTP gene 
expression [27, 28]. Also, it is likely to assume an interaction between the genotype of MTTP 
and cholesterol levels [19] in affecting the risk of CHD. 
Therefore, in the framework of the European Prospective Investigation into Cancer and 
Nutrition (EPIC)–Potsdam Study we investigated the association of the -164T>C variant, used 
as proxy for the three loci, with cardiovascular disease (CVD), myocardial infarction (MI) and 
ischemic stroke (IS) and the presence of an interaction between -164T>C polymorphism and 
total cholesterol in relation to CVD (MI and IS). We hypothesized that in carriers of the 
MTTP -164 C-allele lower cholesterol levels are associated with increased susceptibility to MI 
and IS. 
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METHODS 
EPIC-Potsdam 
The Ethics Committee of the Medical Association of the State of Brandenburg approved the 
study procedures and a written informed consent was obtained from all participants. 
Heinz Nixdorf Recall Study 
The study was approved by the local ethics committees, was conducted in accordance with 
German Good Epidemiologic Practice (GEP) including extended quality management 
procedures and re-certifications according to DIN ISO 9001:2001. Informed consent was 
obtained from all participants. Information on genotype, sex, age, diabetes, anti-
hyperlipidemic drugs and CVD was available for up to 1,513 of 4,814 participants.   
Study population 
EPIC-Potsdam 
Between 1994 and 1998, as a part of the large-scale European prospective cohort study EPIC, 
the EPIC-Potsdam Study enrolled from the general population 16 644 women (aged 35 to 65 
years) and 10 904 men (aged 40 to 65 years for), for a total of 27 548 participants [29]. 
At baseline, self-administered questionnaires on diet and lifestyle, PC-guided interviews with 
additional questions on prevalent diseases, blood pressure and anthropometric measurements 
were collected following standard procedures [30].  
Every two years, information on incident diseases and changes in lifestyle are collected by 
self-administered questionnaires [31], with response rates during follow-up exceeding 90% at 
all occasions. 
A case-cohort study consisting of all incident cases identified during a mean follow-up of 8 ± 
2.2 years [32] and a sub-cohort of 2 500 individuals randomly selected from the EPIC-
Potsdam cohort [33], was used to assess the association of the 164T>C variant with CVD risk 
(including both MI and IS).  
With this type of study, the results are expected to be representative of the entire cohort [34,  
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35]. After the exclusion of participants with prevalent MI and stroke at the baseline, 269 
individuals with incident MI and 246 individuals with incident stroke were identified (199 IS, 
41 haemorrhagic strokes, and 6 strokes with undefined pathogenesis). Among the sub-cohort, 
non-ischemic strokes were not considered as cases, while for individuals who experienced 
both MI and IS only the first event was considered [36]. After exclusion of prevalent CVD 
and missing follow-up dates, 2 368 participants remained to be in the sub-cohort. After further 
exclusion of subjects with a history of diabetes at the baseline and/or treated with anti-
hyperlipidemic drugs, and those with missing MTTP genotype, biochemical or covariates data 
the final case-cohort consisted of 2 302 individuals (324 CVD cases: 193 MI and 131 IS, and 
1 978 non-cases). Among CVD cases, 37 were part of the subcohort. 
Heinz Nixdorf Recall Study 
For the replication we analyzed data from the Heinz Nixdorf Recall (Risk Factors, Evaluation 
of Coronary Calcium and Lifestyle) study comprising 4,814 participants aged 45–75 years. 
The participants were randomly selected from registration lists of the densely populated Ruhr 
metropolitan area in Germany between 2000 and 2003. The rationale and design of the study 
have been described in detail [37]. Between 2006 and 2008 incident cases were identified 
during the 5-year follow-up examination.  
The genotyping of the MTTP SNP –I128T (rs3816873) was already available in a random 
selected sample of n=1,513 Heinz Nixdorf Recall participants out of 4,814. After exclusion of 
participants with a history of CVD and/or diabetes at baseline and/or treated with anti-
hyperlipidemic drugs, the final replication cohorts consisted of n=1,218 individuals (30 CVD 
and 1,188 non-cases). 
Ascertainment of CVD  
EPIC-Potsdam Study 
As described elsewhere [32], all possible cases of MI or stroke were identified by self-report 
or by death certificate in one of the four follow-up questionnaires and further verified by 
contacting the patients’ attending physician or by review of death certificates according to 
WHO MONICA criteria. 
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Heinz Nixdorf Recall Study 
Incident CVD (n=30) included fatal and nonfatal MI (n=24) and other CVD (n=6), were 
identified.  
Primary endpoints for this study were based on unequivocally documented incident coronary 
events that met predefined study criteria. We considered a myocardial infarction event based 
on symptoms, signs of electrocardiography, and enzymes (levels of creatine kinase (CK-MB)) 
as well as troponin T or I, and necropsy as 1) non-fatal acute myocardial infarction and 2) 
coronary death, which occurred between the baseline examination and five years after study 
entry [38, 39]. For all primary study endpoints, hospital and nursing home records including 
electrocardiograms, laboratory values, and pathology reports were collected. For deceased 
subjects, death certificates were collected and interviews with general practitioners, relatives 
and eyewitnesses were undertaken if possible. Medical records were obtained in 100% of all 
reported endpoints. An external criteria and endpoint committee blinded for conventional risk 
factor status and CAC scores reviewed all documents and classified the endpoints thereafter. 
Due to the small number of cases only total CVD were considered for the replication analysis. 
Other measurements 
Prevalent diabetes mellitus was identified by a physician and based on self-reported medical 
diagnoses, medication records and dieting behavior. Prevalent hypertension was defined as 
follows: systolic blood pressure #140 mm Hg or diastolic blood pressure #90 mm Hg or self-
reporting of a diagnosis or use of antihypertensive medication. Education, lifestyle 
characteristics (including alcohol consumption), regular sport activity and smoking history 
were assessed at baseline by trained interviewers during a PC-guided interview. Trained 
personnel took anthropometric and blood pressure measurements.  
Biochemical analyses 
EPIC-Potsdam Study 
At baseline, 30 ml of venous blood was taken from the respected participant (non-fasting or 
fasting blood) and, after fractionation into serum, plasma, leukocytes, and erythrocytes 
immediately stored at -196°C in liquid nitrogen [31]. All biomarkers were determined in 2007 
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in the Department of Internal Medicine, University of Tübingen. Plasma glucose, high-density 
lipoprotein cholesterol (HDL), total cholesterol and triglycerides were measured with an 
automatic analyzer (ADVIA 1650, Siemens Medical Solutions, Erlangen, Germany). LDL-
cholesterol was calculated using Friedewald’s formula [40]. To account for citrate’s dilution 
factor concentrations of total, HDL-, LDL-cholesterol and triglycerides were multiplied by 
1.1.  
Heinz Nixdorf Recall Study 
At baseline, plasma cholesterol levels were measured with an automatic analyzer (ADVIA 
1650, Siemens Medical Solutions, Erlangen, Germany).  
Genetic analyses 
EPIC-Potsdam Study 
DNA extraction was performed using a commercial kit (Qiagen, Hilden, Germany). In 2009 at 
the Max Delbrück Center for Molecular Medicine, Berlin, Germany, the MTTP SNP -164T>C 
(rs1800804) was genotyped by TaqMan technology (Applied Biosystems, Foster City, CA, 
USA) using 5 ng of whole-genome amplified DNA per sample. The call rate for the SNP 
assay exceeded 98%. 
Heinz Nixdorf Recall Study 
Lymphocyte DNA was isolated from EDTA anti-coagulated venous blood by a Chemagic 
Magnetic Separation Module I (Chemagen, Baesweiler, Germany). The MTTP SNP –I128T 
(rs3816873) was genotyped using four different platforms: Illumina Hap300, Illumina 
Hap550, Illumina Human660W-Quad and Illumina HumanOmni1-Quad. The call rate for this 
SNP was 99.9%. 
Statistical Analysis 
For both EPIC-Potsdam and Heinz Nixdorf Recall Studies statistical analyses were performed 
with the use of SAS software package, release 9.2 (SAS Institute, Cary, NC). 
EPIC-Potsdam Study 
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Data on triglyceride measurements were transformed into natural logarithms to reduce 
skewness and data were reported as geometric means and 95% confidence interval (CI).  
The deviation from Hardy-Weinberg equilibrium (HWE) was measured using the "2 test. 
The HWE was tested in the subcohort. Age and sex adjusted analysis of variance was used to 
describe general characteristics according to -164T>C genotype. Data were reported as means 
and standard error (SE). P for trend was calculated from age and sex adjusted linear 
regression model. To investigate the impact of total cholesterol on the associations between 
genotype and CVD we performed stratified analyses according to low (<200 mg/dL) and 
borderline-high/high (#200 mg/dL) cholesterol levels as defined in the Adult Treatment Panel 
III (ATP III) report [41]. Multiplicative interaction between cholesterol levels and genotype as 
well as sex and genotype in relation to CVD was tested with cross-product term. As a measure 
of additive interaction between cholesterol levels and genotype we further calculated the 
Synergy Index (SI) and the relative excess risk due to interaction (RERI) and their 95% 
confidence interval (CI) [42], as suggested by Rothman [43]. SI>1 and RERI>0 suggest a 
positive interaction (superadditive effect); SI<1 and RERI<0 suggest a negative interaction 
(subadditive effect); SI=1 and RERI=0 suggest absence of interaction.  
Both the multiplicative and additive interactions were also tested for triglycerides, HDL- and 
LDL-cholesterol. The choice of the cut-off values for these biomarkers was also based on the 
ATP III criteria (lower and higher than 130 mg/dL for LDL-cholesterol; lower and higher 
than 40 mg/dL and lower and higher than 50 mg/dL for HDL-cholesterol, respectively, in men 
and women; lower and higher than 150 mg/dl for triglycerides) [41]. 
Cox proportional-hazard regression modified according to the Prentice method [34] was used 
to compute the age and sex adjusted hazard ratio (HR) and 95% CI for the associations 
between MTTP -164T>C and risk of MI, IS and total CVD (combined endpoints). In the 
counting processes age was the underlying time variable with “entry time” defined as age at 
baseline and “exit time” as age at CVD event (MI or IS) or censoring. Associations between 
MTTP -164T>C and CVDs were tested in three models: additive, dominant and recessive. 
Furthermore, competing risk analyses were performed to test whether the associations of 
MTTP -164T>C with cardiovascular events differed between MI and IS, as described by Lunn 
and McNeil [44]. 
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The power to detect an association between the MTTP -164T>C SNP and CVDs (MI, IS and 
combined endpoints) was computed with Quanto (http://hydra.usc.edu/GxE/) [45], in relation 
to a desirable power =80%, assuming ) = 0.05 and a disease prevalence of 3.1% for CVD 
(n=847), 2.0% for MI (n=544) and 1.1% for IS (n=303), reflecting the baseline prevalence 
data in the EPIC-Potsdam population. The detectable odds ratio per risk allele equals 1.30, 
1.39 and 1.47, respectively for CVD, MI and IS.  
Heinz Nixdorf Recall Study 
Cox proportional-hazard regression was used to compute the age and sex adjusted hazard ratio 
(HR) and 95% CI for the associations between MTTP –I128T and risk of total CVD. 
Associations between MTTP –I128T and CVDs were tested using the additive model. 
RESULTS 
General characteristics 
The genotype distribution of the -164T>C and –I128T SNPs followed the HWE (P=0.37 and 
P=0.71, respectively for the EPIC-Potsdam subcohort and for the replication Heinz Nixdorf 
Recall Study). There were 1 114, 758 and 143 subjects with genotypes TT, CT, CC 
respectively (738 men and 1 277 women) observed in the sub-cohort. The C allele frequency 
was 0.26 for both studies. According to -164T>C genotype, age- and sex-adjusted baseline 
characteristics of subjects who did or did not develop cardiovascular events during the follow-
up period are shown in Table 1. In particular, 58.5% of subjects with incident CVD (n=324; 
193 incident MI; 131 incident IS) were men, older, smokers and with a lower educational 
level than individuals who remained free of CVD (n=1 978) during a mean follow-up of 8.2 
years. Furthermore, they had a higher prevalence of abdominal obesity and hypertension, 
slightly higher total and low density lipoprotein- (LDL-) and lower HDL-cholesterol levels 
(Table 1). According to genotype no significant differences in central obesity, obesity and 
hypertension and socio-demographic characteristics were observed in subjects with or without 
CVD (Table 1). In contrast, opposite trends were observed for total-, LDL-cholesterol and 
triglyceride levels. In the group free of CVD carriers of the C-allele showed slightly higher 
total- and LDL-cholesterol levels (Ptrend = 0.036 and Ptrend=0.026, respectively). In the group 
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of CVD carriers of the C-allele showed lower triglyceride (Ptrend=0.016) along with slight 
lower total-cholesterol levels (Ptrend=0.033) (Table 1).  
Association between MTTP -164T>C polymorphism and incident CVD 
The association between the MTTP -164T>C polymorphism and CVD events was tested also 
for MI and IS separately, taking into consideration the additive, dominant and recessive 
models (Table 2). Since there were no sex differences in the association between MTTP -
164T>C and CVD (P for interaction = 0.86), we combined men and women in all analyses. 
After adjustment for age and sex, Cox regression analyses revealed no significant association 
between the -164T>C variant and CVD risk considering the additive (HRadditive: 1.04, 95% CI: 
0.86 to 1.25; P=0.714), dominant (HRCT+CC vs TT: 1.09, 95% CI: 0.85 to 1.39; P=0.505) and 
recessive (HRCC vs CT+TT: 0.90, 95% CI: 0.55 to 1.46; P=0.662) models. Nevertheless, the 
multiplicative and additive interactions between the -164T>C polymorphism and total 
cholesterol (dichotomous) in relation to CVD risk were significant and in the same negative 
direction ($multiplicative interaction = -0.55 ± 0.19; P=0.004; SIadditive interaction = 0.31, 95% CI: 0.16 to 
0.62 and RERIadditive interaction = -1.44, 95% CI: -2.37 to -0.51).  
Stratified analyses according to low (<200 mg/dL) and borderline-high/high (#200 mg/dL) 
cholesterol levels showed significant positive associations between MTTP -164T>C and CVD 
in subjects with cholesterol levels <200 mg/dL, considering both the additive (HRadditive= 1.38, 
95% CI: 1.07 to 1.78; P=0.014) and the dominant models (HRCT+CC= 1.76, 95% CI: 1.22-
2,54; P=0.002) (Table 2). Analyzing MI and IS separately, the associations seemed to be 
stronger for stroke (HRadditive:=1.60, 95% CI: 1.16 to 2,20, P=0.004; HRDominant= 2.22, 95% 
CI: 1.35 to 3.64, P=0.002) than for MI (HRadditive= 1.19, 95% CI: 0.82 to 1.72, P=0.353; 
HRDominant= 1.41, 95% CI: 0.85 to 2.33, P=0.186). However, results from the competing risk 
analysis (IS versus MI) provided a Wald test P value equal to 0.28 and 0.20, respectively, for 
the additive and dominant model. Further adjustment for other CVD risk factors (i.e. body 
mass index, waist circumference, prevalent hypertension, sport activity and alcohol 
consumption) led to similar HRs depicted in Table 2 (data not shown).  
In subjects with cholesterol levels # 200 mg/dL we observed a borderline inverse association 
between MTTP -164T>C and CVD in the additive model (HRadditive= 0.77, 95% CI: 0.58 to 
1.03, P=0.075) and significant relationships in the dominant model (HRdominant= 0.67, 95% CI: 
Chapter 5!-164T>C MTTP polymorphism and CVD risk!
 
121 
 
0.48 to 0.94, P=0.021; HRdominant= 0.65, 95% CI: 0.43 to 0.97, P=0.036, respectively, for CVD 
and MI)(Table 2).  
We performed additional analyses by testing both the multiplicative and additive interactions 
for triglycerides, HDL- and LDL-cholesterol. The interactions between MTTP/triglycerides 
and MTTP/HDL-cholesterol in relation to CVD were not significant (P=0.18 and P=0.11, 
respectively), whereas they were significant and in the same direction as those found for total 
cholesterol when LDL-cholesterol was analyzed (multiplicative interaction: P=0.023; SIadditive 
interaction = 0.33 95% CI (0.15-0.73) and RERIadditive interaction = -1.17 95% CI (-2.01—0.33). 
Stratified analysis according to the 2 LDL-cholesterol categories (<130 and #130 mg/dL) 
showed an increased CVD (HRadditive: 1.24; 95% CI: 0.98 to 1.56; HRdominant: 1.51; 95% CI: 
1.09 to 2.08) and IS risk (HRadditive: 1.30; 95% CI: 0.96 to 1.75; HRdominant: 1.66; 95% CI: 1.07 
to 2.57) in the low LDL group when MTTP was considered in a dominant fashion. A 
decreased CVD (HRadditive: 0.80; 95% CI: 1.58 to 1.09; HRdominant: 0.69; 95% CI: 0.47 to 1.00) 
and MI (HRadditive: 0.74; 95% CI: 0.51 to 1.07; HRdominant: 0.62; 95% CI: 0.39 to 0.96) risk was 
observed, instead, in the high LDL group, always in a dominant fashion (data not shown). 
In the replication cohort we did observe a trend toward a decreased CVD risk in individuals 
with cholesterol levels higher than 200 mg/dL (HRadditive= 0.60, 95% CI: 0.29 to 1.25; 
P=0.17). No association was observed in the other strata (<200 mg/dL) (HRadditive= 1.06, 95% 
CI: 0.33 to 3.40; P=0.92). 
DISCUSSION 
In this study, we anticipated an interaction between total cholesterol levels and the MTTP -
164T>C polymorphism with regard to the CVD risk. The presence of a statistically significant 
interaction confirmed our hypothesis and indicated carriers of the C allele of the MTTP -
164T>C polymorphism with plasma total cholesterol levels lower than 200 mg/dL had an 
increased risk of CVD. The association seemed to be stronger for IS than for MI, but 
differences in the associations were not supported by competing risk analysis. Conversely, the 
MTTP -164 C-allele showed a lower CVD, and MI, risk in participants with cholesterol levels 
higher than 200 mg/dL. Similar relationships were observed considering LDL-cholesterol 
with levels lower and higher than 130 mg/dl suggesting that LDL is the driving cholesterol 
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component. However, the value of LDL levels seems to be limited as estimated based on the 
Friedewald formula [46]. In fact further studies are needed to replicate these findings. 
The association between MTTP –I128T polymorphisms and CVD risk observed in the 
replication cohort showed a similar trend within the strata of cholesterol levels higher than 
200 mg/dL. However, considering that the number of cases in the Heinz Nixdorf Recall Study 
is small further replication studies are needed. To our knowledge, this is the first prospective 
study showing such an effect of MTTP on risk of IS.  
With regard to the association between the MTTP -164T>C polymorphism and cholesterol 
levels, previous studies observed inconsistent results. Few studies reported a slight cholesterol 
lowering effect of the rare alleles of the MTTP promoter polymorphisms [7, 10]. Ledmyr et al. 
investigated the association between the MTTP -493 G/T polymorphism and cholesterol in 
both healthy and hyper-cholesterolemic individuals, and observed decreased levels of total 
cholesterol in carriers of the -493 T variant [7, 10]. Furthermore, Phillips et al. in a small 
study including 82 patients with type 2 diabetes mellitus (T2DM) of a Caucasian population 
found that the subjects heterozygous for the -493 G/T had lower LDL-cholesterol and, in the 
postprandial phase, higher apoB48 levels in the VLDL fraction. The authors suggested that 
the -493 G/T polymorphism seemed to confer protection against atherosclerosis in T2DM 
patients [12]. In contrast, Jou et al. observed that total cholesterol, LDL-, and non HDL-
cholesterol levels were higher according to the rare allele of the MTTP -493 G/T 
polymorphism when disease free young African Americans were investigated [19, 20]. 
Further, Lundahl et al. observed lower serum triglyceride levels in subjects affected by 
familial hypercholesterolemia and homozygous for the rare allele of the MTTP -493 G/T 
genotype [8].  
Overall, these studies seem to suggest that MTTP regulates lipids differently in the presence 
or absence of disease, although the occurrence of a possible interaction between the LDL 
receptor and the MTTP genes is not excluded [7, 14]. Our results seem to be in line with these 
hypotheses. On one hand we observed slightly higher total and LDL-cholesterol levels in 
subjects free of CVD and homozygous for the rare -164 C allele, and on the other, lower total 
cholesterol and triglyceride levels according to the rare allele of the MTTP -164T>C 
polymorphism in the group of future CVD cases.  
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It has been shown that the C–allele of the MTTP-164 T>C polymorphism is homologous to a 
putative sterol response element (SRE) binding site and as such confers a reduced MTTP 
expression [26-28]. These findings come from an experimental study in which Hagan et al. 
demonstrated that human MTTP promoter activity is up-regulated by cholesterol [27]. The 
mechanism based on which cholesterol regulates MTTP gene expression is linked to the 
presence of a modified SRE in the MTTP promoter [27]. When cholesterol levels are low, the 
sterol regulatory element binding protein (SREBP) acts as transcription factor, binds to the 
SRE thereby inhibiting MTTP gene expression [28]. In contrast, in presence of cholesterol the 
modified SRE likely binds a new SREBP family member thus up-regulating MTTP 
expression [27, 28]. These observations suggest that MTTP gene expression is differently 
regulated by high and low cholesterol levels.  
Despite the lack of significant associations between the -493G>T or -164T>C single 
nucleotide polymorphisms (SNPs), coronary heart disease and blood lipids observed in two 
previous studies [24, 25], recently Aminoff et al. put forward that carriers of the rare -164C 
allele are at increased risk of IHD [26]. They substantiated their findings by showing in vivo 
that the presence of the rare alleles of the -493G>T and -164T>C SNPs confer lower MTTP 
transcription in the heart, liver and macrophage. This mechanism, in turn, by causing the lipid 
accumulation in the heart would provoke an increased IHD risk. Indeed, our findings are in 
line with those of Aminoff et al. though they concluded that the increased IHD risk observed 
according to the -164C variant was independent of plasma lipids. As mentioned above, 
because human MTTP promoter activity is positively regulated by cholesterol [27], it is 
reasonable to assume that subjects with low cholesterol levels have, in general, a lower MTTP 
gene expression. Thus, in this low risk group carriers of the -164C variant, compared to 
carriers of the common allele, might be at increased CVD because of their lower MTTP gene 
expression. At the same time, if one would consider the observed associations as those 
mimicking MTTP inhibitors, then these findings could further highlight the concerns 
expressed by Aminoff et al. regarding the long term side effects MTTP inhibition may 
generate [26, 47]. 
In contrast, in subjects with higher cholesterol levels we observed a reduced, though 
borderline significant, CVD risk accordingly to the MTTP gene -164 C variant. Our findings 
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suggest that there could be an antagonistic (qualitative) interaction between cholesterol levels 
and MTTP -164 T>C polymorphism. These observations warrant further investigation. 
The main limitation of this study is that the plasma lipoprotein and apolipoprotein levels, 
which are important in the effect of MTTP in cardiovascular disease, were not measured; our 
analyses on triglyceride levels were based on both fasting and non-fasting subjects; we 
estimated the LDL-cholesterol levels based on Friedewald equation. Strength of our study 
includes its prospective design. Furthermore, all cases of MI and IS were validated by medical 
records and were derived from a cohort population with a very high follow-up coverage.  
CONCLUSIONS 
The findings of this study suggest that in the subjects investigated an interaction between 
MTTP -164T>C functional polymorphism with total cholesterol levels predisposes risk allele 
carriers with low cholesterol levels to an increased risk of developing CVD, which seems to 
be abolished among risk allele carriers with high cholesterol levels. However, further studies 
are warranted in order to shed more light on these complex mechanisms. 
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Table 2: Hazard rate ratios (HR) and 95% confidence intervals (95% CI) for the associations 
between MTTP -164 T/C polymorphism, CVD (combined endpoint), MI and IS. 
  Cholesterol < 200 mg/dL Cholesterol # 200 mg/dL 
  HR (95% CI)* HR (95% CI)* 
 CVD MI IS CVD MI IS 
Cases, n 139 69 70 185 77 40 
       
C allele 1.38 (1.07-1.78) 1.19 (0.82-1.72) 1.60 (1.16-2.20) 0.77 (0.58-1.03) 0.76 (0.54-1.07) 0.77 (0.48-1.23) 
Padditive 0.014 0.353 0.004 0.075 0.113 0.273 
       
Dominant  1.76 (1.22-2.54) 1.41 (0.85-2.33) 2.22 (1.35-3.64) 0.67 (0.48-0.94) 0.65 (0.43-0.97) 0.69 (0.40-1.18) 
Pdominant 0.002 0.186 0.002 0.021 0.036 0.172 
       
Recessive 0.73 (0.31-1.69) 0.71 (0.21-2.39) 0.75 (0.25-2.27) 0.98 (0.53-1.82) 0.99 (0.47-2.06) 0.93 (0.33-2.66) 
Precessive 0.458 0.580 0.616 0.948 0.969 0.892 
aAdjusted for age and sex. 
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ABSTRACT 
Applications for automating the most commonly used dietary surveys in nutritional research, 
Food Frequency Questionnaires (FFQs) and 24 h Dietary Recalls (24HDRs), are reviewed in this 
paper. A comprehensive search of electronic databases was carried out and findings were 
classified by a group of experts in nutrition and computer science into: (i) Computerized 
Questionnaires and Web-based Questionnaires; (ii) FFQs and 24HDRs and combinations of both; 
and (iii) interviewer-administered or self-administered questionnaires. A discussion on the 
classification made and the works reported is included. Finally, works that apply innovative 
technologies are outlined and the future trends for automating questionnaires in nutrition are 
identified.
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1. INTRODUCTION 
Dietary factors are linked to the leading non-communicable causes of death [1]: cardiovascular 
diseases, some cancers, type 2 diabetes, etc. The study of the interaction between diet and the 
genome is crucial to prevent and treat these diseases. The assessment of a person’s diet is a 
painstaking task which consists of analysing their daily intake over one or more years. However, 
in epidemiological studies of diet-disease association, this assessment is not feasible and, in 
practice, only a portion of the intake information is evaluated and then the habitual participants’ 
intake is extrapolated. In order to obtain enough statistical power to avoid measurement errors 
and changes in diet, it is necessary to obtain repeated measures of dietary information from a 
large number of participants over time. For extracting information on participants’ diet, 
nutritionists use Food Frequency Questionnaires (FFQ), 24 h dietary recalls (24HDRs), dietary 
records or dietary histories. These surveys collect data on consumed foods or dishes, which can 
be transformed into energy and nutrient intake using food composition tables (FCTs).  
FFQs and 24HDRs are the most widely used tools to extract information on diet in the field of 
epidemiological studies. Both techniques assume that participants have some regularity in their 
diet and are able to quantify it.  
FFQs ask participants to report their usual frequency of consumption of each food from a list and 
for a specific period of time [2]. They assess habitual consumption of foods or nutrients. FFQs 
present general questions such as ‘Do you eat olive oil?’ and if participants respond ‘yes’, the 
FFQs ask the frequency of consumption (i.e. ‘How often do you eat olive oil? Units per 
day/week/month/year, etc.’). The FFQs that include portion-sizes of foods are also referred to as 
semiquantitative FFQs. The use of FFQs is widespread because of their advantages such as easy 
administration and translation into nutrients, and also because they can cover seasonal intake 
variations and foods of occasional consumption. However, the automation of nutrient calculation 
is intensive and requires considerable computing and nutritional expertise [3]. Many FFQs were 
developed for different purposes, from capturing usual intake among large population-based 
samples [4] to tailoring the questionnaire to measure intake of a particular nutrient/food/food 
group in small specialized samples such as: iron [5], omega-3 fatty acids [6], calcium [7], 
phytosterols [8], etc.  
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24HDRs ask the respondent to recall all the foods and beverages consumed in the preceding 24 h 
or day [2]. They usually use open-answer questions, such as ‘List all the beverages you drank and 
all the foods you ate yesterday between midnight and midnight’ (unstructured recall) or ‘List all 
the beverages you drank and all the foods you ate yesterday for breakfast/lunch/dinner/snacks’ or 
‘What did you eat when you woke up?’ (meal based recall). 24HDRs are used to collect high-
quality dietary data because: (i) they are based on short-term memory, (ii) they do not consist of a 
closed list of foods and (iii) they provide quantitative information rather than consumption 
ranges. Therefore they do not require adaptation to specific populations such as FFQs. A single 
24HDR is not considered representative of an individual’s usual diet, so multiple 24HDRs are 
preferred for many nutritional studies. They also require highly trained interviewers, thus 
24HDRs are not considered economical or practical in research settings with large samples and 
FFQs are frequently used. If 24HDRs could be self-administered using computer technologies to 
substitute the interviewer, they could be more feasible for large-scale studies [9].  
Dietary records are more precise than 24HDRs because food intake is registered at the time of the 
eating. However, dietary records present high respondent burden, high investigator cost, and an 
extensive training and motivation of participants [2]. Therefore dietary records are usually 
substituted by 24HDRs in nutrition studies. The same disadvantages are present in diet histories 
in large population nutritional studies because they collect information not only about the food 
frequency of intake but also about the typical makeup of meals [2]. They also include more than 
one intake survey, such as the combination of a 24HDR, a FFQ and 3-day diet records [10]. 
Moreover they sometimes involve difficult cognitive tasks for the respondents, are not 
quantifiably precise and can have a high investigator burden [2]. 
There is no ideal method of reference or gold standard for estimating the validity of a food 
survey. In practice, relative validations of a questionnaire (i.e. FFQ) are performed with respect 
to another questionnaire (i.e. 24HDRs) taking into account that the sources of error between the 
reference questionnaire and that evaluated must be as independent as possible. By comparing 
both surveys, correlation coefficients are obtained which indicate the validity of the instrument 
and the calibration coefficients to be applied for correcting further executions. This is the reason 
why studies usually combine FFQ and 24HDRs for obtaining results and validate them [11,12].  
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Traditionally, FFQs and 24HDRs were administered in paper (i.e. Harvard paper FFQs1). 
However, as information and communication technologies have gained importance in recent 
years, great efforts have been made to automate the questionnaires involved in epidemiological 
and other nutritional studies in order to save costs.  
First, computer programs were developed for helping researchers to administer questionnaires to 
participants and to accelerate the extraction and processing of the important data from FFQs [13–
15,3,6,16] and from 24HDRs [17–19]. Then, other software applications automated self-
administered FFQs [20,21,5,22,6,7], 24HDRs [23–25], and combinations of both [26] were 
developed. And all these tools needed a specific computer system in order to function correctly.  
When the World Wide Web became widespread, dietary Web-based questionnaires substituted 
computerized questionnaires for improving accessibility and for obtaining a multi-platform 
functionality, such as on-line FFQs [8,27–39], on-line 24HDRs [9,40–43] and combinations of 
both [11,44,45].  
In literature there are numerous works concerning the development, validation, repeatability of 
FFQs and 24HDRs in epidemiological studies. However, there are fewer approaches describing 
engineering developments for the automation, evolution and acceleration of results extraction in 
epidemiological studies. Our contribution here is: (i) to provide a broad state-of-the-art review 
from a technological point of view of studies that used an automated FFQ or 24HDR, (ii) to 
compare them and discuss their characteristics, (iii) to present recent developments that use 
innovative technologies, and (iv) to outline future prospects.  
A few similar reviews are found in the literature [46,47,1,48]. A very brief review on 
technologies applied to FFQ was presented by García-Segovia et al. [46]. A classification of Web 
tools and other computer applications used in nutrigenomic research was undertaken by Stumbo 
et al. [47]. They presented the most commonly used tools in US and Europe providing a 
description from the point of view of a researcher in nutrition. Long et al. [1] presented a review 
of the evidence on the effectiveness of technology-based methods for dietary assessment by 
reporting six technology-based methods. Ngo et al. [48] reviewed automated nutrition 
questionnaires and outlined some innovative methods for automating questionnaires, such as 
smart cards, personal digital assistants (PDAs) and mobile phones. In this paper, a wider period 
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of time is taken into consideration, a broader description is presented regarding computerized and 
Web-based FFQs and 24HDRs, a comparative discussion is provided on the automation and 
administration of questionnaires and also innovative technologies are reported. An engineering 
perspective of all the works is given, when available, and useful recommendations for automating 
questionnaires in nutrition are outlined.  
The rest of this paper is organized as follows. Section 2 explains the methodology used for 
carrying out the state-of-the-art review and presents a classification of all the works found in the 
literature. Section 3 describes the computerized systems that implemented FFQs and 24HDRs, 
whereas Section 4 explains the Web-based FFQs and 24HDRs. Section 5 reports on recent 
innovative technologies and, in Section 6 a discussion is presented. Section 7 presents 
conclusions and future prospects. 
 
2. METHODOLOGY 
Two researchers undertook an independent review of nutritional studies in which the design, 
development and/or use of automated (computerized or Web-based) FFQs and 24HDRs were 
described. Electronic databases including PubMed, EMBASE and Web of Science were searched 
from 1980 to December 2011. Hand searches of published conference proceedings, key nutrition 
journals and reference lists of retrieved papers were also undertaken. The search terms used were 
based on the following titles/ topics and keywords/abstracts searches: 
- Computer* food* questionnaire*, computer* 24 h* recall*, 
- Web* food* questionnaire*, Web* 24 h* questionnaire*, Web* 24 h* diet* 
- Internet* food* questionnaire, Internet* 24 h* recall*, Internet* 24 h* questionnaire, Internet* 
24 h* diet* recall*. 
The papers obtained were first classified from a computational science point of view into two 
study types: (1) Computerized Questionnaires and (2) Web-based or Internet-based 
Questionnaires. Secondly, those works were classified from a nutritional point of view into: (1) 
FFQs, (2) 24HDRs and (3) combinations of FFQs and 24HDRs. And finally, a last classification 
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was made regarding the type of administration to participants: (a) interviewer-administered or 
used by the researcher for interviewing the participants, and (b) self-administered or completed 
by the participants themselves. Tables 1 and 2 show the results of this classification.  
 
3. COMPUTERIZED QUESTIONNAIRES 
The advantages that computerized questionnaires offered with respect to paper questionnaires 
caused their progressive introduction into nutritional studies, such as:  
- The higher speed of data collection because answers are automatically stored on databases 
saving the time required to enter data manually;  
- The higher quality of data extracted since there is an immediate and automatic control for 
incomplete and implausible data;  
- The direct data transfer to the centre of study (avoiding costs of printing, postage and data 
typing);  
- The easy and plausible introduction of help wizards on portion size estimation and recognition 
of food using real color illustrations;  
- The small extra cost of adding a few thousand participants to the study once the system for 
handling the questionnaires is developed and established.  
These advantages were provided by computerized questionnaires appearing in literature which 
have been classified in Table 1 and described below. Section 3.1 presents works that used 
computerized FFQs, whereas Section 3.2 describes computerized 24HDRs. Section 3.3 presents 
one computerized FFQ and 24HDR.  
 
3.1. Computerized food frequency questionnaires (C-FFQs)  
Several research studies describing the development and application of computer programs for 
automating data extraction from FFQs can be found in the literature [13,20,21,14,5,15,22, 
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3,6,16,7]. From the point of view of engineering technologies, perhaps some of the most recent 
and relevant studies would be the following:  
1. CAFE [3]: Compositional Analyses from Frequency Estimates program, which automated the 
FFQ developed for the European Prospective Investigation into Cancer and Nutrition Study in the 
United Kingdom (EPIC-Norfolk and EPIC-Oxford). CAFE was written in SAS3 linked to an 
Oracle4 relational database which allowed predefined entries (numeric codes for frequency 
responses) and free text entries for registering new food items and nutrients. CAFE uses the EPIC 
nutrient database and the food composition table by McCance and Widdowson [49,50]. 
2. NUTRISOL [16]: a nutritional freeware program for analysing dietary food intakes and 
translating them into nutrients using the food composition tables (FCTs) developed by the 
Spanish National Research Council (CSIC) [51] and also using domestic commonly used 
measures for local dishes description. NUTRISOL was developed on MS Access using Visual 
Basic 6.0 and ran under Windows OS. It was PC-compatible and it needed a processor running at 
least at 200 MHz, 16 MB of RAM and 80 MB of hard disk free space. The results produced were 
exportable to statistical programs such as MS Excel and the Statistical Package for Social 
Sciences or SPSS5 v. 11. NUTRISOL was used for analysing the diet of some populations in 
Málaga and Cádiz (south Spain) through studies carried out by the Nutrition and Food 
Technology Institute6 at Granada University (Spain) and by the University Clinic Hospital in 
Málaga (Spain). The computerized FFQ developed also allowed the FCTs to be adapted/changed 
for other populations/countries.  
Other studies also used computerized FFQ but technological descriptions of the design and 
development of their programs were not available:  
i. RIBEPEIX [6]: a c-FFQ designed to quantify the intake of fish and shellfish omega-3 fatty 
acids and chemical contaminants in a general population. A MS Access database was created 
with the concentrations of fatty acids and pollutants of each sea food.  
ii. Heath et al. [5] developed and validated a computerized FFQ in order to estimate the iron, 
vitamin C and calcium consumption of a population of young adult New Zealand women using 
the New Zealand Food Composition Database [52], and their phytate consumption using the 
Canadian food composition database [53]. Results were exportable to SPSS v. 6.1.1.  
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iii. Vandelanotte et al. [22] developed and validated a computerized FFQ to estimate fat intake in 
Belgium using the Belgian [54] and Dutch [55] food composition tables. Results were exportable 
to SPSS v. 11.  
 
3.2. Computerized 24 h dietary recalls (C-24HDRs) 
In the literature, few research studies on the development of computerized 24HDRs have been 
published [17,23,18,19,24,25]. Chronologically, these studies are:  
1. EPIC-SOFT [17]: a computerized questionnaire developed to obtain standardized 24HDRs 
between the nine countries involved in the European Prospective Investigation into Cancer and 
Nutrition (EPIC). This program was written in Clipper, it ran on MSDOS v.3 and it was PC IBM-
compatible needing 2MB of RAM and 5MB of hard disk free space. The nutrient databases 
implemented in the system and used to calculate energy and macronutrients were temporary 
FCTs derived from national values.  
2. FIRSSt [23]: the Food Intake Recording Software System designed for use with fourth-grade 
children in USA. It used interactive multimedia to facilitate a child’s self-report of diet by 
simulating a multiple pass 24HDR. FIRSSt included a computerized tutorial about how to use the 
program and it organized foods within a group hierarchy in which commonly consumed foods 
were also included. FIRSSt was programmed in Director 6.5, Foxpro was used to create a 
database, and data were downloaded into MS Access. The Continuing Survey of Food Intakes by 
Individuals food coding system was used to identify foods and identify amount of foods in food 
groups for mixed dishes.  
3. The US Department of Agriculture (USDA) is the world leader in 24HDR methodology having 
used 24HDRs as the primary dietary assessment method in American surveys of food 
consumption since 1965. Their Dietary Intake Data System (summarized by Raper et al. [18]) is 
composed of three separated computer systems: (1) the Automated Multiple Pass Method 
(AMPM) for collecting food intakes using a 24HDR programmed using a MS Access database 
and Blaise programming language which was used by Moshfegh et al. [19] for assessing nutrient 
intake and appropriateness from the dietary interview component of the National Health and 
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Nutrition Examination Survey (NHANES): What We Eat In America (WWEIA); (2) the Post-
Interview Processing System (PIPS) for reformatting data and assigning food codes; and (3) the 
Survey Net system for final coding and editing, quality review, and nutrient analysis. The Food 
and Nutrient Database for Dietary Studies (FNDDS) is used by the AMPM to calculate the food 
decomposition in nutrients. The FNDDS includes food descriptions, food portions and their 
weights, and their corresponding nutrients and it is reviewed periodically by dietary coders who 
make corrections if needed and assign codes to any unmatched responses.  
4. YANA-C [24]: the “Young Adolescents Nutrition Assessment on Computer” is a self-
administered 24HDR structured in six meal occasions including 18 food groups and a 19th group 
for the items not listed in the menu. It also included photographs for portion size estimation 
which changed every time a participant pushed the ‘more’ or ‘less’ button and other information 
such as ‘Don’t forget mayonnaise if you ate French fries...’. YANAC was developed using MS 
Visual Basic v. 6.0 and the total energy and nutrient intakes were computed using the Unilever 
Becel Nutrient Calculation Program v. 5.037 and the Belgian [54] and Dutch [55] FCTs. The 
YANA-C was also applied to 3 SAS SW v.8, SAS Institute Inc., Cary, NC, USA. Healthy 
Lifestyle in Europe by Nutrition in Adolescence or the HELENA study [56,57]. The feasibility of 
self-administration was analyzed [56] and compared to administration by a dietitian concluding 
that both methods were comparable.  
5. NDSR [25]: Nutrition Data System for Research software by the Nutrition Coordinating 
Center (NCC) at University of Minnesota is a Windows-based dietary analysis program designed 
for the collection and analyses of 24HDRs and the analysis of food records, menus, and recipes. 
Calculation of nutrients occur immediately providing data per ingredient, food, meal, and day in 
report and analysis file formats. The software includes a dietary supplement assessment module, 
so that nutrient intake from both food and supplemental sources may be captured and quantified. 
NDSR may be installed on standalone computers or in a network environment and is supported 
on Microsoft Windows 7/Vista/XP. The minimum recommended hardware for NDSR 2011 on 
Windows 7 are: 2.2 GHz of processor speed, 2 GB of RAM, and 36 GB of hard disk free space. 
The NDSR uses the Food and Nutrient Database developed by the NCC [58], which includes 
over 18,000 foods, 7000 brand products, 162 nutrients, etc.  
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The NDSR has been used in several nutrition studies. For example, in order to increase portion 
size estimation accuracy, Toobert et al. [59] developed an interactive CD-ROM program to 
estimate fruit, vegetable and fat intake in USA populations from two dietary screeners: the 
National Cancer Institute’s revised Fruit and Vegetable Scan [60] and the Block Fat Screener 
[61]. They validated that CD-ROM program comparing it to a computerized 24HDR carried out 
on participants by expert dietitians using the NDSR software v. V2007 and V2008.  
 
3.3. Systems integrating both: C-FFQs and C-24HDRs  
In the literature, CAPI [26] a computer-assisted personal interviewing seafood consumption 
survey tool is presented. The CAPI contains a 24-h recall and food frequency questionnaire, and 
assesses seasonal seafood consumption and temporary changes in consumption. It was developed 
from existing the Pacific NW Native American seafood consumption survey methodology. The 
CAPI is used with a booklet of harvest locationmaps and species and portion size images. 
Moreover, it is used by tribal interviewers reducing potential bias. CAPI survey software was 
developed using Microsoft Access 2000. Tribes are provided with a supervisor’s software module 
to configure the CAPI for their tribe and they can select fish and shellfish consumed by a tribe 
from a prepopulated species library included in the CAPI. The supervisor can preview and test 
the customized CAPI and then deploy the survey software to one or more interviewer computers. 
The supervisor can add new species to the database that were identified during interviews with 
tribal members. Data can be exported for further analysis using statistical software.  
 
4. WEB-BASED OR INTERNET-BASED QUESTIONNAIRES  
In the last few years, a considerable number of research works in nutrition that use Web-based or 
Internet-based questionnaires have appeared in the literature. The significance of these 
questionnaires increased with the broadcasting of information and communication technologies. 
Web-based questionnaires provide all the advantages of computerized questionnaires and others 
such as:  
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- The higher compliance, provided by more flexibility of completion at any time and location, 
and the personalized feed-back and interactive help features provided (self-administered);  
- The ability to communicate with geographically dispersed research groups (interviewer-
administered) or populations (self-administered), potentially internationalizing research, and 
groups often difficult to sample.  
The nutritional Web-based questionnaires most widely referenced in the literature can be 
classified as Table 2 shows into: (i) Web-FFQs, described in Section 4.1, and (ii) Web-24HDRs, 
described in Section 4.2.  
 
4.1. Web-based food frequency questionnaires (Web-FFQs)  
With the increased number of research studies using Web- FFQs in the last few years [8,28–
30,32,35–39] their validity and reproducibility has also been evaluated [27,31,33,34]. From the 
point of view of engineering technologies, some of the most interesting developments that 
appeared chronologically in the literature are the following:  
1. FITUVEROLES [8]: a Web service for calculating phytosterol intake in a Mediterranean 
population using a Web-FFQ developed by physicians, computer science engineers and other 
researchers in biomedicine for estimating the intake of phytosterols of the participants from 
previously validated FFQs that included 101 food items divided into 11 food groups. Results are 
calculated using three nutrient data sources for comparing and providing the robustness of the 
estimation: the Finnish Food Composition Database [62], the National Nutrient Database for 
Standard Reference by USDA [63] and the data provided by Jiménez-Escrig [64] for Spanish 
foods. FITUVEROLES was programmed using PHP, XHTML and JavaScript and the database 
engine was MySQL. The results produced were exportable to SPSS.  
2. DHQ [30]: the Diet History Questionnaire funded by the American National Cancer Institute 
(NCI) with their DHQ Nutrient Database and data analysis used in cancer research. The DHQ is a 
food frequency questionnaire (FFQ) which consists of 124 food items and includes both portion 
size and dietary supplement questions. Beasley et al. [31] added pictures to this DHQ in order to 
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represent portion sizes and they developed the Web-based pictorial diet history questionnaire 
(PDHQ).  
3. Galante and Colli’s [28] on-line semi-quantitative FFQ to evaluate calcium and iron intake. 
The contents of the study were stored in a database with a copy on a CD-ROM. To ensure the 
confidentiality of the information and the privacy of the individuals, access to the communication 
tool was made available through an individual password, and data transmission was performed 
through personal e-mails. The statistical analysis of the results was carried out using the Virtual 
Nutri SW.8  
4. Apovian et al. [33] developed and validated a Web-FFQ for capturing food servings in the 
Dietary Approaches to Stop Hypertension or DASH diet recommended by the US Department of 
Agriculture (USDA). It was implemented on HTML using check boxes and entry fields for self-
administration and it was placed on a secure Web server at Boston University’s Data 
Coordinating Center.  
5. The Web-based assessment tools in Epidemiology9 by the German Institute of Human 
Nutrition Potsdam-Rehbrücke (DIfE) [36]: (1) EPIC Potsdam FFQ; (2) European FPQ [65] 
containing 116 foods organized into 10 families and graphics for displaying portion sizes; (3) 
German FPQ; (4) European- Hellenic FPQ. They are usually self-administered or telephone-
assisted. The participants must log into the Web service with the user name (ID) and password 
they received from the study office so that they are connected to the right questionnaire. Then 
they receive further information about filling in the online forms and who to ask in case of 
needing assistance. These Web-FFQs are used in the study of chronic diseases such as cancer, 
cardiovascular diseases or diabetes.  
6. The VioFFQ by Viocare enterprise [38]: a self-administered Web- FFQ that collects data on 
dietary behavior and food patterns, estimates nutrient intake, and delivers a dietary change report. 
Dietary analysis is undertaken using the food and nutrient information from the Nutrition 
Coordinating Center (NCC) Food and Nutrient Database by the Division of Epidemiology and 
Community Health at the University of Minnesota. The VioFFQ was used in several 
epidemiological studies, for example, the recent study by McDaniel et al. [66] on polyunsaturated 
fatty acid ratios and their association with numerous chronic inflammation-related diseases.  
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7. The Block FFQ [39] by NutritionQuest [67]: a turn-key system, which provides an on-line 
structure for integrated data collection, nutrient and physical activity analysis, and data 
management. Questionnaires can be interviewer- or self-administered. Block FFQ accessed on-
line and self-administered was used by Anderson-Bill et al. [68] for estimating the intake of fat, 
fiber, fruits and vegetables of the participants of a study for examining the behavioral 
characteristics of Web-health users.  
Other important studies that use Web-FFQs, but which do not provide technological descriptions 
of the design and development of their programs are also available:  
i. Matthys et al. [27] implemented and validated a Web-FFQ for analysing adolescents’ food 
habits and proved its validity and reproducibility. The security of the system was achieved by 
providing a login name and a session-specific password to the participants. This FFQ contained 
questions on the average consumption of 69 food items during the past month and the food items 
listed were based on the classification system described in the Flemish Food Guide, commonly 
referred as the Food Triangle [69]. The energy intake was calculated [70] using the Belgian [54] 
and the Dutch [55] FCTs;  
ii. RIBEFOOD [29] developed by the same authors of the computerized program RIBEPEIX [6] 
determines the dietary intake of a number of chemical contaminants (i.e., metals, dioxins and 
furans, PCBs, polycyclic aromatic hydrocarbons, etc.) using a FFQ carried out on a Web service;  
iiii. Probst et al. [32] developed a Web-FFQ which automated the sequence of questioning that a 
dietitian usually takes with a client when conducting a diet history interview and they also 
connected aWeb camera to the computer for video-recording and analysing the participants’ 
behaviors related to the type of foods appearing in the questionnaires;  
iv. Vereecken et al. [35] developed a Web-FFQ for the Healthy Lifestyle in Europe by Nutrition 
in Adolescence or HELENA Study [56]. The reproducibility of this FFQ was analyzed in 
comparison to the YANA-C computerized 24HDR [24] and it has been recently validated by 
Maes et al. [71].  
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4.2. Web-based 24 h dietary recalls (Web-24HDR)  
Studies using automated 24HDRs and on-line technologies appearing in the literature [9,40–43] 
are:  
1. ASA24 [9,72] a Web-based Automated Self-Administered 24HDR developed by the American 
National Cancer Institute (NCI) which was inspired by the USDA’s Automated Multipass 
Method or AMPM [18,19] and that incorporated and extended the Food Nutrient Database for 
Dietary Studies or FNDDS [18] and the food portion pictures of Food Intake REcording SW 
System or FIRSSt [23].  
2. SNAPTM or the Synchronized Nutrition and Activity Program [40]: a Web-based software 
designed and evaluated for obtaining self-reported 24HDRs and physical activity questionnaires 
in school children. SNAPTM was written using PHP v. 4.0.1, MySQL v. 3.22 and JavaScript v. 
1.3 to ensure data transfer and storage and its interface is intuitive and user-friendly for children 
to use. The dietary intake was measured using counts for 21 food groups and the list of 
commonly consumed foods and drinks was developed from a combination of findings from the 
National Diet and Nutrition Survey [73]. A free-text option box was also included to capture any 
unlisted food or drink. The data analysis was carried out using STATA10 v.8. software and the 
accuracy of the computer tool was provided by a Passing-Bablok method comparison technique 
using the Analyze-it11 software.  
3. DietDay [41,74]: a fully automated, self-administered, Web- 24HDR inspired on the 
Automated Multiple Pass Method (AMPM) by USDA which is consisting of 9349 foods and over 
7000 food images in 61 modules. Portion sizes are quantified by household measures using 
images of different amounts of food on a standard plate, glass, or bowl. Food preparation 
methods are also assessed, as well as condiments and additions. In DietDay usual consumption is 
asked by time of day. Nutrient values in the program are based on USDA values and expanded to 
include mixed dishes and product labeling information.  
4. Web-SPAN [42]: a Web-Survey of Physical Activity and Nutrition presented and evaluated the 
appropriateness of a Web-based method for assessing dietary intake and physical activity in 
young students. The Web-based 24HDR data was transferred to ESHA Food Processor [75] and 
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the Canadian Nutrient File database [76] was used for calculating the macronutrient and 
micronutrient of the intakes.  
5. The Oxford WebQ [43]: a self-administered Web-24HDRs which estimates nutrients 
automatically, providing a low-cost method for measuring dietary intake in large-scale studies.  
 
4.3. Systems integrating both: Web-FFQs and Web-24HDRs 
Approaches that integrate Web-FFQs and Web-24HDRs [11,44,45] are:  
1. Hanning et al. [11] developed a Web-based Food Behaviour Questionnaire (FBQ), which 
included a 24HDR and a FFQ, which analyzed nutrients using ESHA Food Processor [75] and 
the Canadian Nutrient File database [76]. This FBQ was used for assessing dietary energy as a 
function of gender and weight status among Ontario and Alberta adolescents [77]. Later this was 
validated with students of grades six to eight obtaining positively correlated energy and nutrient 
intakes between FFQ and dietitian interviews [12].  
2. OBENUTIC [44]: This Web service was developed to assist in the research of the relation 
between food intake and obesity and related diseases in Spanish Mediterranean populations. It 
provides dynamic generation of FFQs and 24HDRs according to the study defined. OBENUTIC 
uses, as nutrient data sources, either one of the following four FCTs or combinations of them: the 
Spanish tables by Mataix [78] and CESNID [79], the Finnish Food Composition Database [62] 
and the USDA’s National Nutrient Database for Standard Reference [63]. A nutrient and food 
ontology, NutriOntologia, was developed for the alignments between food names [80,81] in each 
database. Results were customizable and exportable in a format suitable for SPSS. OBENUTIC 
was programmed using PHP, XHTML and JavaScript languages. The database engine was 
MySQL and the framework XAJAX in PHP was used for developing interfaces.  
3. my DIDeA [45]: a Web-based dietary intervention for type 2 diabetes patients which included 
a semi-FFQ for recording participants’ dietary intake and two days 24HDR for analyzing their 
nutrient intake using the Axxya Systems Nutritionist ProTM Diet Analysis.12  
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5. INNOVATIVE TRENDS  
In the symposium by the European Nutrigenomics Organization (NuGO) [82] the following 
innovative applications used in nutritional studies were presented:  
1. The ACASI [83,84], an audio computer-assisted program for interviewing participants so that 
they fill in a diet history questionnaire while listening to the questions;  
2. The IMM [85], an Interactive Multimedia computerized recall that incorporates a touch screen 
and audio functions to help data input;  
3. The Wellnavi [86,87], a Pocket-PC with digital camera and mobile phone for direct electronic 
data transfer to a dietitian in the study centre;  
4. The Technology Assisted Dietary Assessment (TADA) project [88–90] used a mobile device 
with an embedded camera to estimate daily food and nutrient intake from digital images taken by 
the participants. Food recognition in digital images is achieved using segmentation methods 
combined with Gabor filters for texture comparison and statistical pattern classification 
techniques such as Support Vector Machines (SVMs). Food portion size is estimated in cm3 and 
the Food and nutrient Database for Dietary Studies (FNDDS) is used for obtaining weight 
measures. Moreover, X-ray computerised microtomography (XMCT), 3D laser imaging, and 
other techniques are used to measure food density (g/cm3) to convert portion estimates to a 
weight measure. 
Other innovative applications can be found in the literature [91,92]. Image-Diet Day [91] is an 
automated image-capture method to aid dietary recall consisting of a user-initiated camera- 
equipped mobile phone programmed to automatically capture and transmit images to a secure 
website in conjunction with computer-assisted and multipass 24HDRs. Participants used the 
device on three independent days and then they used the captured images using ImageViewer 
Software while completing the 24HDR on the following day. Image processing filters 
successfully eliminated underexposed, overexposed and blurry images. Participants concluded 
that the images were helpful but that wearing the device around their neck was not easy and they 
also had problems such as limited battery life, self-consciousness about wearing the device in 
public and concerns about the field of view of the camera. Therefore, there is still work to be 
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done to solve these problems and to meet the challenge of managing the thousands of images 
generated. Lambert et al. [92] tested how useful smart cards were for assessing food intake. They 
provided smart cards to school children and when they paid for their meal, the foods on the tray 
were recorded at the cash desk and sent to a central computer. Moreover, the date and time of the 
meal was stored and also the data on the computer can be linked to a nutrient database. However, 
they observed that this method was useful for collecting information about participants’ food 
selection but not for their food intake because they sometimes exchanged trays or paid each 
other’s meals and the real portion of the intake was not known and it had to be estimated.  
 
6. DISCUSSION  
After analysing all the works appearing in the literature related to the automation of 
questionnaires in nutrition, a discussion is presented comparing: (i) automated vs. paper 
questionnaires (Section 6.1); (ii) computerized vs. Web-based questionnaires (Section 6.2); (iii) 
interviewer- vs. self-administered questionnaires (Section 6.3); and (iv) Web-based 
questionnaires vs. Innovative technologies (Section 6.4).  
 
6.1. Automated vs. paper questionnaires  
In a comparison between the use of a Web-questionnaire and a similar printed questionnaire, 
Balter et al. [93] found that the willingness to answer the second part of the questionnaire was 
higher with a Web-questionnaire than with the printed questionnaire, which suggests that the 
participants responding to the Web-based questionnaire found the process more appealing than 
those who responded to the printed questionnaire. Therefore, they recommended the use of Web-
questionnaires if Internet access is high for the population involved. Another study [94] for 
comparing Web vs. paper questionnaires in adolescents concluded that most of the participants 
required less time to fill in the Web-questionnaire and they also felt less observed and more 
independent while completing it. Finally, a comparison of Web and paper versions of self-
administered questionnaires used in the NutriNet-Santé Study [95,96] concluded that the quality 
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of information provided by the Web-questionnaire was equal to, or better than, that of the paper 
version, with substantial logistic and cost advantages.  
 
6.2. Computerized vs. web-based questionnaires 
Administration of paper questionnaires started to be replaced in the early eighties by researcher-
administered computerized questionnaires. These tools helped researchers to store dietary 
information and to calculate nutrients and energy intake in an easier way. At the beginning of 
2000, the first Web-questionnaires started to be available. They offered the advantages that they 
were accessible around the world by means of Internet, and that information could be stored in a 
centralized Web-server. Due to the spread of the WWW, these new applications allowed the 
possibility of self-administration of questionnaires to a wide range of participants. Furthermore, 
since the Semantic Web gained importance, developments of ontologies related to food intake, 
recipes and nutrition have been developed. Pattern recognition algorithms were also improved 
allowing the introduction of free entrances in 24HDRs questionnaires because the contents of the 
answers were automatically interpreted. Also, Web-based questionnaire developments improved 
in their portability, allowing their administration on standard PCs, PDAs, tablet computers or 
mobile phones only using Internet connection.  
 
6.3. Self-administered vs. interviewer-administered questionnaires 
Interviewer-administered questionnaires avoid excluding from the studies segments of population 
without Internet access or ability to use computers. Moreover, as interviewer-administered 
questionnaires are made in front of the participants, an expert dietitian is able to recognize 
nonverbal behavior that potentially may aid in minimizing social desirability bias. As Probst et al. 
[32] concluded, recognizing that a client is shifting in the chair, touching their face, etc. when 
asked about dessert, for example, may assist in determining the appropriate types of questions to 
be asked and whether or not to ask additional probing questions in order to gain more detail.  
On the other hand, as the WWW increasingly spread in recent years, self-administered 
questionnaires are becoming more popular. A comparison between interviewed-administered 
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24HDRs and interactive Web-based self-administered 24HDRs [97] concluded that the latter 
permit considerable logistic simplification and cost saving and that they may be highly 
advantageous for large population-based surveys. Moreover, Web-based self-administered 
questionnaires can also be completed at any time from any location with centralized monitoring 
of participant completion. However, from the point of view of information technologies, a self-
administered Web-based questionnaire must be developed more accurately because it is not 
completed by an expert dietitian or computer scientist. Therefore, some considerations have to be 
taken into account:  
(1) The participants must receive information regarding: (a) the Web address, and (b) a unique 
ID-number and a secure password for each participant in order to ensure the confidentiality of the 
data provided to the system. This information can be provided by e-mail to accelerate the process 
of data gathering.  
(2) The interface must guide all the participants equally and minimize potential errors derived 
from their varying degrees of knowledge. For that, help screens, a tutorial or an animated agent 
who guides participants through the Webside can be used.  
(3) Including colour photographs showing different portion sizes per food items or/and dishes to 
obtain trustworthy information regarding food portion-size.  
Moreover, Web-based self-administered questionnaires are not usually designed to capture the 
social desirability of a particular food. However, they may incorporate video recordings of 
participants’ body movement and facial expression at the time of food reporting. Later, this video 
may be processed by intelligent systems for identifying such desirability. An initial study 
described the differences in the observed behaviors according to the type of foods selected by 
participants using a prototype version of a Web-based video-recorded dietary assessment [32].  
 
6.4. Web-based questionnaires vs. new innovative technologies  
Some innovative technologies such as personal digital assistants (PDAs) with camera, 
dictaphones or mobile phones are interesting because they allow the participants to store 
electronic food records in the moment of eating.  
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However, as Illner et al. [98] mentioned: portable food records (i.e. the mobile phone with 
camera by Boushey et al. [88]) are innovative ideas suitable for reaching low-literacy groups, 
adolescents and elderly, but like all new techniques on food records, application in large-scale 
studies is hindered by costs and training burden. Moreover, new technologies such as mobile 
phones with camera or portable barcode readers with PDAs are more useful for capturing diet 
snapshots (detailed information on dietary practise at a certain point in time, such as single meals 
or purchases) than for capturing complete dietary sequences like diet throughout a day.  
Finally, the identified future trends for administration of questionnaires from the point of view of 
computer engineering and nutrition are: (1) using mobile devices such as mobile telephones, 
PDA-like devices or tablets with a built-in camera, network connectivity, and a microprocessor 
for integrating image analysis, visualization tools, etc.; (2) programming nutritional assessment 
tools programed as mobile phone applications which the participants may download from public 
markets on their personal mobiles and use for self-administration; (3) introducing multimedia 
functions in questionnaires automated for mobile devices such as: selection of foods by touching 
the screen, naming the food appearing in photographs using a handwriting-note application; 
speech synthesizers for reading the questionnaire, etc.; (4) introducing computer vision 
technologies for recognition of foods (i.e. Gabor filters and Support Vector Machine algorithms, 
etc.), for calculating food portions and weight in the photos made by the participants’ mobile 
devices; (5) using computer vision methods for identifying the barcode of some foods difficult to 
decompose in components (i.e. precooked foods) in order to obtain the specification of the exact 
ingredients used by the manufacturer; (6) using pattern recognition algorithms and language 
processing techniques for identifying the contents of free text entrances; (7) developing and using 
ontologies for assigning meaning (interpretable byWeb agents) to the food, recipes and other 
nutrition information extracted from the questionnaires; (8) cameras (in portables or mobile 
phones) for video-recording and recognizing participants’ behaviors when completing 
questionnaires with the aim of minimizing social desirability bias.  
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7. CONCLUSIONS AND FUTURE PROSPECTS  
FFQs and 24HDRs dietary recalls have been automated in a variety of ways in different studies. 
Depending on the aim of the study and on the population analyzed, a method for automating 
nutrition questionnaires would be more suitable than others. In this state-of-the-art review, 
nutritional studies conducted or published since 1980, in which the use of automated 
(computerized or Web-based) nutrition questionnaires, have been described. In order to identify 
relevant studies that describe the design, development and/or use of food questionnaires, a 
comprehensive search procedure was developed using the electronic databases PubMed, Embase 
and Web of Science and searches of published conference proceedings, key nutrition journals and 
reference lists of retrieved papers. The works obtained were classified from a nutritional point of 
view and regarding the type of administration to participants. Several studies that apply 
innovative technologies have been outlined too. And finally, a discussion has been provided on 
the classification made and the works reported.  
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Table 1 Classification of Computerized FFQs, 24HDRs, and combination of both. The works in 
each box are listed chronologically 
Type of Administration C-FFQs C-24HDRs C-FFQ + C-24HDRs 
Interviewer-administered Baghurst & Record [13]   
 Smith et al. [14]   
 Geekie et al. [15] EPIC-SOFT [17] CAPI [26] 
 CAFE [3] AMPM [18,19]  
 RIBEPEIX [6]   
 NUTRISOL [16]   
Self-administered Engle et al. [20]   
 Suitor & Gardner [21] FIRSSt [23] – 
 Heath et al. [5] YANA-C [24]  
 Vandelanotte et al. [22] NDSR [25]  
 Wong et al. [7]   
 
 
Table 2. Classification of Web-based FFQs, 24HDRs, and combination of both. The works in 
each box are listed chronologically. 
Type of Administration Web-FFQs  Web-24HDRs  Web-FFQ + Web 24HDRs
Interviewer-administered FITUVEROLES [8] –  OBENUTIC [44] 
 RIBEFOOD [29]   
Self-administered Matthys et al. [27]   
 Galante & Colli [28]   
 Probst et al. [32]   
 DHQ [30], PDHQ [31] ASA24 [9,72]  
 Mart*-Cid et al. [29] SNAP [40] FBQ [11] 
 FFQ-DASH [33] DietDay [41] my DIDeA [45] 
 Vereecken et al. [35] Web-SPAN [42]  
 Labonté et al. [34] Oxford WebQ [43]  
 EPIC-FFQs [36]   
 VioFFQ [38]   
 BlockFFQ [39]   
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Chapter 7: discussion 
 
In this thesis, genetic determinants of intermediate and final phenotypes of cardiovascular risk 
were examined in Spanish and German studies. Also a systematic review on available tools for 
food questionnaires automation in medical studies was conducted. Although results from each 
study have already been discussed in the chapters where they were presented, in the present 
chapter the main findings are summarized and some methodological issues are discussed. 
 
7.1 MAIN FINDINGS AND COMPARISON OF RESULTS OF RECENTLY PUBLISHED 
STUDIES  
Chapter 2, entitled “Association of the LCT-13910C>T polymorphism with obesity and its 
modulation by dairy products in a Mediterranean population”, investigated the impact of the 
SNP rs4988235 C/T from the MCM6 gene, located upstream the LCT gene, on measures of 
anthropometry in the PREDIMED-Valencia cohort. Being the first study of its kind in a 
Mediterranean population, it was found that homozygotes for the C allele (genotype consistent 
with a lactase non-persistent phenotype), had a lower mean BMI and waist circumference and a 
lower odds of obesity compared to the rest of participants. This was independent of sex, age, 
diabetes, physical activity and energy intake. This finding agrees with the results from the only 
study that was subsequently published (1). That study had a cross-sectional design and included 
551 randomly selected adults belonging to the Canary Islands Nutrition Survey in Spain (aged 
18-75 years) (1). Further, in PREDIMED-Valencia, it was observed that differences in waist 
circumference and obesity between genotypes were greater when lactose intake was high. 
In Chapter 3 (Significant associations of the rs2943634 (2q36.3) genetic polymorphism with 
adiponectin, high density lipoprotein cholesterol and ischemic stroke) the role of the SNP 
rs2943634 C/A on the risk of MI and IS was investigated. This SNP is located in a non-coding 
region of chromosome 2q36.3 and had previously been associated with coronary artery disease in 
two GWA studies. While no significant associations were observed for MI, carriers of the minor 
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allele of rs2943634 had a lower risk of IS. Further, the association of rs2943634 with 12 
intermediate risk phenotypes was cross-sectionally explored. In line with the lower stroke risk, 
carriers of the minor allele showed slightly higher HDL-cholesterol and adiponectin levels. These 
intermediate phenotypes, however, could not explain the association with IS, which leaves open 
the need of further studies to clarify the underlying mechanisms. Following this study, other 
authors also investigated the role of this SNP in atherosclerotic diseases. In line with our findings 
suggesting a protective effect of the rare allele of rs2943634, a cross-sectional study in 1886 
participants from the two EPIC centers of the Netherlands reported an inverse association with 
the MetS (odds ratio 0.88, 95% CI 0.79; 0.97) (2). Further, its major allele, compared to the 
minor, was associated with incident coronary heart disease (CHD) in two out of five US cohorts 
of different race/ethnicity in a study where follow-up ranged between 9.1 and 15.7 years. 
Significant associations were observed in a cohort of 12316 white participants (3963 cases, HR 
1.07 95%, CI 1.04-1.11), and in a cohort of 883 Asian and Pacific Islanders (65 CHD cases, HR 
2.00 95%, CI 1.20-3.33). In contrast, no associations with incident CHD were found in 3 cohort 
studies, including a cohort of 6502 African Americans (677 cases, HR 1.02, 95% CI 0.93-1.12), a 
cohort of 203 Indian-Americans (20 cases, HR 1.29, 95% CI 0.76-2.16), and a cohort of 1897 
Hispanics (113 cases, HR 0.95, 95% CI 0.76-1.18) (3). Finally, in a collaborative consortium of 
12 studies, involving 25,000 participants and 5794 incident CHD events, the major allele of 
rs2943634 was associated with a slightly higher CHD risk (odds ratio 1.08, 95% CI 1.03-1.14). 
However, no associations were found for any of the 13 investigated biological risk factors for 
CVD (4). 
Chapter 4, entitled “Heterogeneity of the Stearoyl-CoA desaturase-1 (SCD1) gene and metabolic 
risk factors in the EPIC-Potsdam Study”, is the largest study conducted so far to evaluate the 
impact of SCD1 heterogeneity on MetS-related traits and on markers of liver fat and 
inflammation. Despite the strong interest in SCD1 due to its important role in the de novo 
lipogenic pathway (5), most of the existing knowledge on its function comes from mice models 
(5). After publication of the EPIC-Potsdam studies, no other studies have been published. Prior to 
our study, the impact of SCD1 heterogeneity on metabolic risk factors had only been investigated 
in four human previous studies (6-9) which had provided mixed results. The findings of the study 
described in Chapter 4 do not suggest a modulation of the investigated traits by means of the 
SCD1 common genetic variants investigated. However, given its biological relevance, genetic 
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heterogeneity of human SCD1 in relation to impaired metabolism rewards further investigation in 
independent study populations, in particular with regards to rare genetic variants.  
Chapter 5 entitled “Microsomal triglyceride transfer protein -164 T > C gene polymorphism 
and risk of cardiovascular disease: results from the EPIC-Potsdam case-cohort study” tested the 
hypothesis that a SNP in the promoter region of MTTP, could modulate the risk to develop a 
cardiovascular event, depending on cholesterol levels. This SNP had inconsistently been 
associated with CVD in previous studies. In EPIC-Potsdam, participants with lower cholesterol 
levels (<200 mg/dL) showed indeed an increased risk, while participants with higher cholesterol 
levels showed a decreased risk. This last result could also be observed in a smaller replication 
cohort, suggesting that risk allele carriers with low cholesterol levels may be predisposed to an 
increased risk of developing CVD, which seemed to be abolished among risk allele carriers with 
high cholesterol levels. Other similar studies have not been published to date. 
Chapter 6, entitled “Automation of Food Questionnaires in Medical Studies: A state-of-the-art 
review and future prospects”, presents a review of different technological approaches used in 
nutritional epidemiological studies, for the automatization of FFQs and 24HDRs. For this 
purpose, a search in different electronic databases for articles on studies published until 
December 2011 was undertaken. The identified tools were first classified into computerized 
questionnaires vs. Web-based or Internet-based questionnaires. A further division was then made 
based on method of dietary assessment (that is, FFQs, 24HDRs, or combinations of both). A final 
classification was made by taking into account the type of administration to participants, that is, 
interviewer vs. self-administered methods. Additionally, some recent developments in the use of 
innovative technologies, such as audio, multimedia touch-screen, pocket-PC, digital camera and 
mobile phone, were described. This review shows that FFQs and 24HDRs dietary recalls are 
used/can be used in several automated forms in different studies. Depending on the aim of the 
study and on the study population, a method for automating nutrition questionnaires would be 
more suitable than others. 
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7.2 METHODOLOGICAL CONSIDERATIONS 
Study populations 
Chapter 2 presents a cross-sectional genetic association study, conducted on a high 
cardiovascular risk population, the PREDIMED-Valencia cohort. This cohort has its basis in the 
Faculty of Medicine and Odontology of the University of Valencia. Details on recruitment 
procedures have been explained in detail elsewhere (10). Briefly, potential participants were 
selected from records of a convenience sample of general practitioners of the Valencia region, 
Spain. Practitioners directly invited their patients to participate, and 70% of them agreed. 
Inclusion criteria consisted on being aged 55–80 years old for men and 60–80 years old for 
women; not having prevalent CVD, and having either type 2 diabetes or at least three of the 
following cardiovascular risk factors: current smoking, hypertension, dyslipidemia, overweight 
and family history of premature CVD. Exclusion criteria included: severe chronic illness, 
immunodeficiency, human immunodeficiency virus positive status, illegal drug or alcohol 
misuse, allergy to olive oil or nuts and low predicted likelihood of changing dietary habits. 
The characteristics of this highly selected population may have compromised the extent to which 
results inferred from this genetic association study can be generalizable to other populations (that 
is, its external validity). Nevertheless, the findings were consistent with those reported in other 
populations (1, 11). 
Studies on Chapters 3 to 5 are based on a subsample of the EPIC-Potsdam cohort. EPIC-Potsdam 
has its basis in the German Institute of Human Nutrition and includes 27,548 persons from the 
general population of the city of Potsdam and surroundings (Brandenburg, Germany). 
Participants were recruited between 1994 and 1998 and the procedures have been described in 
detail elsewhere (12). Briefly, it was based on addresses from general population registries. 
Participants were initially approached by mail. Those who did not respond within 2 weeks were 
re-contacted again either by mail or telephone. The participation rate, compared to the invited 
number of subjects, was 22.7% with a considerable variation by municipality and gender. Men 
(39.6%) were mainly aged 40-65 and women 35-65 years old at recruitment. After recruitment, 
participants have been re-contacted and asked to fill in follow-up questionnaires every 2-3 years. 
This is done to identify incident cases of chronic diseases and changes in diet and lifestyle. The 
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response rate of the follow-up has so far ranged between 92-96%, depending on the follow-up 
wave.  
Being a random sample of EPIC-Potsdam, studies on chapters 3 to 5 shared the limitations of 
cohort studies, which include been sensitive to selection bias due to participation. Selection bias 
occurs when there is a difference in characteristics between people who participate in the study 
and those who do not. First, this may occur because the people who participate are different than 
those in the source population. A comparison of general characteristic of the EPIC-Potsdam 
cohort with data from the German National Health Survey 1991/1992 showed that the study 
population had higher socio-economic status and was healthier than the source population (12). 
This is in line with the observed fact that health-conscious people are often more likely to 
participate in health-related studies than others. While the selective participation in this study 
may have affected the external validity of the findings, conversely, it most likely played a role 
safeguarding the internal validity of the prospective study, by ensuring high participation rates 
across the follow-up rounds (12). Second, selection bias may occur if many participants drop out 
of the study during follow-up due to factors related to the exposure or outcome. However, as 
noted above, response rates during follow-up were high, which makes this form of selection bias 
unlikely. Furthermore, it has been suggested that when disease associations are estimated as 
relative risks, selective participation is unlikely to lead to wrong etiological conclusions (12). 
 
Study design 
Classical study designs for genetic association studies, include, but are not limited to, case–
control, nested case-control, cohort, and cross-sectional designs. More recently also the case-
cohort design has been used. 
Chapters 2 to 5 present cross-sectional results for the association between SNPs and intermediate 
phenotypes of CVD. Unlike prospective designs, cross-sectional studies have the limitation that 
exposure is measured at the same time as the phenotype of interest, which opens the possibility of 
reverse causality. For genetic association studies using SNPs as exposure, however, this is less of 
a problem given that genotype does not change over the time. 
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Studies on Chapter 4 and 5 follow a case-cohort design (13), which combines the advantages of a 
prospective cohort study with the efficiency of a case-control design. This type of design is useful 
in follow-up studies when large cohorts are needed to acquire enough cases and it is not feasible 
to collect data on all covariates for the entire cohort. In case-cohort studies, the study set is 
constituted by a random subsample (subcohort) of the study population, and all members of the 
cohort developing the disease of interest during follow-up, in this case myocardial infarction and 
ischemic stroke. With a sufficiently large subcohort, it is expected that the characteristics of the 
subcohort are comparable to those of the total cohort. For the EPIC-Potsdam Study, the subcohort 
was indeed similar to the entire cohort with regard to socio-demographic, lifestyle, and 
anthropometric characteristics at baseline. Therefore, the results from the case-cohort study are 
expected to be generalizable to the entire cohort without the need to measure biomarkers and 
genotype SNPs in the all participants. Further, compared to nested case-control studies, the case-
cohort design is more flexible, as it allows the use of the same subcohort to investigate the effect 
of the exposure on different outcomes. However, members of the subcohort can potentially 
develop the disease outcome of interest (given that they are representative of the total cohort) and 
would, therefore be excluded to safeguard the prospective design. Therefore, slightly more 
controls need to be selected in case-cohort studies than in nested case-control studies to achieve 
the same statistical power for the same number of cases (14). 
The theoretical background for the case-cohort design was formulated in 1986 by Prentice (15), 
and it is suitable to measure risk ratios (14). The statistical analyses involve models for survival 
data (e.g. Cox regression) with some form of weighting to take into account the sampling from 
the original cohort (16). Three weighting methods have been proposed by Prentice, Self-Prentice, 
and Barlow. They differ in the way to handle subcohort members and cases outside the subcohort 
(external cases) at the time the event of interest occurs (16). Methods proposed by Prentice and 
Self-Prentice use weights 1 and 0. Subcohort members have weight 1 at all times. For the 
Prentice method, external cases have weight 0 at all times, until precisely the time of failure, in 
which the weight becomes 1. For the Self-Prentice method, external cases have weight 0 at all 
times (16). In the approach from Barlow, cases’ weight is always 1 and the subcohort is weighted 
by the inverse of the sampling fraction (16). The three methods have shown to result in very 
similar effect estimates and standard errors. However, when the size of the subcohort is small, the 
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estimates given by the Prentice method have been suggested to better resemble the estimates 
from a full-cohort analysis (17). 
 
Metabolic syndrome  
Study on Chapter 2 contemplated the concept of MetS, while study on Chapter 3 looked at single 
components of this syndrome (among other biomarkers) but not at overall MetS. The concept of 
MetS focuses attention on the complex multifactorial health problems of abdominal obesity, high 
triglycerides and low HDL-cholesterol concentrations, elevated blood pressure, and glucose 
intolerance (18). Individuals with MetS are at increased risk for CVD and type 2 diabetes; the 
more individual MetS traits a person clusters, the greater the chances of developing an adverse 
outcome (19). 
Although MetS is influenced by lifestyle and genetics (20), its exact pathogenesis remains 
unclear (21). The last report of a World Health Organization Expert Consultation described MetS 
as a useful educational concept, but with limited practical utility as a diagnostic or management 
tool (18). Moreover, Reaven, the first to propose the MetS (22), recently questioned the 
etiological role of abdominal obesity in the development of the other components of the MetS, 
and also concluded that the Framingham Risk Score performs better predicting CVD, and fasting 
plasma glucose concentrations might be better for predicting type 2 diabetes (19). While these 
arguments would not favour the use of MetS as a concept, there is general agreement that glucose 
intolerance, high triglycerides, low HDL-cholesterol, and elevated blood pressure tend to cluster 
together, and that obesity increases chances for this cluster to occur (19). In this context the MetS 
concept provides a framework to explore possible basis for the observed group of risk factors. 
Since the term was first classified, various definitions for MetS have been proposed by different 
organizations (23-26), the most recent come from the International Diabetes Federation (IDF) 
(25) and the American Heart Association /National Heart, Lung, and Blood Institute 
(AHA/NHLBI) (26). After harmonization, the difference among them concerns the measure for 
central obesity, which for the IDF is lower and ethnic specific (27). Due to the absence of a clear 
mechanism for the pathogenesis of MetS, these definitions can only be considered provisional 
(18). 
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Genetic factors as exposure 
Unlike other exposures, single-nucleotide polymorphisms (SNPs) are stable throughout life and 
not influenced by age, sex, calendar year, or disease status. Although this makes SNPs insensitive 
to confounding and reverse causation, there are other factors that may obscure its findings. In 
studies with different ethnic groups confounding (or bias) can be introduced by population 
stratification if the phenotype of interest varies with ancestry (28). Throughout this thesis, 
confounding by population stratification was avoided because both cohorts examined were 
homogeneous in terms of race and ethnicity. 
Another potential source of confounding in SNP studies are characteristics that are genetically 
driven (at least to some extent) and associated with the investigated phenotypes. The influence of 
this potential form of confounding was reduced by including such characteristics in different 
adjusting models. However residual confounding due to potential measurement error in the 
variables adjusted for can never be excluded in observational. 
Also, by testing multiple hypotheses, false-positive associations may arised due to chance 
statistical fluctuations. The possibility of chance findings was lowered through the use of a 
correction for multiple testing by means of the Bonferroni method (29). However, it may have 
resulted in too conservative estimates (false-negatives), given that the assumption of 
independency among tests was not strictly fulfilled (30) 
Measurement error in genotyping also can be a source of biased results (31). In order to minimize 
this threat, biological samples from all the study participants investigated in each cohort were 
drawn and stored under identical conditions. Further, genotyping was conducted by standardized 
procedures, with validated assays and according to suppliers’ protocols. In the special case of 
rs4988235 (Chapter 2), a commercially available assay was not available. Thus, it was necessary 
to design a customized assay and to use additional quality control measures to ensure that the 
new assay was valid. Accordingly, the SNP was additionally genotyped with a standard RFLP 
method in a random subset consisting of 50% of the study population. Concordance between 
techniques was higher than 95%, and discrepant samples were sequenced. As a result of quality 
control measures, all the SNPs investigated in this thesis showed a high call-rate and followed 
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Hardy-Weinberg equilibrium (HWE), which otherwise often points at a possible genotyping 
problems (31). 
While results from genetic-association studies are a valuable tool to generate hypothesis 
concerning a given gene in the etiology of a particular phenotype, functional studies are 
subsequently needed to infer causality. Also, even though the genome has a static secuence, there 
are other genetic factors that may play an important role in the modulation of intermediate and 
final phenotypes of CVD. For instance, the complex compaction of the DNA molecule inside the 
cell nucleus has an influence on which genes become accessible for transcription (32). Also 
epigenetic changes, can also regulate gene expression. Examples are DNA methylation and 
histone modification (33) 
 
Need of replication studies in independent cohorts 
Given that variants contributing to complex traits are likely to have modest effects, and that 
testing multiple hypotheses requires corrections (such as Bonferroni), which limit the power of 
the studies, small sample sizes may result in insufficient statistical power to detect minor 
contributions of the alleles to the modulation of the investigated phenotypes. Thus to evaluate the 
results of this work, further studies in independent cohorts analyzing the same SNPs, or those in 
perfect linkage disequilibrium, are indispensable (34). This may be done in collaborative research 
consortia, which combine several large studies. One example is the METASTROKE 
collaboration, which included 12389 IS cases and 62004 controls of European ancestry from 15 
case-control studies. The novel associations identified, were further replicated in the same study 
in an independent set of 13347 cases and 29083 controls from 18 case-control studies (35). 
 
Use of food-frequency questionnaires 
In the study of Chapter 2, food consumption was determined by a validated semi-quantitative 
food-frequency questionnaire (FFQ). FFQs are widely used in epidemiological studies because 
they are easy to administer, relatively cost effective, and typically cover habitual diet of the past 
year. However, they also have limitations, including the inability to assess absolute intakes and 
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their susceptibility to measurement error. It is well-known that FFQs generally tend to over-
estimate food consumption. Further, misreporting of dietary intake may also differ according to 
age, sex, BMI, and educational attainment. Further inaccuracies may result from incomplete food 
lists contained in the FFQ. Due to these limitations, FFQ are better used to rank participants 
according to food consumption rather than for estimating absolute levels of intake, like it was 
done for lactose intake for the study in Chapter 2. The performance of FFQs in terms of validity 
and reproducibility always needs to be assessed against other assessment methods, such as the 
24-h dietary recall. Advantages of the 24-h recall over the FFQ, include that it collects data based 
on short-term memory and that it provides absolute intake information rather than consumption 
ranges. Further, it doesn’t consist of a closed list of foods and it does not require adaptation to 
specific populations. However, a single 24-h recall is not representative of an individual’s usual 
diet, therefore multiple 24-h recalls are needed to assess diet. Details on how the FFQ used in the 
study of Chapter 2 was validated have been described elsewhere (36, 37), briefly: the FFQ was 
administered twice to explore reproducibility at 1 year. Four 3-days dietary records were used as 
reference to explore validity. This FFQ was designed to be interviewer-administered on an 
optically readable paper. It is likely that the elderly population of this study had limited access to 
the Internet and reduced computer skills. Thus, a self-administered computerized or Web-based 
questionnaire, could have translated into a drop-out of the study and therefore in participation 
bias. The scanning of the questionnaire for its translation into nutrients, most likely reduced 
transcription errors, data entry expenses and speeded processing. However, regardless of the type 
of automatization method, computer-aid questionnaires share the same methodological 
limitations as their source tools. These limitations may be to some extent overcome by integrative 
methodological approaches that could combine dietary information from multiple measures (38), 
and also by the use of dietary biomarkers, which assess dietary consumption without the bias of 
self-reported dietary intake errors (39). 
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CONCLUSIONS 
 
A general conclusion of the work described in this thesis is, that within the candidate genes 
analyzed in the different populations, a wide genetic variability exists. Furthermore, although 
some of these genetic variants were not directly associated with intermediate or final phenotypes 
of cardiovascular diseases, other variants were. Thus, genetic factors, as measured by means of 
polymorphisms analysis, contribute to explain a portion of the variability of the intermediate or 
final phenotypes investigated. However, this association does not seem to be deterministic, given 
that we were also able to observe the existence of statistically significant gene-diet interactions, 
meaning that the association between the genetic polymorphism with the cardiovascular 
phenotype varied with diet. Awareness of these interactions will be very important for a more 
effective primary and/or secondary prevention, affirming the multifactorial etiology of 
cardiovascular diseases. Accordingly, the large amount of data generated when studying the 
factors involved in multifactorial diseases, requires a specific and combined treatment that largely 
profits from the usage of informatic tools for the storage, recovery and analysis of data. 
Specific conclusions: 
1. In the EPIC-Potsdam study population, the functional genetic polymorphism 164T> C 
of the MTTP gene showed an interaction with total cholesterol levels, which 
predisposed risk allele carriers (allele C) with low cholesterol levels, to an increased 
risk of developing a cardiovascular event. However, this excess risk could be 
abolished among risk allele carriers with high total cholesterol levels. Further studies 
are warranted to confirm these results and, when confirmed, to clarify the underlying 
mechanisms of this interaction. 
2. Common variants of the SCD1 gene within the EPIC-Potsdam cohort do not appear to 
be relevant genetic factors given their lack of direct statistical associations with 
metabolic factors that may be affected by the enzymatic activity of SCD1 
(triglycerides, body mass index, waist circumference, glycated hemoglobin, high-
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sensitivity C-reactive protein, gamma-glutamyltransferase, alanine aminotransferase 
and fetuin-A). However, given its biological relevance, together with the very limited 
number of studies available and the inconsistency of their results, genetic 
heterogeneity of human SCD1 in relation to impaired metabolism needs further 
investigation in independent study populations, in particular with regard to rare 
variants of SCD1. The inconsistent results of the few studies currently available may 
be due to interactions with dietary factors. Genetic associations may only be 
detectable when certain dietary factors are present. 
3. In the EPIC-Potsdam Study, the minor allele of the rs2943634 SNP (allele A), was 
associated with lower risk to develop an ischemic stroke, but not by means of the 
biological risk factors investigated in the study (body mass index, waist 
circumference, blood pressure, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglycerides, blood glucose, glycated hemoglobin, hs-C-reactive protein, adiponectin, 
creatinine). Although rs2943634 was associated with plasma levels of HDL-
cholesterol and adiponectin these factors also did not explain the lower risk associated 
with the rs2943634. Further investigations are needed to confirm these results and to 
clarify the mechanisms underlying the association. 
4. The previously reported association between the genetic variant LCT %13910 C/T and 
body mass index was confirmed in a Mediterranean population at high cardiovascular 
risk (PREDIMED-Valencia). Furthermore we reported for the first time upon a 
potential modulation of the effects of this SNP by lactose intake. These findings also 
suggest that some of the inconsistencies observed among results from previous studies 
investigating the association of dairy products intake and obesity, may be explained 
by the potential heterogeneous effects of these products on lactase non persistence and 
lactase persistence individuals.  
5. In recent years, the tedious task of assessing a person's habitual dietary intake, has 
greatly benefited from the rapid development of information and communication 
technologies. This has enabled the automation of dietary intake assessment by means 
of computerized questionnaires and also, since the expansion of the Internet, by means 
of Web-based questionnaires. Some of the available tools allow self-administration of 
Chapter 8 ! Conclusions 
 189
questionnaires, while others are designed for administration by a healthcare 
professional. Other innovative technologies lately becoming available include audio, 
pocket-computers, touch screens, digital cameras and mobile phones. The accessible 
variety of tools enables the study of the diet as a risk factor for various chronic 
diseases in large epidemiological studies at lower costs and with greater validity and 
precision. 
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CONCLUSIONES 
 
Como conclusión general del trabajo compilado en esta tesis, podemos afirmar que existen una 
amplia variabilidad genética en los genes candidatos analizados en las distintas poblaciones. 
Además, algunas de estas variantes genéticas no muestran asociación directa con fenotipos 
intermedios o finales de enfermedad cardiovascular, pero otras sí que han mostrado su relevancia. 
Ello nos lleva a afirmar que los factores genéticos, medidos a través del análisis de polimorfimos, 
sí que contribuyen a explicar de manera significativa una parte importante de la variabilidad de 
los fenotipos intermedios o finales analizados. Pero esta asociación no parece determinista, ya 
que también hemos podido observar la existencia de interacciones gen-dieta estadísticamente 
significativas de manera que la asociación del polimorfismo genético con el fenotipo 
cardiovascular varía según la dieta. El conocimiento de estas interacciones será muy importante 
para una prevención primaria y/o secundaria más eficaz reafirmando el carácter multifactorial de 
las enfermedades cardiovasculares.  De acuerdo con ello, la gran cantidad de datos que se genera 
en el estudio de los factores implicados en las enfermedades multifactoriales, requiere un 
tratamiento agregado y específico que se beneficia enormemente de la aplicación de herramientas 
informáticas, tanto en el almacenaje como en su recuperación y análisis. 
Conclusiones específicas: 
1. En la población del estudio EPIC-Potsdam, la variante genética funcional -164T> C del 
gen MTTP, mostró una interacción con niveles plasmáticos de colesterol total que 
predisponía a los portadores del polimorfismo de riesgo (alelo C) con niveles bajos de 
colesterol, a un mayor riesgo de desarrollar un evento cardiovascular. Sin embargo este 
exceso de riesgo podría verse anulado para aquellos portadores de la variante con niveles 
altos de colesterol. Son necesarias investigaciones adicionales para confirmar estos 
resultados y clarificar los mecanismos que subyacen a esta interacción. 
2. En la población del estudio EPIC-Potsdam, variantes genéticas comunes del gen SCD1 no 
parecen ser factores genéticos relevantes en su asociación estadística directa con factores 
metabólicos que podrían estar relacionados con la actividad de la enzima SCD1 
(triglicéridos, índice de masa corporal, circunferencia de cintura, hemoglobina 
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glucosilada, proteína-C-reactiva de alta sensibilidad, gamma-glutamyltransferasa, alanina 
aminotransferasa y fetuina-A). Sin embargo, dada su importancia biológica, el número 
todavía escaso de estudios disponibles y la inconsistencia de sus resultados, la 
heterogeneidad genética del gen humano SCD1 en relación con alteraciones metabólicas 
requiere investigación adicional en poblaciones de estudio independiente, en particular 
con respecto a variantes genéticas raras. Estos resultados también nos hacen concluir que 
pueden existir importantes interacciones con la dieta, y en función de la composición de la 
misma que se lleguen a magnificar o no las posibles asociaciones genéticas. 
3. En la población europea del estudio EPIC-Potsdam, el alelo menos frecuente del SNP 
rs2943634, (alelo A) se asoció con menor riesgo de desarrollar ictus hisquémico, pero no 
por medio de los factores de riesgo investigados en el estudio (índice de masa corporal, 
circunferencia de cintura, presión arterial, colesterol total, colesterol-HDL, colesterol-
LDL, triglicéridos, glucemia, hemoglobina glicosilada, proteína-C-reactiva de alta 
sensibilidad, adiponectina y creatinina). El polimorfismo rs2943634 se asoció también 
con niveles plasmáticos de colesterol-HDL y de adiponectina. Son necesarias 
investigaciones adicionales para confirmar estos resultados y aclarar los mecanismos que 
subyacen a la asociación. 
4. Replicación en población mediterránea de alto riesgo cardiovascular (PREDIMED-
Valencia), de la asociación previamente sugerida en otras poblaciones, de la variante 
genética LCT-13910C/T con índice de masa corporal. Además, es la primera vez que se 
aporta información acerca de una posible modulación de los efectos de este SNP por 
mediación de ingesta de lactosa. Los resultados de este estudio también sugieren que 
algunas de las inconsistencias observadas entre resultados de estudios previos sobre la 
asociación de consumo de productos lácteos y obesidad, podrían deberse a la 
heterogeneidad del efecto de estos productos en individuos con y sin persistencia del 
enzima lactasa. 
5. En los últimos años, la tediosa tarea de evaluar la dieta de una persona, se ha beneficiado 
del rápido desarrollo de las tecnologías de la información y la comunicación. Este 
desarrollo ha permitido la automatización de la medida de la dieta mediante cuestionarios 
computarizados y también, desde la expansión de Internet, mediante cuestionarios 
basados en Web. Algunas de las herramientas disponibles permiten la autoadministración 
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de cuestionarios, mientras que otras están diseñadas para la administración por un 
profesional sanitario. Otras tecnologías innovadoras que comienzan a estar disponibles 
incluyen audio, ordenadores de bolsillo, pantallas táctiles, cámaras digitales o teléfonos 
móviles. La variedad de herramientas permite el estudio de la dieta como factor de riesgo 
para diferentes enfermedades crónicas en grandes estudios epidemiológicos a costes 
inferiores y con mayor validez y precisión. 

! 
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Chapter 9: Investigación predoctoral adicional 
 
Durante los años de formación predoctoral, además de los trabajos presentados en el compendio 
de publicaciones que conforman esta tesis, la doctoranda tuvo la oportunidad de participar en 
proyectos de investigación adicionales que complentaron su formación en diversas áreas de la 
epidemiología genética y nutricional. 
Así, en colaboración con el Departamento de Lenguajes y Sistemas Informáticos de la Universitat 
Jaume I de Castellón, participó en proyectos del ámbito de la informática biomédica aplicada a la 
investigación en nutrigenética (proyectos FITUVEROLES y OBENUTIC) y en colaboración con 
el Departamento de Departamento de Medicina Preventiva y Salud Pública, Ciencias de la 
Alimentación, Toxicología y Medicina Legal, participó en estudios de asociación genética de 
polimorfismos en genes candidatos (SCD1, INSIG2, MCM6, NPPA, TAGLN2, THR!) con 
fenotipos intermedios de riesgo cardiovascular en población mediterránea de alto riesgo 
cardiovascular. 
Como resultado de este trabajo, la doctoranda obtuvo el título de Diploma de Estudios Avanzados 
expedido por la Universitat de València. El trabajo de investigación fue titulado “Efecto 
hipolipemiante de los fitoesteroles de la dieta y su modulación por genes candidatos. Diseño y 
validación de un cuestionario para su medición, modelado bioinformático para el proceso 
integrado de datos y resultados de un estudio de intervención”. Asímismo fue coautora de dos 
artículos de revista sobre las características de la Bioinformática Clínica y de diversas 
comunicaciones en congresos nacionales e internacionales. 
La descripción de los resultados obtenidos en el marco de estos proyectos, queda fuera de los 
objetivos de este documento de tesis, sin embargo, dado que el trabajo fue realizado en periodo 
de formación predoctoral, en este capítulo se ennumeran las tareas realizadas dentro de los dos 
proyectos principales, FITUVEROLES y OBENUTIC y se ofrece el listado de las publicaciones 
obtenidas. 
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9.1 TAREAS REALIZADAS EN EL MARCO DEL PROYECTO FITUVEROLES 
El objetivo general del proyecto FITUVEROLES consistió en diseñar y validar los instrumentos 
necesarios para conocer la ingesta de esteroles vegetales en población mediterránea española y 
estimar los efectos de la suplementación con esteroles vegetales sobre los principales parámetros 
del metabolismo lipídico y otros fenotipos intermedios de riesgo cardiovascular relacionados, 
estudiando también su modulación por polimorfismos genéticos. Este objetivo general se abordó 
a través de las siguientes actividades específicas: 
% Diseño y validación de un cuestionario de frecuencia de consumo de alimentos 
(CFCA) específico para conocer la ingesta de fitoesteroles en población mediterránea 
española, utilizando y comparando distintas tablas de composición de alimentos 
(TCA). 
% Diseño de una infraestructura de soporte informático para la automatización de la 
medida de la ingesta de fitoesteroles en estudios epidemiológicos. 
% Estudio de intervención para conocer el efecto de la ingesta de alimentos enriquecidos 
con fitoesteroles sobre parámetros del metabolismo lipídico, hidrocarbonado e 
inflamación en población general mediterránea española normocolesterolemia o con 
hipercolesterolemia moderada. 
% Estudio de la modulación genética de los efectos de los fitoesteroles en el 
metabolismo lipídico analizando polimorfismos en genes candidatos relacionados con 
estos compuestos (ATP-binding cassette, sub-family G (WHITE), members 5 and 8, 
ABCG5 y ABCG8). 
 
9.2 TAREAS REALIZADAS EN EL MARCO DEL PROYECTO OBENUTIC 
El objetivo general del proyecto OBENUTIC consistió en diseñar y validar los instrumentos 
necesarios para facilitar la medida de la dieta y de ingesta de nutrientes en grandes estudios 
epidemiológicos. Este objetivo general se abordó a través de las siguientes tareas específicas: 
% Desarrollo de «NutriOntología», ontología para el alineamiento de alimentos y de sus 
componentes en cuatro TCAs, estableciendo una jerarquía de clases, subclases e 
instancias de alimentos y nutrientes. Para cada instancia de NutriOntología se 
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determinó el peso en gramos de tres raciones estándar, de tamaño grande, mediano y 
pequeño.  
% Diseño puesta a punto y validación de «OntoReceta», soporte informático Web para la 
especificación y almacenamiento de recetas estándar. 
% Diseño y validación de «OBENUTIC-R24h», infraestructura de soporte informático 
para administración electrónica on-line de recordatorios 24h, que ofrece un soporte 
computacional para el cálculo de la ingesta de alimentos y nutrientes. 
% Diseño y validación de «OBENUTIC-CFCA», infraestructura de soporte informático 
para la administración electrónica on-line de CFCA a la carta, que ofrece un soporte 
computacional para el cálculo de la ingesta de alimentos y nutrientes. 
% La validación y puesta a punto de las herramientas diseñadas incluyó el reclutamiento 
de 200 participantes de la Comunidad Valenciana, a los que se administró tres R24h y 
dos CFCA. OBENUTIC-R24h y OBENUTIC-CFCA se sirven del conocimiento 
almacenado en NutriOntología y OntoReceta para transformar la información de 
ingesta alimentaria de R24h y CFCA en ingesta de nutrientes. 
 
9.3 PUBLICACIONES ADICIONALES DERIVADAS DEL TRABAJO PREDOCTORAL 
Las publicaciones ennumeradas en este apartado se divididen en tres secciones: publicaciones 
relacionadas con la bioinformática clínica, publicaciones en el ámbito de la informática 
biomédica aplicada a la epidemiología nutricional y publicaciones derivadas de estudios de 
asociación genética. 
 
Publicaciones relacionadas con la bioinformática clínica 
Coltell O., Arregui M., Falomir Z., Puig A.  La Bioinformática Clínica: aplicación en el ámbito 
de la sanidad. Todo Hospital, Julio-Agosto 2005; 218: 426-435. ISSN 0212-19721. 
Coltell O, Arregui M, Fabregat A, Portolés O. Integration of clinical and biological data in 
clinical practice using bioinformatics. Rev Med Chil. 2008 May;136(5):645-52. 
Coltell O, Arregui M; Fabregat A, Causanilles M, Vázquez R, Portolés O. Las Redes Temáticas 
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de Investigación Cooperativa: INBIOMED y el Nodo UJI – IRIS. I Jornadas de seguimiento del 
convenio UJI – UO. Santiago de Cuba. 16-20 de enero de 2006. ISBN: 978-84-8021-610-4.  
 
Publicaciones relacionadas con la informática biomédica aplicada a la epidemiología 
nutricional 
Proyecto FITUVEROLES  
Arregui M, Coltell O, Vázquez R, Fabregat A, Portolés O, Corella D. FITUVEROLES: un portal 
Web piloto para la determinación de fitoesteroles ingeridos en la dieta mediante cuestionarios 
digitalizados. Public Health Nutrition 2006; 9(7A): 255. ISSN 1368-9800 
Izquierdo-Galbis A, Alegría-Torán A, Lagarda M.J, Farré-Rovira R, Arregui M, Corella D. 
Diseño y validación de un cuestionario para estimar el aporte de esteroles vegetales a través de la 
dieta en población española. Public Health Nutrition 2006; 9(7A): 284. ISSN 1368-9800 
Portolés O, Arregui M, Fabregat A, Farré R, Corella D, Coltell O. Estimación de la Ingesta de 
Fitoesteroles en Población Española Mediante Cuestionario Informatizado: Diferencias de 
Consumo egún el Origen de las Tablas de Composición Utilizadas.  V Congreso de la Sociedad 
Española de Nutrición Básica y Aplicada SENBA. Bilbao, 25-27 de abril de 2007. 
Fabregat A, Portolés O, Arregui M, Núñez M, Barrera E, Corella D, Coltell O. Servicios Web 
para la Investigación Biomédica: Aspectos de Soporte a la Gestión en el Proyecto Fituveroles. 
Actas del X Congreso de Informática y Salud, INFORSALUD 2007, Madrid; 2007: 133-138. 
ISBN: 84-610-2927-4. 
Fabregat A, Arregui M, Portolés O, Barrera E, Andreu Y, Vázquez R, Causanilles M, Corella D, 
Coltell O. Servicios Web para la investigación biomédica: aspectos de gestión de seguridad y 
protección de datos en el proyecto FITUVEROLES. Actas del XI Congreso Nacional de 
Informática Médica, INFORMED 2006, Murcia, 2006:32-38. ISBN: 690-0102-7. 
Coltell O, Arregui M, Fabregat A, Barrera E, Causanilles M, Guillén M, Corella D, Portolés O. 
Nutriontología: Construcción de una Ontología Nutricional Integrando Diversas Tablas de 
Composición de Alimentos para la Investigación en Genómica Nutricional. VI Conferencia 
Iberoamericana en Sistemas, Cibernética e Informática: CISCI 2007. Orlando, Florida (EE.UU.), 
12-15 de julio de 2007 ISBN 1-934272-03-5.  
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Arregui M, Fabregat A, Barrera E, Portolés O, Corella D, Coltell O Fitosteroles y síndrome 
metabólico: diseño y validación de recursos informáticos para la medición de la ingesta de 
fitoesteroles en población española. IX Simposium Nacional de Obesidad: Aspectos Básicos y 
Aplicados. Reus, 24-25 abril 2008 
 
Proyecto OBENUTIC 
Arregui M, Fabregat A, Añíbarro E, Barrera E, Portolés O, Corella D, Coltell O. Instrumentos 
para la Investigación en Dieta y Arteriosclerosis: Integración de la Gestión de Recetas en el 
Recuerdo de 24 Horas por Medio de una Ontología Biomédica. Clínica e Investigación en 
Arteriosclerosis 2008; 20 (Supl 3): 68. ISSN: 0214-9168. 
Coltell O, Arregui M, Fabregat A, Barrera E, Añíbarro E, Corella D.  OBENUTIC-24H: 
computer tools for data acquisition of diet and its transformation in nutrients from 24 h recalls in 
nutricional studies Obesity Metab, 2009; 5(1S): 36.  
Fabregat A, Barrera E, Arregui M, Portolés O, Corella D, Coltell O. BOGENVI: A Biomedical 
Ontology for Modelling Gene*Environment Interactions on Intermediate Phenotypes in 
Nutrigenomics Research. 21st IEEE International Symposium on Computer-Based Medical 
Systems (CBMS2008).Jyväskylä, Finland; June 2008; 302-307. ISBN: 978-0-7695-3165-6.  
Arregui M , Fabregat A, Barrera E, Corella D, Coltell O. Experiencia del empleo de las 
herramientas tic «OBENUTIC-r24h», «OntoReceta» y «NutriOntología» para la determinación 
de la ingesta de alimentos y nutrientes en el estudio epidemiológico nutricional «OBENUTIC». 
XII Congreso Nacional de Informática Médica, INFORMED 2008, Santa Cruz de Tenerife, 2008: 
125-132. ISBN: 978-84-691-6687-1. 
A. Fabregat, M. Arregui, O. Portolés, E. Barrera1, D. Corella, O. Coltell. NutrigenOntología: 
ontología biomédica para la investigación en genómica nutricional integrando genotipo, ambiente 
y fenotipo. Actas del I Symposium del CIBER «Fisiopatología de la Obesidad y Nutrición», 
Santiago de Compostela; 2007: 113. 
Fabregat A, Añíbarro E, Arregui M, Portolés O, Barrera E, Corella D, Coltell O. OntoReceta: 
Integración de la gestión de recetas en una Ontología Biomédica como soporte para la 
investigación en Genómica Nutricional. Actas del X Congreso de Informática y Salud, 
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INFORSALUD 2008, Madrid; 2008: 234-239. ISBN: 978-84-691-2468-0. 
Coltell O, Arregui M, Fabregat A, Barrera E, Añíbarro E, Corella D. OBENUTIC-24H: 
computer tools for data acquisition of diet and its transformation in nutrients from 24 h recalls in 
nutricional studies. Proceedings of the II SIMPOSIUM CIBER Fisiopatología de la Obesidiad y 
Nutrición. Isla de la Toja, 2008: 159. ISBN: 978-84-936158-8-8. 
Fabregat A, Arregui M, Barrera E, Portolés O, Corella D, Coltell O. NutriGeneOntology: A 
Biomedical Ontology for Nutrigenomics Research.  The International Conference on BioMedical 
Engineering and Informatics (BMEI2008). International Conference on Biomedical Engineering 
and Informatics (BMEI), IEEE Conference #13886, Proceedings code PR3118. Sanya, China; 
March 2008; 915-919. ISBN: 978-0-7695-3118-2China. 
Barrera, E., Antonio Fabregat Mundo, María Arregui Rementería, Corella, D., Oscar Coltell 
Simón. Cálculo de la Ingesta de Nutrientes en Base a Respuestas de CFCA y Ontologías de 
composición de Alimentos y Recetas.. XII Congreso Nacional de Informática de la Salud. 
Madrid: 16-03-2009. Nacional. 2009 CEFIC. ISBN: 978-84-691-9561-1. 
Sorlí JV; Fabregat A; Arregui M; Barrera E; Corella D; Coltell O. BIGR24H: aplicación web 
para la valoración del aporte de energía y consumo de nutrientes en Atención Primaria. 30 
Congreso de la Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC).  Valencia, 
Junio 2010 Spain 2010 
Coltell O, Arregui M, Fabregat A, Grao E, Beltrán A, Madueño F, Ordovás JM, Corella D. 
Diseño y validación de Software "online" para la automatización del procesado de recuerdos de 
24 h en amplios estudios epidemiológicos XXIV Congreso Nacional de la Sociedad Española de 
Arteriosclerosis y XIII Congreso Internacional de la Sociedad Iberolatinoamericana de 
Arteriosclerosis. Publication: Clin Invest Arterioscl. 2011;23(Espec Cong):55-56. Sevilla, 25-27 
de mayo de 2011 
 
Publicaciones derivadas de estudios de asociación genética 
Corella D, Arregui M, Carrasco P, Francés F, Sorlí JV, Saiz C, Ruiz de la Fuente S, Sabater A, 
Coltell O, Portolés O. Ausencia de asociación del polimorfismo rs7566605 cercano al gen 
INSIG2 con parámetros antropométricos y lipídicos en una población mediterránea de alto riesgo 
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cardiovascular. XX Congreso Nacional de la SEA. 26-29 mayo de 2007, ISSN 02149168. 
Arregui M, Ortega-Azorín C, Carrasco P, Sotos-Prieto M, Guillén M, González  JI, Corella D. 
Impact of the C to T substitution at -13910bp upstream the lactase gene (rs4988235) on 
consumption of dairy products and obesity risk in a Spanish Mediterranean population. 
Proceedings of the II SIMPOSIUM CIBER Fisiopatología de la Obesidiad y Nutrición. Isla de la 
Toja, 2008: 159. ISBN: 978-84-936158-8-8. 
Ortega-Azorín, C., Godoy, D., Sorlí, J.V., Arregui M, Ordovás, J.M., Corella, D.. Elevado 
desequilibrio de ligameiento de los polimorfismos rs17145738 y rs3812316 del Gen MLXIPL y 
su asociación con triglicéridos plasmáticos en población mediterránea de alto riesgo 
cardiovalscular. Clínica e investigación en arteriosclerosis. Num. Vol 21. pp. 27. 2009 
Internacional.  
Corella D, Portolés O, Arregui M, Guillen M, Ortega C, Carrasco P, Sotos M, Guillén-saiz P, 
Ordovas JM. TAS2R38 Polymorphisms Bitter Perception, Food Intake and Obesity Risk in a 
Mediterranean Population. Journal of Nutrigenetics and Nutrigenomics 2008: 290-291. ISSN 
1661-6499. On-line ISSN: 1661-6758 
Corella, D, Carrasco, P, Ortega C, Portoles O, Guillen M, Coltell O, Arregui M, Estruch R, 
Ordovas, JM, Sorli JV. Study of Genetic Variation in FTO and MC4R with food intake and body 
mass index in a Mediterranean Population. 3 congress onf the International Society of 
Nutrigenetics/Nutrigenomics. Bethesda, Maryland: 21-10-2009. Internacional. 2009 . ISBN: 
Arregui M, Coltell O, Portolés O, Sorlí JV, Verdú JJ, Corella D. Estudio de la asociación del 
polimorfismo rs10883463 del gen de la EstearoilCoA-1 desaturasa (SCD1) con medidas 
antropométricas y bioquímicas en población mediterránea española. X Edición del Simposium 
Nacional de Obesidad: aspectos básicos y aplicados, (Simposium Satélite del II Congreso 
FESNAD) Nutr Hosp, 2010; 25 (3): 493  Reus, 1-2 Marzo 2010  : Spain 2010  
Arregui M, Coltell O, Portolés O, Asensio EM, Olivares L, Corella D. Asociación del 
polimorfismo rs3754686 del gen MCM6 con peso y obesidad en población mediterránea 
española. X Edición del Simposium Nacional de Obesidad: aspectos básicos y aplicados, 
(Simposium Satélite del II Congreso FESNAD) Publication: Nutr Hosp, 2010; 25 (3): 491 Reus, 
1-2 Marzo 2010  Spain 2010 
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Arregui M; Estruch R; Salas J; Coltell O; Covas MI; Ros E; Guillem P; Osma R; Corella D. 
Influencia de las variantes rs198358 (T>C) y rs5068 (A>G) en el gen NPPA (precursor del 
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XXVIII Reunión Cientifica de la Sociedad Española de Epidemiología. Gac Sanit, 2010, 24 (Esp 
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Chapter 2 
Figure 1 Modulation by dairy lactose intake of the association between the LCT %13910C>T 
polymorphism and waist circumference (cm) in the elderly Mediterranean population.  
(a) Predicted values of waist circumference by the LCT %13910C>T  
(b) Adjusted means of waist circumference (cm) in the study subjects (n = 940) depending on the 
LCT %13910C>T polymorphism according to three strata of lactose intake: low (&8 g lactose/day; 
20% of the population (n = 68 CC, 122 CT+TT)), intermediate (8–24 g lactose/day; 50% of the 
population (n = 188 CC, 284 CT+TT)), and high (>24 g lactose/day; 30% of the population (n = 
101 CC, 177 CT+TT)). 
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